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Colorectal cancer (CRC) has become the second most common cause of cancer death 
worldwide, indicating the need for novel therapies to reduce mortality rates and the global 
burden of this disease. Therapeutic subunit vaccines are a safe and promising method for the 
treatment of established cancers. These vaccines aim to stimulate the patient’s immune system 
to recognize and eradicate malignant cells. Robust immune stimulation is necessary to maximize 
the therapeutic potential of the cancer vaccines and in the case of CRC, this can be achieved via 
oral vaccine administration. Anti-tumour immune responses can then be initiated at the tumour 
location, specifically, at the lymphoid tissues of the gastrointestinal tract. However, vaccines 
delivered orally require protection from the harsh conditions found in the gastrointestinal tract. 
This protection can be provided through the use of appropriate delivery systems, which also 
facilitate the addition of vaccine adjuvants.  
The hypothesis of this research was that orally delivered therapeutic subunit cancer vaccines in 
lipid-based formulations stimulate local and systemic anti-tumour immune responses that 
would lead to CRC elimination in a preclinical orthotopic mouse model.  
The hypothesis was tested initially with oral subunit vaccine formulations composed of a 
peptide containing epitopes for CD8+ and CD4+ T cells, in combination with the Toll-like receptor 
2 (TLR2)-stimulating adjuvant, Pam2Cys. These formulations were encapsulated in liposomes 
and in water-in-oil-in-water (W/O/W) double emulsions. Following optimisation of the 
formulations, the emulsion vaccine induced local immune cell accumulation and systemic 
lymphocyte activation after oral vaccination. Furthermore, both emulsion and liposome 
vaccines demonstrated therapeutic potential by significantly reducing the growth of CT26 
tumours injected intracaecally into mice.  The findings confirmed that positive therapeutic 
effect can be achieved with oral subunit vaccines delivered in lipid-based formulations. 
Although both vaccine candidates demonstrated promising treatment outcomes, they were not 
able to completely eliminate the tumours. Therefore, a number of modifications were made to 
the vaccine and/or the therapy including; using self-adjuvanting peptides, modifying liposomes 
for targeted delivery, and combination therapy with a nonsteroidal anti-inflammatory drug 
(NSAID) with or without an immune checkpoint inhibitor. The self-adjuvanting construct was 
not effective when delivered orally or with lipid-based formulations, underlining the need to 
further investigate the immunostimmulatory activity of these constructs as oral vaccines. 
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Targeting of liposome to M cells with the Ulex europaeus agglutinin I (UEAI) lectin also did not 
improve therapeutic outcomes. It was not clear if this was due to the lectin not improving 
liposome uptake by the M cells or if improved uptake had occurred but was not translated into 
therapeutic effect. Combination therapy with the NSAID licofelone was the most promising 
strategy with a partial response to vaccination and reduced tumour growth. The addition of the 
checkpoint inhibitor anti-programmed cell death protein 1 (PD-1) was of no benefit in this 
mouse model. This is likely due to insufficient lymphocyte infiltration into the tumour. 
A novel technique utilising bacterial ‘microswimmers’ to improve the delivery and 
immunogenicity of the oral vaccines, was explored and adapted for the preclinical evaluation of 
immunotherapeutic CRC treatment. Escherichia coli (E. coli) were attached to liposomes or 
emulsion vaccine particles and used as an oral vaccine microsystem. Microswimmer vaccines 
were not toxic and demonstrated favourable immunostimulatory profiles in cell culture, as 
expected due to the natural pathogen associated molecular patterns (PAMP), which could 
interact with pattern recognition receptors (PRR) on dendritic cells (DC). Improved therapeutic 
outcomes were observed after treatment with emulsion microswimmers in mice, confirming 
that bacteria can be a powerful immunostimulatory agent and boost immune responses to 
orally delivered vaccine antigens. Although tumour growth was reduced with the emulsion 
microswimmers, the liposome microswimmers did not demonstrate the same effect. The likely 
reason for this is the stability of the bacterial attachment. 
The study evaluated strategies for the treatment of established colorectal tumours with oral 
subunit vaccines administered in lipid-based formulations. The preclinical vaccine development 
study provided important insights for the future investigation of therapeutic oral CRC vaccines. 
The findings confirmed the potential of these vaccines to be used in human therapy as the 
vaccine candidates demonstrated immunostimulatory and therapeutic capacity to induce 
multiple anti-tumour immune responses and reduce tumour growth. The emulsion vaccine 
candidate is being further investigated for use in clinical trials as it produced the best results 
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1 General introduction 
1.1 Colorectal Cancer 
Colorectal cancer (CRC) is the uncontrolled and abnormal growth of cancer cells inside the large 
intestine (1). CRC remains the third most often diagnosed cancer worldwide and, over the past 
few years, it has become the second most common cause of cancer death reaching around 881 
000 deaths in 2018 (2, 3). Surgical resection, chemotherapy, radiation and immunotherapy are 
used to treat CRC. The 5-year relative survival rate is 91% for early stage CRC patients but it is 
only 12% for advanced CRC patients, according to the 2019 survivorship statistics (4). The 
highest incidence and mortality rates are observed in high and middle-income countries. 
However, the incidence and mortality rates have stabilised or are decreasing in the highest 
income countries, while they are rapidly increasing in developing countries (3). It has been 
suggested that the reason why CRC rates positively correlate with economic development is 
that developing countries tend to adopt a ‘western’ life-style (5). Westernisation is associated 
with a more sedentary lifestyle and lack of activity, changes in diet, high consumption of 
processed and red meat, increasing obesity, alcohol drinking and smoking (6-8). All these factors 
have been linked to a higher risk of CRC (9). Since rates of CRC increase together with economic 
development, this type of cancer might become the main concern in many countries due to 
global economic growth (3, 10). 
1.1.1 Colorectal cancer screening 
To overcome an increasing threat of CRC, health and science organisations have started 
numerous programs and research projects that aim to improve prevention and treatment of 
CRC. Screening programs for CRC have been introduced in many countries and have reduced 
mortality due to improved early detection of disease (5, 11). 
The most common screening strategies that are used for CRC detection include colonoscopy, 
sigmoidoscopy, digital rectal exam and faecal occult blood testing (1). These strategies have 
been implemented in many countries for secondary CRC prevention (12). Colorectal cancer 
develop over many years, therefore, screening strategies enable detection of the early and 
curable stages of CRC. The faecal occult test is used to detect small amounts of blood in stool 
samples that can be associated with precancerous lesions or tumour in the gastrointestinal tract 
(GIT). Colonoscopy, sigmoidoscopy and digital rectal exam enable direct detection of 





incidence and mortality rates in many countries while the negative impact of the screening is 
associated with minor physical and psychological harms (5). Screening programs are highly 
beneficial for CRC prevention, however, despite the best screening programs, effective CRC 
treatment strategies are crucial to reduce mortality rates for those people who develop CRC. 
1.1.2 Advances in therapies 
Surgery, chemotherapy and radiation therapy are common CRC treatment strategies that have 
been used to treat various solid cancers (1, 11). More recently, combined proteogenomic and 
meta-analysis are investigating CRC-associated genetic factors, proteins and neoantigens in 
order to discover new targets for CRC treatment (13-15). Cancer research has led to discoveries 
of novel drugs such as angiogenesis and epidermal growth factor-targeting agents (anti- 
vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) 
antibodies) for targeted therapy or checkpoint inhibitors (anti-programmed cell death protein 
1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies) for 
immunotherapy (1, 16, 17). Despite the advances being made, CRC still remains one of the 
deadliest cancers worldwide. Therefore, new generation treatment methods are necessary to 
decrease CRC cancer burden and mortality rates. 
1.1.3 Subtypes of CRC 
Colorectal cancer is a heterogeneous group of diseases at the biological, pathological and 
molecular level. Global classification systems based on cellular, molecular, pathological or 
genetic CRC profile have been introduced to facilitate the differentiation of the disease and find 
the most suitable treatment methods, depending on the cancer subtype. 
Anatomical subtypes of CRC can be defined by tumour site: left-sided (proximal), right-sided 
(distal) colon cancers and rectal cancers (5). Molecular characterisation confirmed that colon 
and rectal tumours are indistinguishable at the genomic level, however a higher frequency of 
hypermutated cancers originate from the right colon, compared to left colon and rectal tumours 
(13). In addition to the difference in molecular features, right-sided cancers can be more 
resistant to chemotherapy than left-sided tumours, are more common in females, have an 
increased immune infiltration and poor survival (11, 18). The reasons for these variations are 
not completely understood although it might be linked to differences in microbiota, pH and 





Colorectal cancer can be distinguished by genetic (microsatellite or chromosomal instability) or 
epigenetic (CpG island methylator phenotype) aberrations. Microsatellite instability (MSI) 
status is characterised by alterations in microsatellite regions due to impaired DNA mismatch 
repair in the cancerous cells (19). Cancers can show a high or low rate of MSI (MSI-H or MSI-L). 
Non-MSI cancers are categorised as microsatellite stable (MSS) cancers (5, 19). However, due 
to subtle differences, MSI-L and MSS are usually categorised into one group. MSI-H constitutes 
around 15% of all CRC and are more commonly right-sided tumours, with increased 
hypermutations, upregulated expression of immune checkpoint receptors, increased 
infiltration of CD8+ T cells and are correspondingly more susceptible to immunotherapeutic 
treatments than MSS cancers (20, 21). MSI status is often associated with alterations in 
mismatch repair (MMR) genes. MSI-H is linked to mutations and defects in these genes resulting 
in MMR deficiency (dMMR), while MSS or MSI-L have a MMR proficient (pMMR) genetic 
phenotype (22). Therefore, CRC is commonly classified into dMMR-MSI-H and pMMR-MSS (MSI-
L) genetic subtypes (23). This classification, while simplified, does have implications for 
responses to immunotherapeutic treatment (24). 
As a heterogeneous disease, CRC from different patients reacts differently to cancer treatment. 
There was a necessity to develop a new classification system to overcome inconsistencies to 
drug responses and facilitate therapeutic decisions. As a result of this, classification systems 
based on gene expression levels were merged and CRC was divided into four consensus 
molecular subtypes (CMS): CMS1 (MSI immune, 14%), CMS2 (canonical, 37%), CMS3 (metabolic, 
13%) and CMS4 (mesenchymal, 23%) (18). The remaining 13% of CRC have mixed characteristics 
and have transitional phenotypes and/or intratumoural heterogeneity. CMS1 cancers tend to 
be hypermutated, MSI-H, demonstrate strong immune activation, are mostly found in females, 
are left-sided and show poor survival after relapse. CMS2 are distinguished by having epithelial 
differentiation, left-sidedness, activated WNT and MYC pathways and good survival rates after 
relapse. CMS3 tumours also have epithelial differentiation but additionally have metabolic 
dysregulation and KRAS mutations. The final CMS4 signature is associated with TGFβ activation, 
stromal invasion and angiogenesis, which are more common to advanced stages of disease (18). 
Recently, the CMS classification system has been evaluated to determine if it can be used as a 
prognostic marker to predict chemotherapeutic outcomes of patients with metastatic disease. 
The results confirmed a correlation between the CMS subtype and therapy efficacy, supporting 





1.1.4 Tumour microenvironment and immune system 
The immune system is involved in an every step of carcinogenesis from initiation to tumour 
proliferation, angiogenesis and invasion (27). One popular model describes the 3Es model of 
cancer immunoediting: elimination, equilibrium and escape (Figure 1.1) (28). During the 
elimination stage, innate and adaptive immune cells detect and remove malignant cells (Figure 
1.1 A) (29). The equilibrium phase starts when the immune system can no longer eliminate 
tumour cells but stops further growth by establishing tumour-suppressive environment (Figure 
1.1 B). This stage can last for decades until the tumour cells acquire new mutations allowing 
them to overcome immune suppression and enter into the escape phase (Figure 1.1 C). In this 
step, the immune system is incapable of preventing malignant cells from growing and tumour 
cells start to proliferate uncontrollably (28). 
 
Figure 1.1 The three Es of cancer immunoediting. A) Elimination phase, immune cells are able 
to recognise and kill cancer cells. B) Equilibrium, immune cells cannot eliminate cancer cells 
but prevent from uncontrolled growing. C) Escape, cancer cells proliferate and grow 
uncontrollably. Figure adapted with permission from Dunn et al. (28)  
The immune system is closely connected to every step of tumour pathogenesis with immune 
function being regulated by secreted mediators (cytokines, chemokines, eicosanoids, 
prostaglandins, growth factors, reactive oxygen species or nitrogen intermediates) or direct cell-
to-cell interaction. These mediators and interactions can push cells towards a pro- or anti-
tumourigenic status (27, 29-31). The majority of immune cells (dendritic cells, T cells, regulatory 
T cells, macrophages) can have both pro- and anti-tumourigenic roles in cancer development 
and their roles often depends on interaction with other cells (immune, stromal or cancer cells) 
or inflammatory mediators produced in tumour microenvironment (TME) (27, 32). Cells, surface 
markers and other mediators that control and interfere in cancer pathogenesis, can be used as 






Mediators (immunostimulatory or immunosuppressive) released by myeloid and lymphoid cells 
in the TME can result in the development of pro- or anti-tumourigenic niches that may favour 
tumour growth, or the infiltration of cells of the immune system into established carcinomas. 
The infiltration of CD3+ and CD8+ cells around and into tumour tissues has been termed an 
‘Immunoscore’ and has been used to characterise CRC, predicting the risk of recurrence and 
possible disease outcomes (33). It was reported that the infiltration of CD3+ and CD8+ cells into 
colorectal carcinomas (high Immunoscore) is higher in hypermutated CRC tumours (subtype 
CMS1), which tend to have a higher neoantigen load than non-hypermutated tumours (18, 34). 
Neoantigens originate from somatic mutations in cancer cells and are specific to an individual 
patient. In addition to the composition of the immune infiltrates, immune signalling and 
mediator secretion by the cells are key influencers in promoting an anti-tumour immune 
response (32). The main cells involved in modulating immune responses in CRC are described 
below (Figure 1.2). 
 
Figure 1.2 Variety of cells involved in CRC pathogenesis. Red arrows indicate pro-tumourigenic 
responses. Green arrows indicate anti-tumourigenic responses. MDSC – myeloid-derived 
suppressor cells; CAF – cancer-associated fibroblasts; DC – dendritic cells; NK – natural killers; 
Treg – regulatory T cells 
Myeloid-derived suppressor cells (MDSC) are the major immune suppressor cells found in the 
TME. These cells are a heterogeneous population consisting of immature myeloid cells such as 
the progenitors of macrophages, granulocytes and dendritic cells (DC). Infiltration of MDSC into 
the TME is associated with poor overall survival and positively correlates with cancer 
progression (35). Inflammatory cytokines and modulators (IL-1β, IL-6 and prostaglandin E2 
(PGE2)) recruit MDSC to the tumour site and activate them throughout carcinogenesis. In 





of MDSC cells and delayed cancer development in the early stages of gliomagenesis (36). MDSC 
promote tumour development in multiple ways; they secrete chemokines that recruit 
immunosuppressive regulatory T cells (Treg) cells to the TME (37), they can induce metastasis 
and vascularisation by producing metallopeptidase 9 and TGFβ (38) and can supress effector T 
cells via production of arginase I (27). Generally, MDSC are highly suppressive cells with limited 
anti-tumorigenic properties. 
Cancer-associated fibroblasts (CAF) are abundant stromal cells in the tumour and are derived 
from activated normal fibroblasts, mesenchymal stem cells or epithelial cells that undergo 
epithelial-to-mesenchymal transition (39). This heterogeneous cell population promotes 
tumour growth in multiple ways by producing cytokines, chemokines, growth factors and other 
mediators (40). CAF support tumour-promoting inflammation via an IL-1β-dependent 
upregulation of NF-κB signalling (41). Moreover, CAF exclude CD8+ T cells from tumour via 
upregulated TGF-β signalling; boost tumour cell growth by expressing hepatocyte growth factor; 
induce extracellular matrix remodelling, metastasis and angiogenesis; recruit MDSC; activate 
STAT3 signalling and upregulate expression of checkpoint inhibitor PD-1 ligands; which all 
contribute to carcinogenesis (39, 42). However, despite the multiple tumour-promoting effects, 
some studies have shown that depletion of CAF leads to reduced survival in mice demonstrating 
tumour-inhibiting characteristics, which needs further investigation (40). 
Effector T lymphocytes are the main regulators of antigen-driven anti-tumour immunity. There 
are a few subtypes of tumour infiltrating T cells that are involved in cancer pathogenesis. One 
of the main cells involved in these processes are the cytotoxic T lymphocytes (CD8+ T cells). 
These cells support tumour elimination by inducing apoptosis of malignant cells and producing 
anti-tumourigenic cytokines (IFNγ) (43). CD8+ T cells recognise endogenous tumour antigens 
presented on MHC (major histocompatibility complex) class I receptors on cancer cells (44). 
Activated CD8+ T cells, after T-cell receptor (TCR)-MHC class I interaction, can directly lyse 
tumour cells and produce cytotoxic granzymes and perforin (43, 45). For these reasons, tumour-
specific CD8+ T cells are the most powerful tumour-eliminating cells. Immunoscore analysis has 
shown that the infiltration of these cells into colon tumours lower the risk of cancer recurrence 
(33).   
Another major effector T cell subtype, the CD4+ T lymphocytes, also have an important role in 
cancer immunity (43). Main roles of CD4+ T cells in anti-tumour activity include CD8+ T cell 





B cells (46, 47). CD4+ T cells support CD8+ T cell priming and activation by binding to CD40 
receptors on DC cells via CD40 ligand, which strengthens DC co-stimulatory responses. Upon 
interaction with DC, CD4+ T cells produce effector cytokines that recruit immune cells, including 
CD8+ T cells, and promote CD8+ T cell activation (46). If tumour cells express MHC class II 
receptors, CD4+ T cells can recognise malignant cells and induce direct tumour cell apoptosis by 
producing cytotoxic granules or binding death ligands on tumour cells. Moreover, CD4+ T cells 
facilitate humoural immune responses via interaction of CD40 ligand on CD4+ T cells through 
CD40 receptor on B cells, which drives B cell maturation and differentiation into plasma cells 
(47). CD4+ T cells are a heterogeneous cell population with a high level of cellular plasticity. This 
cell population generates immune responses by producing various cytokines and can be further 
categorised into T helper 1 (Th1), Th2, Th17 and Treg subtypes based on cytokine production 
(48). The Th1 subtype support anti-cancer immunity and maintenance of CD8+ T cells by 
producing various (e.g. IFN-γ, TNF) cytokines (49-51). Infiltration of these cells into colon 
tumours has been correlated with prolonged survival (48). In contrast, Taylor et al. reported a 
negative impact of IL-2-producing T cells in CRC patients suggesting that complex interactions 
between the cells in the TME results in different disease outcomes (51). Th2 cells are less 
effective in killing cancer cells, thus this favours tumour growth (49, 52). However, infiltration 
of Th2 cells into CRC was not associated with a poor prognosis (48). IL-17-producing T cells may 
be involved in disease progression (53). An increase in Th17 cells in CRC correlates with cancer 
progression and poor survival, but was not associated with disease recurrence (48, 51). Effector 
T cells are often exhausted in the TME due to persistent antigen presentation, impaired DC 
interactions and upregulated expression of checkpoint inhibitors (31, 32, 54). These exhausted 
cells lose their effector functions, even if they have potential to eliminate cancer cells. 
FOXP3+ Treg cells are immunosuppressive cells that promote carcinogenesis in various solid 
tumours (55). However, there is conflicting data regarding this in CRC. In some studies, Treg 
cells have been associated with an improved survival and relapse-free survival (56, 57), while 
other studies report Treg cell infiltration as an indicator of poor CRC prognosis in cancer patients 
(55). The beneficial effects of Treg cells have been suggested to be due to Treg cells reducing 
chronic inflammation in the TME, which would suppress pro-tumourigenic inflammatory 
immune responses mediated by Th17 cells (58). The connection between inflammation and 
tumourigenesis has been broadly investigated at all stages of cancer development and the 
findings demonstrate that inflammation has multiple roles in supporting cancer initiation and 





inhibitors on Treg cells (60). Moreover, increased expression of immunosuppressive cytokines 
(IL-10, TGFβ) and PGE2 by Treg cells supports tumour growth (60, 61). 
Tumour-associated macrophages (TAM) are the most abundant myeloid cells in the TME (62, 
63). These cells are responsible for inflammation at the tumour site. TAM originate from several 
different types of circulating precursors that accumulate in tumour tissues (62). TAM are a 
heterogeneous cell population with many different intermediates between pro-tumourigenic 
and anti-tumourigenic cell polarisation (62). TAM polarisation in the TME depends on several 
factors including the origin of the cells, immune signalling and the stage of tumour progression. 
The tumour killing phenotype of TAM is characterised by expression of anti-tumourigenic INFγ 
or TNF cytokines, while other macrophages secrete tumour promoting cytokines (IL-10, TGFβ), 
supress effector T cells and activate Treg cells (63, 64). Besides that, TAM express multiple 
mediators that are inducers of epithelial-mesenchymal transition, angiogenesis, tissue 
remodelling and metastasis (62). TAM infiltration into the majority of solid tumours is 
associated with a poor prognosis, however macrophage infiltration into CRC tumours has been 
also associated with good survival (65, 66). The reason, why TAM in CRC are anti-tumourigenic 
in contrast to other solid tumours, remains unclear. 
The number of neutrophils in blood increases during the development of various cancers. 
Triggered by mediators released by tumours, neutrophils migrate from bone marrow to blood 
and/or accumulate at the tumour site and differentiate into tumour-associated neutrophils 
(TAN) (67, 68). The neutrophil/lymphocyte ratio in the peripheral blood of CRC patients can be 
used as a predictive marker for disease outcomes where high numbers of neutrophils has been 
associated with a poor prognosis (69, 70). Cytokines such as TGFβ and IFNγ activate neutrophils 
and shift the cell profile towards to pro or anti-tumourigenic status (68). The tumour 
suppressive properties include direct killing of tumour cells and metastatic inhibition, while the 
tumour promoting profile supports an angiogenic switch, stimulates increased motility, invasion 
and migration of tumour cells, reduces T cell proliferation and IFNγ production. The location of 
TAN cells in TME is also critical in regulating immune responses as it was shown that 
intratumoural TAN indicate a shift to pro-tumourigenic status and worse survival compare to 
peritumoural or stromal infiltration of neutrophils (67). In addition, Amicarella et al. 
demonstrated that tumour infiltration by IL-17+ cells positively correlated with neutrophil 
recruitment and activation in tumour tissues of CRC patients suggesting an association between 





Natural killer (NK) cells effectively eliminate cancer cells by inducing granzyme B and perforin-
dependent direct cell lysis. NK cells recognise tumour cells that lack MHC class I, which is 
common for malignant cells (72). Additionally, NK cells modulate immune responses via 
cytokine and chemokine production, activate DC and produce IFNγ and TNF (73). The 
functionality of these cells depends on the cytokine profile in the TME, with IL-2, IL-12, IL-15 
and IL-18 cytokines being crucial for NK cell activation (72, 73). Intratumoural infiltration of NK 
cells correlates with good survival in CRC patients (74). However, in general NK cell infiltration 
is very low or absent in CRC tumours despite the fact that the tumour cells are MHC class I-
deficient, this could be due to lack of other mediators that are necessary to recruit NK cells (75). 
Dendritic cells are professional antigen presenting cells (APC). These cells can be found in blood, 
lymphoid tissues, skin, gastrointestinal tract (intestinal DC) or other tissues. DC present 
captured exogenous antigens (on MHC class II molecules),  as well as endogenous antigen (on 
MHC class I) to naïve CD4+ and CD8+ T cells, and initiate anti-tumour immune responses. The 
number of DC in peripheral blood decreases as CRC progresses as these cells migrate to the 
tumour site (76). CRC prognosis has been correlated with the maturation status and location of 
the cells, rather than the total number of the tumour infiltrating DC (77, 78). High numbers of 
DC infiltrating into the CRC intraepithelial compartment positively correlate with good survival, 
while stromal infiltration predicts worse disease outcomes (77). Mature DC are 
immunostimulatory and activate naïve T cells while immature DC support CRC development by 
promoting Treg differentiation (79). In addition, the expression of immune checkpoint receptors 
on DC increases during cancer progression, which further supresses tumour-infiltrating T cell 
(80). 
The role of tumour-associated B cells and humoral immune response in cancer pathogenesis 
have been broadly investigated over the last decades (81). It was found that B cells comprise a 
significant part of immune infiltrates into tumours and contribute to CRC disease outcomes (82). 
Berntsson et al. have reported that an infiltration of B cells and plasma cells lower the risk of 
CRC recurrence, however another study implied that B cell depletion promotes CRC suppression 
(81, 83). Infiltration of plasma cells into oesophageal and gastric cancers has been associated 
with higher overall survival rates, but in ovarian cancer it has been associated with a poor 
prognosis (84, 85). Furthermore, the depletion of B cells enhances growth of hepatocellular 
carcinoma (86). These contradicting results implies multiple roles for B cells in tumour biology. 
The different outcomes may be due to population heterogeneity and, possibly, other factors 





increased number of plasma cells and differentiated memory B cells in peripheral blood and 
tumour tissues while regulatory B cells predominate in metastasis of CRC patients (82). 
Increased numbers of plasma cells and memory B cells might also contribute to cancer 
immunosurveillance and optimal T cell responses (82, 86). However, antibodies produced by 
the plasma cells can trigger chronic inflammation and tissue degradation while regulatory B cells 
induce MDSC activity, which favours tumour progression (81, 87). 
In summary, immune cells have the potential to eliminate cancer cells but are often not present 
and or are not functional in the TME. 
1.2 Cancer immunotherapies 
In the late 19th century, it was discovered that cancer patients could develop spontaneous 
remission after a bacterial skin infection. Inspired by these observations, surgeon William Coley, 
now known as a father of immunotherapy, examined cancer regression following intratumoural 
bacterial injections. The bacterial injections stimulated immune responses against cancer cells 
and reduced tumour size or led to recovery (88). This research launched a new research field 
and a new method for cancer treatment – cancer immunotherapy. However, the first 
immunotherapies were highly dangerous, causing serious adverse effects and had low efficacy. 
Due to these reasons other treatments methods were preferred for many years.  
Over the past century, understanding of the immune system and cancer immunity has 
increased, reigniting interest in cancer immunotherapies. The role of the immune system in the 
suppression of cancer development was investigated and the immune surveillance hypothesis 
was proposed by Thomas and Burnet in the late 1950s (89). In the following decades, intensive 
and groundbreaking research into the immune system contributed to the development of 
cancer immunotherapies. By the end of the 20th century the first cancer cytokine- and bacteria-
based immunotherapies were approved (90). In 2010, the US FDA approved the first therapeutic 
cancer vaccine sipuleucel-T (based on autologous DC therapy), for the treatment of prostate 
cancer (91). The discovery of the checkpoint inhibitors PD-1 and CTLA-4 in the late 20th century 
accelerated the development of immunotherapeutic strategies based on checkpoint inhibition 
and in the last decade multiple active immunotherapies were approved for the treatment of a 
range of cancers (92). The significance of immunotherapies was marked in 2018 when two 
cancer immunologists, Tasuku Honjo and James P Allison, received the Nobel Prize in Physiology 





These scientific achievements have made immunotherapies one of four main cancer treatment 
methods together with surgery, chemotherapy and radiation therapy. 
1.2.1 Principles and challenges of cancer immunotherapies 
Cancer immunotherapies are treatment methods that either use components of the immune 
system to eliminate cancer cells or re-establish the immune system’s natural ability to kill cancer 
cells (93). With cancer, natural immunosurveillance is impaired due to factors such as the 
expression of immunosuppressive mediators on tumour cells or in the TME or a lack of 
successful recognition of malignant cell antigens (23, 28, 32). This means that while the immune 
system has the potential to fight malignant cells, it remains inactive in most cancer patients. 
Cancer immunotherapies are designed to reverse immunosuppression and to activate the 
patient’s immune system to kill malignant cells.  
The idea of using the natural immune system’s ability to cure cancer is very appealing. However, 
immunotherapies face many challenges as cancer cells use a number of strategies to avoid the 
immune system including overexpression of suppressive mediators and receptors, 
accumulation of immune suppressive cells and immune escape due to high mutational rates 
(54, 94). Cancer can be caused by different factors, therefore genetic, molecular and 
immunological profiles of cancer are variable even among the same type of cancer patients. 
Clinical outcomes are therefore often inconsistent with immunotherapies being effective in 
some patients while having no or minimal benefit for others (95, 96). Correlations between 
immunological or genetic cancer profiles and responses to immunotherapies have revealed that 
mutational load and tumour immunogenicity are major factors that impact the effectiveness of 
cancer immunotherapy (26, 33). As a consequence of these findings, the US FDA recently 
approved the first cancer treatment based on the genetic features of the cancer, rather than 
the organ-specific tumour type (95, 97). 
Identifying appropriate targets for cancer immunotherapy is another important factor for 
successful therapeutic outcomes (98). Many immunotherapies have been developed to re-
shape immunity by targeting components such as tumour antigen expression, checkpoint 
inhibition, surface receptor expression, cytokine expression, the TME and various immune cells 
(32, 93). Combination immunotherapies, that target multiple immunosuppressive factors while 
also stimulating effector responses, are being widely used in cancer treatment (93, 99). The 
success of these approaches in human therapy depends highly on the ability to stimulate and 





1.2.2 Immunotherapies for CRC treatment 
After surgical resection, 45% of CRC patients develop recurrent disease within 5 years, often 
resulting in death caused by distant metastasis (100). Therefore, long-lasting durable remission 
achieved by immunotherapy would be appealing for CRC treatment. Numerous 
immunotherapies for CRC treatment are under development with over 150 immunotherapy-
based clinical trials currently active (101). The most successful therapeutic outcomes have been 
achieved with immunotherapeutic treatment of the dMMR-MSI-H subtype of CRC (24). These 
tumours usually have a high mutational load and a high prevalence of immune cell infiltrates, 
therefore the re-activation of the immune system is facilitated by the presence of immune cells 
in tumours (Figure 1.3) (13, 23, 33). In 2017, the US FDA approved the first immunotherapeutic 
treatment (checkpoint inhibition immunotherapy) for dMMR-MSI-H CRC and, so far, it is only 
one approved immunotherapy for CRC (95, 97, 102, 103). However, dMMR-MSI-H CRC tumours 
comprise only around 15% of all CRC tumours, while the majority (85%) are pMMR-MSI-L 
characterised by low tumour immune infiltrates and low mutational burden (23, 33). 
Immunotherapeutic treatments of this CRC subtype have not yet been successful (24, 104). 
Without an effective immunotherapy to treat both dMMR-MSI-H and pMMR-MSI-L subtypes of 
CRC, few CRC patients benefit from cancer immunotherapy. Therefore, new techniques are 
necessary to achieve durable immune responses in CRC patients. The main immunotherapy 
strategies that are being developed and tested for CRC treatment are described below. 
 
 
Figure 1.3 TME in mismatch-repair-deficient with high levels of microsatellite instability 
(dMMR-MSI-H) and mismatch-repair-proficient with low levels of microsatellite instability 
(pMMR-MSI-L) CRC. dMMR-MSI-H CRC have high mutational burden and high levels of 
immune infiltrates. Immune cells are suppressed by checkpoint receptors in these tumours. 
pMMR-MSI-L have low mutational burden and low Immunoscore. Figure taken and adapted 





1.2.2.1 Checkpoint inhibition 
Checkpoint inhibition is one of the leading immunotherapeutic strategies used to successfully 
treat various types of cancer. Immune checkpoints are the major regulators of both self-
tolerance and of effector immune responses (23). Checkpoint receptors are often 
overexpressed in the TME and act as the main mediators of tumour immunosuppression (54, 
105). Therefore, immunotherapeutic agents used in cancer therapy prevent 
immunosuppressive signalling by inhibiting checkpoint receptors expressed on immune or 
tumour cells. Many of these agents are under investigation in clinical trials or are already 
approved for use in CRC cancer therapy (Figure 1.4) (23). Recent findings from clinical trials 
where checkpoint inhibitors demonstrated effective therapeutic outcomes in dMMR-MSI-H 
CRC patients, have led to approvals for their use in the treatment of dMMR-MSI-H CRC (95, 
106). In 2017, Pembrolizumab (PD-1 checkpoint inhibitor) was approved by the US FDA for the 
treatment of any dMMR or MSI-H solid tumours (97). In the same year, the US FDA granted 
accelerated approval for dMMR or MSI-H metastatic CRC treatment using Nivolumab (PD-1 
checkpoint inhibitor) and Ipilimumab (CTLA-4 checkpoint inhibitor) (102, 103). In 2018, the US 
FDA approved combination Nivolumab and Ipilimumab therapy for dMMR or MSI-H CRC 
treatment (92). Finally, in 2020, Pembrolizumab was approved as the first-line immunotherapy 
for patients with dMMR or MSI-H CRC (17). 
 
Figure 1.4 Targets and drugs approved by the US FDA for CRC checkpoint inhibition therapy 
The main targets for checkpoint inhibition are T cells. T cells express multiple surface receptors 
that can induce or suppress their activity after interaction with their ligands (Figure 1.4) (23, 
105). Usually, the TME has an immunosuppressive profile with elevated expression of inhibitory 





T cells and tumour cells or APC. Thus, T cells remain active and preserve their ability to kill cancer 
cells. Since the immunotherapeutic agents target T cells, the presence of T cells in the TME is 
crucial for successful therapy.  For this reason, checkpoint inhibition immunotherapy was most 
successful in treatment of dMMR-MSI-H cancer, as these cancers commonly have immune cell 
infiltration and overexpressed checkpoint receptors, while the same immunotherapy had little 
or no effect in pMMR-MSI-L treatment (24). 
1.2.2.2 Cell-based immunotherapy 
Cell-based therapies utilise the patient’s own cells (monocytes, DC or T cells) for cancer 
treatment. The therapy involves collection of the immune cells (from tumour, lymph nodes or 
peripheral blood), which are then activated or genetically engineered in the laboratory to 
recognise tumour-associated antigens on malignant cells. These cells are expanded and 
reinfused back to a patient, where they stimulate T cells or directly kill tumour cells (93, 99, 
107). 
Provenge (sipuleucel-T), the first FDA-approved therapeutic cancer vaccine for prostate cancer 
treatment, is a cell-based vaccine that was approved in 2010, after the vaccine improved the 
median survival of the patients by 4.1 months (91). The vaccine is composed of activated 
peripheral blood mononuclear cells loaded with tumour antigen. However, this therapy has not 
been widely adopted due to issues relating to cost of therapy (US$100 000 paid up front), 
complexity and efficacy (108). Currently there are no APC-cell based immunotherapies 
approved for CRC treatment. However, clinical trials of DC-based vaccines to treat advanced 
metastatic CRC demonstrated promising results where the vaccines prolonged disease-free 
survival and overall survival (109, 110). However, the immunosuppressive nature of the CRC 
TME remains a major barrier to successful APC-cell based immunotherapy (111).  
Adoptive T cell therapy is another cell-based immunotherapy that utilises natural or genetically 
engineered T cells. Activated T cells express TCR that recognise tumour antigens, while 
genetically engineered T cells are designed to recognise malignant cells via a chimeric antigen 
receptor (CAR) (23, 107). T cells are transduced with a CAR, which results in large numbers of 
cells able to specifically target cancer cell-specific epitopes (107). CAR-T cell therapy had good 
success in the treatment of B cell malignancies and gained US FDA approval in 2017 (92, 112, 
113). CAR-T cell immunotherapies for solid tumour treatment are under investigation in a 
number of clinical trials (NCT03182816, NCT02873390, NCT03179007), however there are again 





CAR-T cell therapy led to regression of metastasis and stable disease in some of the patients. 
However, dose limiting toxicity was observed as the treatment induced severe transient 
inflammatory colitis (114, 115). Beside off target toxicity, another limiting factor of CAR-T cell 
therapy includes the lack of immune memory. In addition, ex vivo expansion and genetic 
engineering are complex and costly processes, which requires trained personnel and specialised 
facilities (93). 
1.2.2.3 Bispecific antibody therapy 
Bispecific antibodies are artificial engineered antibodies that can bind two different antigens. 
For cancer immunotherapy, bispecific antibodies facilitate engagement between cancer and 
immune cells. A bispecific antibody, carcinoembryonic antigen T cell bispecific (CEA-TCB), has 
been engineered to bind to the CEA antigen on cancer cells and CD3 on T cells. This double 
interaction triggered T cells to kill cells that express CEA tumour antigen. The sensitivity of CEA-
TCB has been tested and confirmed on patient-derived CRC organoids in in vitro studies (116). 
The therapeutic effect of CEA-TCB was observed in solid tumours in Phase I clinical trials (117). 
The antibody is currently being investigated in two clinical trials, where patients with solid 
tumours are given CEA-TCB monotherapy (NCT02324257) or in combination with atezolizumab 
(NCT02650713).  
1.2.2.4 Combination immunotherapies 
Monotherapies are often insufficient to eradicate large tumours due to the immunosuppressive 
TME. Therefore, combined immunotherapies are becoming increasingly common for cancer 
treatment (23). Various combination therapies have been used in clinical trials for CRC 
treatment. A combination immunotherapy, recently approved by the US FDA, is dual 
immunotherapy with PD-1 and CTLA-4 checkpoint inhibitors (102). Combination therapies 
improve positive therapeutic outcomes by simultaneously boosting anti-tumour immune 
responses in multiple ways. This is especially important for the treatment of pMMR-MSI-L 
subtypes of CRC, which usually do not respond to monotherapy (24). Checkpoint inhibitors were 
also combined with cytokine therapy (NCT03228667, NCT03256344, NCT02777710, 
NCT03168139), which altered the TME and improved checkpoint inhibitor therapy. Multiple 
different combination therapies for CRC treatment are under investigation in clinical trials.  
Immunotherapies have also been combined with traditional chemotherapy, targeted biological 





targeted by T cells (93). Combination immunotherapy with radiation and chemotherapy showed 
clinical activity in CRC with low toxicity, however benefits of the therapy have to be estimated 
(118, 119). Other CRC immunotherapies combine checkpoint inhibition with EGRF- or VEGF-
inhibitors (NCT03174405, NCT02856425), or targeted signalling pathway therapies, for example 
mitogen-activated protein kinase inhibitors (NCT02788279, NCT03374254, NCT03428126). 
These clinical trials are still ongoing, however, primary results demonstrate low toxicity. 
Another combined therapy targets the inflammatory TME in early CRC patients (NCT03026140). 
In this clinical trial checkpoint inhibition is combined with a nonsteroidal anti-inflammatory drug 
(NSAID) that inhibits COX2 signalling. Previous research has shown that NSAID can act as 
chemopreventive agents reducing CRC incidence (120). 
1.3 Therapeutic vaccines for CRC treatment 
Cancer vaccines can be either prophylactic or therapeutic. While prophylactic vaccines prevent 
diseases, therapeutic vaccines are designed to treat disease. Similar to other immunotherapies, 
therapeutic cancer vaccines aim to reactivate or reinvigorate the immune system to recognise 
and eradicate tumours. Therapeutic vaccines mainly aim to induce tumour-specific CD8+ T cell-
regulated immunity (121). This is an attractive method for tumour treatment as effective cancer 
vaccines would be able to induce durable and long-lasting immunity that could eliminate micro-
metastases and prevent disease recurrence, which is a frequent cause of cancer death. For 
these reasons, a wide range of cancer vaccines (whole cell, vector, subunit) have been 
extensively investigated. However, few therapeutic cancer vaccines have been approved for 
cancer treatment (122). The Bacillus Calmette-Guérin (BCG) vaccine, a live attenuated strain of 
M. bovis, was the first cancer vaccine approved in 1970s for the treatment of bladder cancer. 
Sipuleucel-T, as discussed above, was approved in 2010 for the treatment of metastatic 
castration-resistant prostate cancer (91). Oncolytic viral therapy (T-VEC) for the treatment of 
advanced melanoma was the latest therapeutic cancer vaccine approved by the the US FDA in 
2015 (123). Many vaccine candidates failed to complete clinical trials, mostly due to lack of 
improved overall survival (121). Currently, more than one hundred cancer vaccines are 
undergoing clinical trials for the treatment of CRC, however, none have yet been approved 
(101). 
To build effective anti-tumour immunity, vaccines are designed to activate tumour-specific T 
cells that can recognise and kill tumour antigen-expressing malignant cells (Figure 1.5). The first 





important of which are the DC (124). Tumour antigens can be presented to DC either in vitro or 
in vivo in various forms including synthetic peptides, tumour lysates, nucleic acids, recombinant 
proteins or in bacteria or viral vectors (Figure 1.5). DC can be loaded with tumour antigens and 
activated exogenously when APC are extracted from patient’s blood or tissues, or in situ in the 
cancer patients (111, 124). DC take up or are transduced with tumour antigens, then process 
and present them to T cells. Effective DC maturation and activation is crucial for initiating 
effector tumour antigen-specific T cell responses (125). During antigen presentation, activated 
DC stimulate T cells via the production of stimulatory cytokine and directly via costimulatory 
receptors such as CD80 or CD86. Immature DC may induce tolerance against tumour antigens 
leading to T cell deletion and inability to reject tumours (79, 124, 126). Therefore, DC activating, 
immunostimulatory, molecules are an essential component of therapeutic cancer vaccines.  
In the next step, APC induce T cell priming and promote activation and expansion of effector T 
cells in lymphoid organs. Stimulation of other immune cells at this stage is also important for 
the generation of robust anti-tumour immunity. Effector CD4+ T cells promote CD8+ T cell-
mediated immunity via production of immunostimulatory cytokines (50, 127-129). In the final 
step, tumour-specific effector T cells enter tumour tissues, recognise and kill malignant cells 
(124), while mature B cells generate humoral anti-tumour immunity against tumour antigens. 
At this stage, an immunosuppressive TME can limit effector function of the immune cells and 
because of this, many vaccine candidates fail to induce long-lasting anti-tumour responses and 
successfully eliminate tumours. A number of methods have been introduced in therapeutic 
vaccines to overcome these challenges, which will be discussed below. Another benefit of an 
effective therapeutic cancer vaccine is the ability to induce immune memory against tumour 
antigens. Tumour antigen-specific memory T cells generate durable and long-lasting immunity 
against tumour recurrence by preventing tumour re-growth and eliminating micro-metastasis 
in distant parts of human body, which are usually undetectable and often causes disease 
recurrence. Therefore, an effective therapeutic cancer vaccines should be able not only resolve 






Figure 1.5 The scheme of therapeutic cancer vaccine-induced anti-tumour immunity. DC cells 
are activated with tumour antigens derived from nucleic acids, synthetic peptides, cancer cells 
or viral/bacterial vectors. DC cell present tumour antigens to immune cells. Effector immune 
cells generate cellular and humoral anti-tumour immune responses. Figure taken with 
permission from Maeng et al. (121)  
1.3.1 Challenges of therapeutic vaccination 
Multiple clinical trials have shown that cancer vaccines are well tolerated and safe, but they are 
not always able to demonstrate clinical benefit (130, 131). This suggests there still are a few 
major challenges remaining for therapeutic cancer vaccines to overcome.  
The vaccines activate CD8+ T cells. As previously mentioned, CD8+ T are activated by the 
presentation of endogenous tumour cell antigens on MHC class I receptors by activated APC. 
However, antigens delivered in cancer vaccine are exogenous antigens, which should normally 
be presented on the MHC class II receptors. Cross-presentation is a process that enables APC to 
process and present tumour antigens on MHC class I receptors leading to CD8+ T cell activation 
(132). This is crucial for effective anti-tumour immunity generated by CD8+ T cells. 
Tumour cells are highly susceptible to mutations, which can lead to neoantigens (new tumour 
epitopes). Effector cells can recognise the new or mutated tumour antigens and eliminate the 





and are therefore not highly immunogenic, meaning that the tumour cells can not be killed by 
the immune system (23). If tumour antigens are present, they are often not able to induce long-
lasting and durable immune responses (126, 133). This is because tumour antigens originate 
from mutation of self-antigens, thus due to self-tolerance mechanisms they only inefficiently 
stimulate immune cells. 
In addition, as previously discussed, the TME is generally immunosuppressive. There are 
multiple immunosuppressive cells and mediators in the TME, which prevent tumour antigen-
specific T cells from eliminating cancer cells (32). Combination therapies have been used to 
overcome this challenge by targeting immune system in multiple ways (Section 1.2.2.4). 
Furthermore, therapeutic cancer vaccination is based on the activation of patients’ immune 
system, therefore, it requires immunocompetent cancer patients. This might be incompatible 
with other treatment methods such as chemotherapy, which has a major side effect of killing 
rapidly dividing haemopoietic cells (134). Finally, even if the patient does succeed in developing 
an effective anti-tumour response,  ongoing mutations in rapidly dividing tumour cells can lead 
to altered tumour epitopes meaning that subsets of tumour cells can escape the immune 
system (133).  
Development of therapeutic cancer vaccines and an overall treatment strategy have to be 
adapted to overcome these challenges in order to achieve positive therapeutic outcomes (134). 
Monotherapy with therapeutic vaccination should be used only for the treatment of highly 
mutated (dMMR-MSI-H) tumours with multiple immunogenic epitopes. In addition, therapeutic 
immunisation prior to chemotherapy is preferable to avoid lost efficiency due to a compromised 
immune system. Combined therapy is more suitable for the treatment of cancers that have a 
low mutation burden. Alternatively, treatment should be initiated when tumours are small 
(135).  Combination therapy with checkpoint inhibition immunotherapy, chemotherapy, 
radiation therapy or other immunotherapies is the most reasonable for the treatment of 
advanced cancer (136, 137).  
The composition of the therapeutic vaccine plays a major role in the therapeutic outcomes. 
Appropriate and effective immunostimulatory adjuvants should be used to guarantee sufficient 
DC stimulation and T cell priming (138). Vaccine delivery techniques and routes should be 
adapted to maximise access to immune cells (139). Immunogenic tumour-specific antigens are 





of effector T cells against different tumour antigens, which improves recognition of malignant 
cells (140). Moreover, having multiple targets minimises the possibility that anti-tumour T cells 
will lose the ability to identify tumour cells due to somatic mutations. Overall, these strategies 
maximise effectiveness of therapeutic cancer vaccines. 
1.3.2 Types of therapeutic cancer vaccines 
Therapeutic cancer vaccines can be distinguished based on source of antigen; these are cell-
based, bacterial/viral vector-based, nucleic acid-based and peptide-based vaccines (121, 131, 
141). 
1.3.2.1 Cell-based vaccines 
Cell-based vaccines include both tumour cell vaccines and those that utilise autologous DC that 
are pulsed with tumour antigens and reinfused back to patient. Whole tumour cell vaccines 
involve cancer patients being immunised with autologous or allogeneic tumour cell lysates or 
inactivated whole tumour cells (141, 142). Lysing the tumour cells releases intracellular tumour 
antigens, which are usually hidden, and stimulates CD4+ and CD8+ T cell immune responses 
against multiple epitopes (141).  A 2001 study in advanced colon cancer reported that an 
allogeneic tumour cell vaccine was able to induce specific immune responses and was 
correlated with improved overall survival (143). Tumour cell lysates and inactivated tumour cell 
vaccines are relatively easy to prepare, although they do require some way of sourcing tumour 
cells, and are therefore applicable for a broad usage. However, these vaccines in general 
demonstrate poor clinical efficacy.  This may be due to failure of the vaccines to be taken up by 
and to activate APC in the patient and/or due to self-antigens present in the lysate or on the 
cells inducing self-tolerance or rejection in the case of allogeneic cells (137). 
DC vaccines are prepared by removing peripheral blood mononuclear cells from patient’s blood, 
then pulsing them with tumour antigens along with agents that induce DC activation, 
maturation and expansion, for example granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IL-4, TNF or IFNα (91, 109, 110). The expanded, activated, tumour antigen-pulsed DC 
cells are injected back to the patient where they can activate tumour antigen-specific CD4+ and 
CD8+ T cells. This immunotherapy is expensive, as it requires special equipment, trained 





1.3.2.2 Bacteria, virus and gene vaccines 
Oncolytic viruses and bacteria are also used as therapeutic cancer vaccines. These viruses and 
bacteria preferentially infect and kill tumour cells. Tumour cell death releases virus and bacteria, 
which further spreads at the tumour location. Additionally, tumour antigens, virus or bacteria 
antigens and immunostimulatory mediators are released due to oncolysis, which further 
stimulates immune system infiltration and elimination of cancer cells (141). Two out of three 
licensed cancer vaccines are based on virus and bacteria-based vaccines (T-VEC and BCG 
vaccines, respectively) (122, 123), showing that these vaccines are an effective strategy for 
cancer treatment. However, these are ‘live’ vaccines that can infect healthy tissues and organs 
leading to systemic inflammation. Therefore, there can be safety concerns regarding their use 
in cancer patients. 
Tumour-antigen encoding RNA and DNA gene vaccines have been developed for cancer therapy 
(141). These vaccines rely on transfection of DC with the genetic material and subsequent 
translation of tumour-associated antigens (TAA) and activation of T cells. Poor immunogenicity 
and stability limits the use of these vaccines. However, these vaccines are easy to make (as long 
as tumour antigens have been identified) and offer a safe method of vaccination that does not 
use infectious organisms. Adjuvants can be included or combination approaches utilised in 
order to increase the likelihood of stimulating effective immune responses (121). Personalised 
RNA vaccines have been reported to have induced tumour-antigen specific T cell infiltration and 
killing of tumour cells upon injection into the lymph nodes of melanoma patients (22). A limited 
number of vaccine candidates have been tested in clinical trials in combination with autologous 
DC vaccine therapy (NCT00197522, NCT00004604). 
1.3.2.3 Peptide vaccines 
Peptide vaccines contain tumour specific CD8+ and CD4+ T cell epitopes that activate recognition 
and immunity against tumour cells. Compared to the whole cell lysates or protein cancer 
vaccines, the use of specific peptides reduces the risk of autoimmunity or self-tolerance. 
Peptide vaccines can contain single or multiple CD8+ and CD4+ T cell epitopes and focus immune 
responses against tumour antigens (137). Peptide vaccines usually demonstrate good safety 
profiles (140, 144, 145). This immunotherapeutic strategy is also relatively cheap and more 
suitable for mass production compared to other immunotherapy methods. However, no 
therapeutic peptide vaccines have been approved for clinical usage as many vaccine candidates 





Wilms tumour 1 protein approved by the US FDA in 2017 for the treatment of myelodysplastic 
syndrome, that can develop into acute myeloid leukaemia (146). Currently there are around 
one hundred active clinical trials of peptide vaccines for cancer treatment, a few of them are 
peptide vaccines for the treatment of CRC. Therapeutic vaccines are usually combined with 
surgery (NCT03871790), checkpoint inhibition (NCT04117087, NCT02600949) or multiple 
therapies (NCT03761914, NCT03689192). 
Tumour peptides can be delivered in two forms, short peptides (< 15 amino acids) and long 
peptides (15-40 amino acids) (137). Short peptides do not need to be taken up and processed 
by APC, and can bind directly to MHC receptors. However, without proper co-stimulation they 
may induce tolerance and T cell dysfunction or lead to off-target toxicity by binding to MHC of 
non-professional APC (147, 148). Moreover, short peptides often stimulate only CD8+ T cells 
with lack of CD4+ stimulation leading to impaired CD8+ T cell-mediated anti-tumour immunity 
(50, 149). Therefore, long peptides are preferred and are more commonly used (145, 148, 150). 
Long peptides need to be processed by APC, can contain multiple epitopes and induce balanced 
stimulation of both CD8+ and CD4+ T cells. Additionally, they may induce humoral responses 
(151). Therefore, long peptides containing both CD8+ and CD4+ stimulatory epitopes are the 
most suitable for effective peptide vaccines. 
Tumour antigens can be broadly categorised into two groups, TAA and neoantigens. TAA are 
commonly overexpressed in tumours due to impaired cellular regulation but can also be found 
on some healthy tissues. Neoantigens are tumour specific, unique to an individual’s tumour and 
are used in personalised treatment (136). TAA, because they are a self-antigen, are usually not 
highly immunogenic and vaccines may fail to generate clinical responses (130). Common TAA 
include CEA, p53, EGFR and others (94, 133, 145, 152). However, these vaccines are cheaper 
and convenient for mass production. In contrast to TAA, neoantigens are not expressed in 
healthy cells and are more immunogenic. The use of neoantigens in a cancer therapy has 
expanded recently, as genome sequencing and methods to detect mutations have become 
more widely available. While these antigens are more immunogenic, these vaccines are more 
expensive than TAA vaccines due to the requirement for genetic analysis, and are therefore less 
suitable for a mass production. Neoantigen-based personalised vaccines recently demonstrated 
good clinical outcomes for the treatment of melanoma (22, 140). 
However, the majority of peptide vaccine candidates fail to improve clinical outcomes. The 





immunogenicity are the main factors suggested to influence the clinical effectiveness of 
therapeutic peptide vaccines. A number of strategies can be adopted to overcome these 
limitations and to boost clinical effectiveness of peptide cancer vaccines (134).  
Combination therapies are used to overcome the immunosuppressive TME and eradicate large 
tumours. While radiotherapy or chemotherapy can benefit therapeutic treatment by inducing 
death of cancer cells, some can also compromise the immune system. Thus, the likely impact of 
chemotherapy on the immune system needs to be considered and the combination treatment 
regimen designed to optimise the chance of inducing anti-tumour immunity (137). Combination 
therapy with checkpoint inhibition is another strategy that can be used in order to diminish the 
immunosuppressive TME. This combined immunotherapeutic strategy aims to block 
suppressive signalling through checkpoint receptors while effector T cells infiltrate and 
eliminate malignant cells. A few studies have shown good clinical outcomes from combination 
immunotherapy in preclinical and clinical studies (140, 153). Checkpoint blockade enhanced T 
cell mediated anti-tumour immunity by inhibiting PD-1 or CTLA-4 mediated immunosuppression 
in progressively growing sarcomas in mouse studies (154). Gubin et al. showed that tumour-
specific T cells are reactivated upon checkpoint inhibition therapy, suggesting that the 
combined therapy may be suitable for eradication of large tumours. Data from human therapy 
is consistent with these results as it has been confirmed that tumour-specific T cells are 
reactivated after anti-CTLA-4 treatment in melanoma patients (155). 
1.3.3 Vaccine adjuvants 
Peptide vaccines require additional immunostimulatory agents to effectively activate the 
immune system (156). Moreover, peptide vaccines have to induce robust anti-tumour immune 
responses to make it possible to overcome tumour immunosuppressive mechanisms. 
Therefore, immunostimulatory agents called adjuvants are crucial vaccine components (138). 
Multiple novel and generic adjuvants have been developed over many years of vaccine 
research. 
Macrophages, B cells, but primarily DC, are professional APC that initiate anti-tumour immunity 
by priming T cells, which leads to expansion of tumour-specific T cell populations (138). Efficient 
delivery of tumour peptide to APC and antigen uptake are necessary to initiate antigen 
presentation. Tumour antigens are processed and loaded on MHC class I and II receptors on 
APC cells for presentation to T cells. This process must be supported by co-stimulatory signals 





which facilitates T cell priming and production of inflammatory cytokines (IFNγ, IL-2) (76). 
Insufficient co-stimulation upon antigen presentation can result in tolerance and T cell anergy 
(79, 126, 148). Only fully matured and activated DC express high levels of co-stimulatory 
receptors, therefore DC activation predetermines the overall therapeutic potential of peptide 
vaccines. Consequently, adjuvants are incorporated into peptide vaccines to support vaccine 
effectiveness by boosting antigen uptake, DC activation and maturation, antigen presentation 
and T cell priming (138). 
Antigen presenting cells have a number of different classes of pattern recognition receptors 
(PRR) located both on the cell surface and internally. The role of these receptors is to recognise 
infection and danger (cell death) and to respond via signalling cascades to induce APC 
activation. PRR recognise pathogen-associated molecular patterns (PAMP) that are common to 
bacteria, fungus and viruses, and damage-associated molecular patterns (DAMP) that are 
endogenous stress signals released from damaged cells. Several classes of PRR have been 
discovered including RIG-I-like receptors (RLR), Nod-like receptors (NLR) and Toll-like receptors 
(TLR) that play a key role in innate immune system activation (157). TLR are conservative 
transmembrane proteins that were identified across many animal species, with TLR1-TLR9 
being conserved between human and mouse (158). TLR ligands induce robust activation of 
innate immune cells, production of inflammatory cytokines and chemokines, accumulation of 
immune cells and induction of T cell responses (159, 160). A number of studies have established 
the important link between innate and adaptive immunity provided by PRRs, particularly via 
TLR-mediated maturation of DCs and activation of T lymphocytes. Proinflammatory signaling 
pathways induced by PRRs activate the innate immune response and also play a role in the 
activation, maturation, and shaping of the adaptive immune response. Therefore, TLR ligands 
are powerful immunostimulatory adjuvants that are widely used with vaccines (157). Multiple 
studies have confirmed their effectiveness in peptide vaccines. Some of those being used 
include the TLR3 agonists Poly-IC or Poly-ICLC (Hiltonol®) (140, 144), TLR2 ligand derivatives 
(150, 161), the TLR4 agonist LPS (bacterial lipopolysaccharide) or its derivative MPL® 
(monophosphoryl lipid A) (162), TLR7/8 agonist 3M-052 and the TLR9 agonist CpG (160). These 
adjuvants have been tested in multiple clinical trials of peptide vaccines (130) and have 
demonstrated effective adjuvant properties to induce CD8 T cell responses (163, 164). 
Adjuvants can improve anti-tumour activity in other ways, for example by supporting antigen 
cross-presentation (TLR3 ligand Poly-IC); inducing DC differentiation (GM-CSF) or by modulating 





impact on vaccine delivery (for example Freud’s Adjuvant, which acts as a slow release 
formulation) while some vaccine delivery systems (such as emulsions, liposomes or bacterial 
ghosts) can have adjuvant activity (145, 165-167). These delivery systems can protect vaccine 
components from degradation and facilitate antigen uptake, processing, DC activation or 
antigen presentation to T cells (138). Adjuvants and delivery systems often have multiple 
overlapping activities that contribute to the clinical effect of the vaccine. 
Some vaccines combine multiple adjuvants and/or delivery systems to target several factors 
and support anti-tumour immunity in a number of different ways. Using multiple adjuvants, 
such as several TLR agonists, or using them in combination with T cell-stimulatory molecules 
can induce improved DC stimulation, T cell priming and prolong survival of tumour-bearing mice 
(163, 168, 169). While synergistic stimulation of the immune system can enhance immune 
stimulation, over-stimulation needs to be taken into consideration (156). It is challenging to 
formulate a vaccine with multiple, possibly toxic, immunostimulatory agents. The use of 
numerous adjuvants might increase the occurrence and severity of adverse effects and may 
limit the use of the vaccine in human therapy due to safety concerns. 
1.4 Vaccine delivery 
1.4.1 Route of administration 
Routes of vaccine administration vary in order to achieve maximal effect to immunisation with 
the lowest adverse reactions. The most popular methods for cancer vaccine administration are 
subcutaneous (SC), intradermal (ID), intravenous (IV) and intranodal (IN) injections (170). 
Vaccine delivery route often depends on the physicochemical properties of the antigen and 
adjuvant, accessibility to immune cells, ability to induce immune responses without severe 
adverse effects (anaphylaxis) and the preferred location for accumulation and induction of 
immune responses. 
It has been shown that route of administration of peptide vaccines has an impact on the anti-
tumour responses generated and on therapeutic outcomes (126, 139). Local vaccine 
administration at the tumour site is often preferable as it supports the generation of robust 
local, as well as potentially systemic, immune responses as shown in mouse studies (171, 172). 
However, this approach is limited to the treatment of tumours where local injection is feasible. 
IV delivered peptide vaccines induce robust systemic immune responses against peptide 





anaphylactic shock when peptides with adjuvants are administered systemically (173) and 
localised anti-tumour immune stimulation may not occur (174). Local accumulation of immune 
cells at the tumour site is crucial, as well as systemic responses to protect against metastasis 
(171). Immune cells in tumour draining lymph nodes actively interact with tumours, therefore, 
anti-tumour immune responses generated at the local lymph nodes might maximise anti-
tumour defence mechanisms (175).  
Oral vaccine delivery is advantageous in several ways including the potential to deliver a solid 
dosage form, long shelf life, sustained release and a large surface area for vaccine adsorption. 
Oral vaccines are also a non-sterile pharmaceutical product, which reduces the cost of vaccine 
preparation and can simplify transportation and storage. Moreover, oral delivery is the most 
convenient, is preferred by patients and does not require trained personnel for vaccine 
administration. However, orally-delivered peptide vaccines have to overcome multiple critical 
barriers (pH, enzymes, mucus layer) before they can reach immune tissues and initiate anti-
tumour immune responses (176). 
Degradation and limited adsorption are the two main issues for oral peptide vaccines. These 
limitations result in very low bioavailability (< 1-2%) of orally delivered peptides (177). There 
are a number of causes for the low bioavailability. The first barrier is the harsh GIT environment. 
Low pH and proteolytic degradation in the stomach due to gastric enzymes (pepsin, gelatinase) 
and in intestine (duodenum) due to pancreatic enzymes (lipase, trypsin, amylase, peptidase, 
chymotrypsin) causes degradation of proteins and peptides (176). Mechanical and osmotic 
stresses that can affect vaccine components are also present in the GIT (176). The GIT mucus 
barrier is another major hurdle for tumour peptides (178). The dense viscoelastic mucus layer, 
composed of water and mucin glycoprotein, acts as a selective filter for drugs and other 
molecules and limits their therapeutic efficacy (178, 179). While the thick mucus layer in the 
intestine limits vaccine permeability, rapid mucus secretion and peristalsis rapidly removes 
vaccine particles from the GIT. It has been shown that low peptide permeability significantly 
reduces peptide bioavailability in in vitro models, also demonstrating that cationic peptides 
form stronger interactions with negatively charged mucus (179). The ephithelium itself also 
presents an almost impermeable barrier to hydrophilic (macro-) molecules, viruses and 
bacteria, limiting their entrance into the systemic circulation (180). Finally, even if peptides 
manage to cross the mucus barrier and the epithelium, efflux pumps, proteins that transport 
drug molecules out of the cells to the GIT lumen, may remove the peptides from the cells (181). 





against harmless intestinal microbiota and other components such as food proteins (182). 
Consequently, mucosal immune tolerance may hinder the immunostimulatory capacity of oral 
vaccines, which can affect the therapeutic effectiveness. All of these factors make oral 
vaccination challenging and only a few oral vaccines have been licensed (cholera (Ducoral), 
gastroenteritis (RotaTeq, Rotarix), typhoid (Vivotif), polio (Poliovax)) all of which are whole 
bacteria/virus vaccines and none are for cancer treatment (183). 
A number of strategies have been investigated to overcome the barriers that limit the use of 
peptide oral vaccines. Peptides can be directly modified using polyethylene glycol (PEG)ylation, 
glycosylation, lipidisation or cyclisation methods that improve stability and permeation.  
However, these can reduce the immunogenicity of the antigen and limit co-delivery of peptides 
and adjuvants (181). Gastric enzyme inhibitors can be used to reduce proteolysis in the GIT and 
adsorption enhancers can be used to improve the permeability of peptides (184). Vaccine 
carriers/delivery systems are the most common methods used to facilitate oral vaccine delivery. 
A plethora of delivery strategies can be used to overcome each barrier, without affecting 
vaccine components. Gastric enzyme-, acidic environment- and mechanical degradation-
resistant materials can be used to form particulate carriers (185). Carrier systems can also be 
designed to specifically target cells in the GIT (186). Moreover, cargo release in intestine can be 
regulated using stimuli-responsive (enzyme, pH, heat, pressure, ultrasound, magnetic field) 
delivery systems (185). Therefore, due to multiple advantages and huge potential, a number of 
carrier system have been extensively investigated for the delivery of peptide vaccines (185). 
1.4.2 Delivery systems  
Vaccine delivery systems are used for a number of reasons such as provision of protection, 
targeted delivery, increased immunogenicity, reduced off-target toxicity, increased 
bioavailability and controlled release (90). For subunit vaccines, it is especially important to use 
a carrier system that protects peptides from degradation until it reaches the target site. Also, 
delivery systems enable co-delivery of tumour peptides and adjuvants to the same APC, which 
is crucial for simultaneous APC activation and tumour antigen presentation (138). A vaccine 
delivery system that enables targeted delivery and controlled release reduces the risk of 
systemic side effects.  
For the treatment of CRC, local immune responses have to be generated at the mesenteric and 
tumour draining lymph nodes. Oral administration may be a way of achieving this, if an 





systems are resistance to the GIT environment, the ability to co-encapsulate vaccine 
components without affecting their biological activity, and efficient cargo release at the target 
site. Physicochemical characteristics (size, polydispersity, surface potential) are also important 
as they can influence vaccination outcomes. Vaccine delivery systems that increase 
bioavailability are especially relevant when vaccines are delivered via an oral administration 
(181). Additional enhancements that improve vaccine delivery such as, mucoadhesion, mucus 
barrier-penetration, prolonged release of antigens or specific cell-targeting abilities may be 
beneficial for oral delivery systems (185, 186, 188). Finally, being inexpensive, easily 
manufactured and suitable for a large-scale production with an acceptable safety profile, are 
requirements for an ideal oral delivery system. 
Vaccine carriers are usually nano-scaled structures that can entrap vaccine components, but are 
robust enough to protect them from environmental factors until they deliver the cargo to the 
APC. A number of particulate delivery systems have been developed for the delivery of subunit 
vaccines including liposomes, emulsions, micelles, polymeric nanoparticles, inorganic 
nanoparticles, nanogels, hydrogels, immunostimulating complexes, virus-like particles, bacteria 
and others (166, 189, 190). These vaccine delivery techniques have been widely studied and 
applied in many formulations showing that they have multiple benefits in improving 
immunisation outcomes and can also be classified as adjuvants (90, 138, 189). 
Delivery systems can be highly versatile and easy to manipulate and modify, thus a number of 
strategies can be utilised to improve vaccine delivery, protection, and/or immunostimulation 
(189). For oral delivery, the materials used in the preparation of these nanosystems have to be 
stable to protect antigens from environmental factors such as proteolytic degradation and 
hydrolysis. Therefore, surface modifications with polymers such as polyethylene glycol (PEG) 
can provide protection from enzymatic degradation and hydrolysis (178, 191). Delivery systems 
also being designed using nanomaterials and targeting ligands that improve retention and 
permeability through various barriers (mucosal tissue, skin, blood-brain barrier, TME) (189, 
192). Moreover, delivery systems can be formulated to enhance active targeted delivery to APC. 
This can be achieved by including surface modifications or molecules that specifically recognise 
lymphoid tissues or APC (193, 194). These strategies improve not only targeted delivery to APC 
but also enhance particle uptake by immune cells, which benefits immune stimulation. Finally, 
delivery systems such as virus-like particles or bacteria and cationic lipids may act as 
immunostimulatory agents as they contain multiple PRR ligands and possess adjuvant 





The physicochemical characteristics of vaccine carriers have to be optimised during preparation 
of each formulation, as these characteristics often predetermine the fate of the vaccine 
particles along with interactions with immune cells and immunisation outcomes. Some of the 
most crucial physicochemical properties that characterise delivery systems are particle size, 
surface charge and immunogenicity. Particle size predetermines the fate of the particles in the 
body and interactions with cells. Small particles (< 10 nm) can easily drain to blood from lymph 
nodes and are eliminated from the body, while larger particles are more likely to be retained in 
lymph nodes when vaccine is administered by injection (197). Cellular uptake and antigen 
processing is also size-depending. Small particles enter APC via pinocytosis while large particles 
are more likely taken-up via phagocytosis (197). Particle diameters of 500 nm and below are 
optimal for DC uptake and also can influence T cell immune responses (198, 199). Surface charge 
also affects particle uptake. Positively charged particles enhance uptake by APC via electrostatic 
interactions, as cellular endosomal membranes are negatively charged (167, 200). However, 
cationic liposomes can also destabilise cellular membranes, leading to cellular toxicity. For this 
reason, cationic liposomes are not always preferable for delivery of injectable vaccines (201). 
Immunogenicity of the particles is also an important factor that might have a significant impact 
on the overall immunostimulatory capacity of a vaccine formulation. Delivery systems that 
contain multiple PAMP can bind to PPR on APC and stimulate robust APC activation (157, 159). 
Aluminium salt-based delivery systems have also immunostimulatory and adjuvant activity 
(190). These delivery systems adsorb antigens and form particulate structures that promote 
antigen uptake and immune stimulation. Cationic lipids have also been reported to be potent 
immunostimulatory agents due to previously described affinity to negatively charged cellular 
membrane of APC (200).  Moreover, cationic liposomes demonstrate adjuvant properties due 
to their ability to stimulate expression of some chemokines (chemokine (C-C motif) ligand 2 
(CCL2), CCL3, CCL4) via extracellular-signal-regulated kinase (ERK) and p38 pathways (196). 
Multiple other characteristics need to be considered and adapted for individual vaccine 
formulations, this includes peptide and adjuvant loading capacity, stability of the system, 
release of the vaccine components during storage and in vivo, impact of nanomaterials on 
peptides and adjuvants, route of administration, biocompatibility, interaction with non-specific 
cells and immune cells, combination with other therapies, complexity and manufacturing 
requirements. 
There are a plethora of delivery systems under investigation (reviewed in detail by Bruschi 





favourable properties including entrapment capacity, ease of manipulation of composition 
along with good biocompatibility and safety profiles (203, 204). Two of the most common lipid-
based formulations are liposomes and emulsions. 
1.4.2.1 Liposomes 
Liposome nanoparticles or liposomes are a highly versatile particulate delivery system with a 
number progressing into clinical trials (165, 205). They can encapsulate all types of compounds 
including lipophilic and hydrophilic biomolecules (206, 207). Hydrophobic drugs are entrapped 
in the lipid bilayer while hydrophilic drugs are loaded in the liposome core, facilitating co-
delivery of molecules with distinct physical properties. Liposomes are also easy to manipulate 
and adapt for the delivery of different vaccine formulations. The composition of liposomes can 
be manipulated by changing the components of the lipid bilayer (206). The liposomal surface 
can be coated to provide protection from degradation in the gut or functionalised with ligands 
for targeted delivery (208, 209). A net positive or negative surface charge can be easily achieved 
by including cationic or anionic components, respectively.  
Conventional non-modified liposomes are highly susceptible to degradation in the GIT. Gastric 
lipase and pancreatic lipase destroy up to 20% of triglyceride acyl chains (210). In addition, 
gastric fluids and bile salts are able to disrupt lipid bilayers (188, 211). These factors destabilise 
liposomes and cause payload leakage (212). Liposomes that manage to reach intestinal epithelia 
encounter the mucus barrier, which can be impenetrable for large liposomes, especially for 
those that do not contain mucoadhesive or mucus-penetrating components (178). Mucus 
shedding can eliminate liposomes from the gut before they cross the mucus barrier. Poor 
permeability across the intestinal epithelial is another major hurdle for liposomes (206). Little 
is known about liposome uptake by epithelial cells, therefore the main target of orally delivered 
liposomes is the M cells (membranous epithelial, microfold, microvillous cell) in the follicle-
associate epithelium (FAE) of the Peyer’s patches (PP). However, the M cells comprise only 1% 
of all cells in the intestinal epithelium, which also limits liposome bioavailability (213). For these 
reasons, non-modified conventional liposomes are rarely used as an oral vaccine delivery 
system and usually one or several adaptations are included into liposome formulations to 
overcome these barriers.  
Multiple liposome modifications have been designed to overcome enzyme and gastric 
degradation, improve permeability across the mucus barrier and promote liposome 





components improve liposome resistance to degradation. A few examples include 
incorporation of bile salts, cholesterol, long fatty acids, or coating with chitosan, 
polysaccharides or PEG (191, 203, 209, 212, 214). These modifications not only improve stability 
of the vaccine, they also benefit vaccine delivery in other ways. Bile salts act as surfactants and 
facilitate liposome adsorption in the GIT (207), while chitosan is a natural polymer that improves 
mucoadhesive properties (184).  PEGylated liposomes is used to prolong retention time in 
lymph nodes, circulation in blood and induce mucosal immunity (206, 209). 
Other types of modifications target liposome retention time and adsorption in the GIT. 
Positively charged liposomes have been widely used to improve retention time based on 
electrostatic interactions with negatively charged moieties on mucin (178). Previous studies 
confirmed prolonged entrapment of cationic liposomes in mucus (215). Moreover, cationic 
liposomes are often used as cell transfection reagents that improve liposome penetration into 
cells (204). A number of cationic lipids can be used to formulate positively charged liposomes 
(DOTAP, DDAB, DC-Cholesterol). CAF01 liposomes, containing the cationic surfactant DDA, 
improved mucosal permeability of antigen in vitro and induced cellular as well as humoral 
immune responses in mouse studies after nasal administration (216). Cationic polymers 
(polysaccharides, polyacrylic acid) have been also used as mucoadhesion enhancers to improve 
retention and adhesion of particles (217). Also, liposome functionalisation with ligands that 
target M cells, for example M cell-binding lectins, has been shown to improve liposome 
adsorption in in vitro and in vivo studies (193, 218). 
Liposome size is another controllable parameter that can be adjusted to achieve desirable 
therapeutic outcomes. Liposome size influences particle permeation across the intestinal 
epithelium as well as peptide delivery and interactions with immune cells (199, 219). Smaller 
liposomes (< 100 nm) crossed the intestinal barrier rapidly while larger liposomes demonstrated 
prolonged insulin release, suggesting that larger liposomes have the potential to prolong 
tumour antigen exposure to immune cells (219). However, the adsorption of large liposomes is 
impaired and the efficacy of adsorption negatively correlates with increasing size of the 
particles. It has been reported that large liposomes (> 250 nm) induce Th1 immune responses 
with elevated IFN-γ production (preferable for anti-tumour immunity), rather than Th2 






Emulsions are a highly versatile lipid-based drug delivery platform that is widely used both 
externally and internally in food, cosmetic and pharmaceutical products. Emulsions are 
compartmentalised liquid dispersions that contain hydrophobic and hydrophilic phase(s) 
stabilised by surfactants. As with liposomes, emulsions can co-entrap both lipophilic and 
hydrophilic drugs or macromolecules (220), which is suitable for an oral vaccine delivery system. 
Moreover, emulsions can create a depot at the site of injection and facilitate slow release of 
vaccine components enhancing immune responses (156). Due to these features, emulsions such 
as complete and incomplete Freud’s adjuvant and MontanideTM have been used for many years 
as adjuvant-delivery systems for parenteral vaccine delivery (130, 221). Emulsions are beneficial 
as regards oral vaccine delivery as they can both protect vaccine components and improve 
bioavailability of poorly soluble drugs and peptides in the GIT (222-224). 
Emulsions can be classified by distribution of hydrophilic/hydrophobic phases into water-in-oil 
(W/O) and oil-in-water (O/W) emulsions, or as double water-in-oil-in-water (W/O/W) and oil-
in-water-in-oil (O/W/O) emulsions (225). Double emulsions, especially W/O/W, are the most 
popular type of emulsion for the delivery of pharmaceutic components. For vaccine delivery, 
the inner water phase act as a compartment where antigen with hydrophilic adjuvant can be 
loaded. This compartment is protected in oil droplets, which also prolong the release of vaccine 
components (223, 226). W/O/W emulsions were shown to improve insulin bioavailability in the 
gut and to sustain the release of peptides (222, 224). Moreover, ovalbumin peptide-containing 
double W/O/W emulsions managed to induce local and systemic immune responses in mouse 
studies (217), demonstrating the potential of this formulation for an oral cancer vaccine. 
While emulsions appear promising, stability issues limit their widespread use. Cargo release 
caused by droplet coalescence and ripening is observed in all types of emulsions (220). Multiple 
adaptations have been tested to prepare stable emulsions for pharmaceutical applications 
including the addition of a number of surfactants, stabilisers, thickeners and the use of different 
preparation techniques (225-227). It was found that the stability of double W/O/W emulsions 
highly depends on the stability of the W1/O emulsion, which can be achieved with compatible 
surfactants (225). Thickeners, such as xanthan or guar gum, are added to the outer phase of 
double emulsions to increase viscosity and prevent emulsion phase separation (225). The 
composition of the oil phase also has an impact on cargo release and it was shown that 





stable multi-compartmental system for oral vaccine delivery was prepared by encapsulating 
liposomes into the inner phase of double W/O/W emulsion, which demonstrated prolonged 
cargo release in in vitro studies (227). 
1.4.3 Generating anti-cancer immunity in gut 
Generating anti-cancer immunity via oral vaccination is a multistep process. It begins when 
vaccine components move through the mucus barrier, cross the epithelial cells and reach 
intestinal APC (228). Vaccine components can be adsorbed via transcellular or paracellular 
pathways (203). However, the size of vaccine particles means that transit through enterocytes 
(transcellular pathway) is low and transit between the epithelial cells (paracellular pathway) is 
blocked by the tight junctions (183). Therefore, the main route of entrance of particulate 
vaccines is via the M cells, specialised epithelial cells that are found in the PP (Figure 1.6) (183). 
The PP are mucosa-associated lymphoid tissues (MALT) composed of follicles that contain 
multiple immune cells. M cells are located in FAE on the surface of PP that are mostly located 
in the small intestine, therefore, the majority of vaccine particles are taken up and transit to the 
APC in the small intestine (213). M cells are specialised to sample luminal antigens and deliver 
them to immune cells in the PP, where primary immune responses are initiated (229). M cells 
take up various microorganisms including viruses, bacteria and vaccine particles, and transport 
them to immune cells located in the basolateral pockets of the M cells. It has been shown that 
M cells can effectively sample particles up to few micrometres size and the optimal size of the 
particles is up to 2 µm for the induction of immune responses (213, 219). M cells express various 
surface receptors (glycoprotein 2, PrPC, C5a) that facilitates recognition of foreign antigens (229-
231). These receptors can be used as specific targets for targeted vaccine delivery.  
APC are present in the basolateral pockets of the M cells where vaccine components/particles 
are transported (229). Primary immune responses are generated when vaccine particles are 
taken up by APC. Activated APC present vaccine antigens to T cells in the PP and/or migrate 
through afferent lymph vessels to the mesenteric lymph nodes (mLN), where the immune 
response is amplified (Figure 1.6) (183). Immune cell activation in the PP mostly activates 
mucosal immunity while immunity generated in mLN induces local immune responses in the 
gut (171, 232). Immune responses generated in the mLN, are a balance between immune 
tolerance to commensal microbiota as well as food proteins and inflammatory responses 
against foreign epitopes (233). Dong et al. reported that immune cells in mLN effectively 





(171). In addition, local stimulation in the gut-associated lymphoid tissue (GALT) and mLN 
increase immune cells infiltration in the gut, which may benefit therapeutic outcomes after oral 
vaccine administration (234). The local immune system interacts with systemic immunity and 
can further transfer immunostimulatory signals. Activated immune cells enter the bloodstream 
and migrate to the spleen where they can induce systemic defence mechanisms to induce long-
lasting immunity (235). 
Finally, in the case of anti-tumour immunity, cancer-specific T cells must enter into tumour 
tissue and other organs where they can recognised tumour antigens and kill tumour cells. As 
described previously, there are potentially multiple immunosuppressive molecules and cells 
present in the TME, which may block anti-tumour immune responses. 
 
Figure 1.6 Antigen uptake and development of tumour antigen-specific immune responses. 
M cells capture antigens in the PP and deliver them to APC, which present antigen to T cells. 
Activated cells migrate to mLN where the signal is amplified and local immune responses are 
induced. Further migration to spleen activates systemic immune responses. Immune cells 





1.5 Mouse models of CRC 
For the preclinical testing of oral vaccines for CRC treatment, an appropriate CRC mouse model 
is required. Multiple CRC mouse models have been developed such as genetic, chemical and 
transplantation models (236). 
Genetically engineered mouse models have mutations in genes that are usually involved in CRC 
pathogenesis. The most commonly affected pathways are WNT, TGF-β, PI3K, RAF/RAS and P53 
signalling (13). Predominantly, APC, TRP53, KRAS, PIK3CA genes are impaired in non-
hypermutated carcinomas along with ACVR2A, BRAF, TGFBR2 genes in hypermutated CRC 
tumours (13, 15, 34). The WNT signalling protein adenomatous polyposis coli (APC) is a highly 
CRC-associated tumour suppressor. Moreover, germline mutations in APC have been linked to 
familial CRC syndrome (14, 171). Therefore, mouse models with aberrant APC signalling are the 
most common genetic CRC tumour model (236-238). Depending on the mutation, these mouse 
models develop adenocarcinomas and/or adenomas and also can be used as a model for familial 
adenomatous polyposis syndrome. The most widely used model, APCMin/+, is short-lived, lacks 
tumour heterogeneity and invasiveness, and does not reflect spontaneous CRC development 
(239). For this reason, a variety of other models were developed, which additionally target 
TRP53, KRAS, SMAD4 and other genes. These models more accurately model CRC invasiveness 
and metastasis than APCMin/+ model, however cannot completely reflect natural CRC 
pathogenesis (236).  
Carcinogen-induced CRC tumour models represent sporadic CRC. Various carcinogens have 
been used to trigger the growth of tumours in the intestine such as dimethyhydrazine, 
azoxymethane, heterocyclic amines, aromatic amines, dextran sulfate sodium (DSS) and others 
(240, 241). Similarly to the genetic mouse models, carcinogens cause mutations in genes that 
are associated with CRC pathogenesis (APC, KRAS, TRP53) (241). These models are often used 
for the study of colitis-induced CRC as the development of intestinal tumours is associated 
chronic inflammation. DSS is one of the most used chemically-induced colitis-associated CRC 
mouse models. DSS damages the intestinal mucosa and induces intestinal inflammation, which 
leads to carcinoma formation (239). As with the genetically engineered mouse models, 
chemically induced CRC models often lack invasiveness and metastases. Moreover, the 






Transplantation mouse models of CRC can be further split into xenografts and syngrafts based 
on the source of tumour tissue/cells. Xenograft mouse models receive tumour cells or tissue 
from other species (for example, humans), while syngraft tumours are derived from the same 
mouse strain (236). Xenograft mice have to be immunocompromised (‘nude’) to develop 
xenogeneous tumours, meaning they are not suitable for immunotherapy research. Syngeneic 
tumours do not contain foreign human leukocyte antigen (HLA) antigens, and are not rejected, 
allowing tumours to develop in immunocompetent mice (239). Transplantation mouse models 
can be described by the location of the tumour, which can be orthotopic or ectopic. Orthotopic 
CRC models develop tumour in the large intestine while ectopic tumours are located in other 
places, usually the mouse flank following SC injection of cells or a piece of tumour (239). The 
ectopic model is not complicated to establish and tumour growth can be easily monitored, 
however this model lacks the natural tumour location and TME. Orthotopic mouse models are 
used to reflect natural tumour location and pathogenesis. In CRC, tumour tissue or cells can be 
placed in the wall of murine caecum during intracecal surgery (243). This method is technically 
more challenging than SC tumour injection, however, tumour development mirrors more 






1.6 Thesis aims 
Immunotherapies have been proven to be a highly promising approach to treat various types of 
cancer, including CRC. Therapeutic cancer vaccines are an attractive immunotherapeutic 
method that use the natural immune system’s ability to eliminate cancer.  These vaccines utilise 
tumour antigens to induce anti-tumour immunity to kill malignant cells. Due to the 
immunosuppressive environment associated with tumours, combination therapies utilising 
vaccines with other treatment modalities may be necessary to achieve effective therapeutic 
outcomes. Due to the specific location of CRC, oral immunisation is the most convenient vaccine 
delivery route to induce not only systemic but also local anti-tumour responses at the tumour 
site. Oral delivery route requires bespoke vaccine delivery systems to enable vaccine 
components to survive GIT transit, to cross the gastrointestinal barriers and to effectively 
stimulate immune responses. 
The hypothesis of this thesis was that the formulation of peptide antigen, comprised of chimeric 
AH1 antigen from CT26 cells linked to tetanus and diphtheria toxoid peptides, co-delivered with 
immunostimulatory adjuvant Pam2Cys in robust and customised vaccine delivery systems could 
stimulate effective therapeutic local and systemic anti-CRC immunity following oral 
administration.  
The initial aims were to design and characterise oral therapeutic lipid-based vaccine candidates 
and evaluate them in an orthotopic mouse model of CRC used to mimic natural CRC tumour 
location and pathogenesis. The characterisation studies would include examination of the 
formulations, and of the immune responses generated by the vaccines in tumour-free and 
tumour-bearing mice. Based on these studies, further vaccine adaptations to improve vaccine 
uptake or immunostimulatory effects and combination therapies with a nonsteroidal anti-
inflammatory drug and/or an immune checkpoint inhibitor were developed to maximise 
therapeutic outcomes. A novel vaccine delivery in a bacteria microsystem was also investigated. 
The overall objective of this study was to identify, in preclinical studies, the best therapy for 
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2 Preparation, evaluation and testing of lipid-based vaccine 
formulations for colorectal cancer treatment 
2.1 Introduction 
Oral vaccines are technically challenging to develop due to the harsh gastric environment. 
Nevertheless, they have numerous benefits including high patient acceptability and the 
potential to stimulate local mucosal immune responses. Local mucosal immunity may be of 
benefit in the treatment of CRC due to the tumour location in the large intestine. Vaccines for 
cancer treatment are usually ‘subunit vaccines’ that are composed of peptide or protein tumour 
antigens delivered in combination with immune stimulating agents. Subunit antigens are 
susceptible to degradation in the gut and must be delivered in a suitable delivery system that 
can provide protection against gastric hydrolysis (190) and then deliver them intact to the PP in 
the small intestine. Vaccines are then captured by M cells and the antigens are presented to 
immune cells (229). Oral therapeutic cancer vaccines must stimulate local and systemic anti-
tumour immune responses, which can be measured in mLN and spleen, respectively (30, 244). 
Efficacy of therapeutic vaccines can be determined by their ability to recruit immune cells into 
tumours and shift the TME from immunosuppressive to immunostimulatory, ultimately 
reducing tumour growth (32). 
Among all the different types of vaccine delivery systems, lipid-based formulations are easy to 
manufacture, possess the potential to co-load peptide antigens and hydrophobic immune 
stimulatory agents, and increase bioavailability (204, 223, 245). 
2.1.1 Subunit vaccine for CRC therapy 
Subunit cancer vaccines contain immunodominant protein or peptide antigens that are over- or 
specifically expressed by tumours and can stimulate CD8+ T cells to kill cancer cells (130). 
However, tumour antigens are often poorly immunogenic and do not reliably stimulate anti-
tumour immunity and other components must be included, for example antigens to stimulate 
helper CD4+ T cells (246, 247) and adjuvants to activate APC (150, 248).  
AH1 (gp70423-431) is the immunodominant peptide from the murine CT26 colon adenocarcinoma 
and has been shown to stimulate cytotoxic anti-tumour CD8+ T cell responses (249). In order to 
activate CD4+ T cells, the AH1 peptide was joined to a chimeric tetanus-diphtheria toxoid 





long peptide for combined CD8+ and CD4+ T cell stimulation. Tetanus-diphtheria toxoid peptide 
is a universal CD4+ T cell peptide that effectively stimulates memory immune response in 
human, mice and non-human primates (251). Therefore, it can be utilised in pre-clinical mouse 
studies as well as for human immunotherapy. Even though endogenous CD4+ T cell peptides 
from CT26 cells have been identified and used in pre-clinical mouse studies (252), exogenous 
tetanus-diphtheria toxoid peptide has been chosen in this study to make a more broadly 
applicable vaccine. The use of a universal CD4+ T cell peptide removes the requirement for 
having to find CD4+ epitopes for each tumour contributing to a lower cost of vaccine 
preparation. Moreover, it has been shown in mouse studies that strong exogenous peptides in 
vaccine formulations are as effective as endogenous, therefore the exogenous tetanus-
diphtheria toxoid peptide can be used to generate effective immune responses (253). 
Adjuvants are included in subunit vaccines to improve the immune response generated by a 
vaccine. Adjuvants act as ‘danger’ signals, enhancing APC activation and stimulating robust and 
durable immune responses (248). These immunostimulatory agents are often PAMP that 
contain features present on pathogens. These structures are recognised by APC cell via PRR 
such as the TLR2 (197, 254). One of these agents is the TLR2 ligand Pam2Cys lipopeptide, which 
improves the immunogenicity of peptide vaccines by enhancing DC maturation and T cell 
responses (248, 255). Pam2Cys mimics a lipid structure from macrophage-activating lipopeptide 
2 derived from Mycoplasma and is recognised by APC as a foreign molecule. Pam2Cys and its 
analogues have been widely used as adjuvanting agents in subunit vaccines (150, 248, 256). 
2.1.2 Lipid based formulations 
Lipid-based formulations such as liposomes and double emulsions are widely used due to their 
manufacturing and therapeutic advantages. Lipid-based delivery systems increase the 
immunogenicity of vaccines (187, 257) and can enhance bioavailability by protecting active 
components against proteolysis in the GIT (203, 223) and facilitating delivery of vaccine 
components into the GALT and PP (178). 
2.1.2.1 Emulsions 
W/O/W double emulsions have inner (W1) and outer (W2) water phases with an oil (O) phase in 
between. In the formulation developed here (Figure 2.1), the AH1td peptide and Pam2Cys 
adjuvant were loaded into inner W1 phase, meaning that two other emulsion layers protect the 





W/O/W emulsions are dispersions of liquids that are immiscible, thus require surfactants to 
form the dispersions. Surfactants lower surface tension by forming a barrier between each 
phase in the W/O/W emulsion (between the inner water phase and oil phase and between the 
oil phase and the outer water phase). This enables emulsions to avoid phase separation and 
remain in a stable system. Surfactants are amphipathic molecules containing hydrophilic and 
lipophilic groups. These amphipathic molecules are positioned in the interphase with 
hydrophilic regions being oriented toward the water phase and lipophilic groups facing the oil 
phase (258). This orientation creates a barrier of surfactant molecules that reduces surface 
tension at the interphase and enables emulsification of immiscible liquids. Surfactants have 
different degrees of hydrophobicity and lipophilicity, and can be characterised according to 
hydrophilic-lipophilic balance (HLB) values. HLB values describe hydrophilic versus lipophilic 
properties of the surfactants, which are important for selecting correct surfactants to design 
stable emulsions (225). Surfactants with HLB values matching the hydrophilicity/lipophilicity of 
the emulsion phases provides the most stable emulsions (259). The double W/O/W emulsions 
requires multiple surfactants with different HLB values to stabilise each interphase within the 
system.  
The choice of the oil phase is important and it has been shown that emulsions containing 
unsaturated fatty acids are able to enhance intestinal absorption and bioavailability (222). For 
this reason, soybean oil was utilised in this study as it mostly contains unsaturated fatty acids 
(α-linolenic, linolenic, oleic acids). Besides that, soybean oil is broadly used worldwide and is 
classified as generally recognised as safe (GRAS) by the US FDA and is thus suitable for oral 
administration. 
It is crucial to choose optimal surfactants for a stable W1/O emulsion, as this is critical for the 
stability of W/O/W double emulsion (225 65). Physical and chemical properties of surfactants 
contribute to the stability of the emulsion. Non-ionic lipophilic Span 80 (sorbinan mono-oleate) 
surfactant can stabilise water-in-oil emulsions, whereas a hydrophilic derivative of Span 80, 
Tween 80 (polyoxyethylene sorbitan mono-oleate) can stabilise oil-in-water emulsions. These 
two surfactants have balanced HLB and often used for preparation of stable W/O emulsions 
(227). Importantly, these surfactants are suitable for oral consumption as they are non-toxic 
and non-irritating and GRAS (259), thus aligning with the manufacturing requirements for oral 
vaccines. Also, Span80/Tween80 side chains match with the length of tails of the fatty acids 
found in soybean oil, therefore match the HLB and achieve the lowest surface tension between 





ionic surfactant Pluronic F127 was used. It is a widely used surfactant in biomedical fields and 
is especially suitable for the W1/O in W2 emulsification as it contains two hydrophilic and one 
hydrophobic segments, which stabilise aqueous emulsions (260). 
 
Figure 2.1 Schematic representation of W/O/W double emulsion-based oral vaccine 
formulation  
2.1.2.2 Liposomes 
One of the main advantages of liposome-based delivery systems is their versatility and 
plasticity. Liposome composition can be tailored to achieve a desired size, size distribution, 
charge, optimal stability and bioavailability (203, 204, 206). Liposomes entrap hydrophilic 
cargoes inside the core whereas lipophilic drugs interchelate into the lipid bilayer. Therefore, 
liposomes are a particularly suitable delivery system for vaccines with hydrophobic and 
hydrophilic components. The majority of the AH1td peptide amino acids are hydrophobic 
(56.52%) making this peptide more hydrophobic than hydrophilic, likewise while the 
lipopeptide Pam2Cys-SKKKK adjuvant is soluble in water, it can be entrapped in the liposomal 
bilayer due to the two ester bound fatty acids (Figure 2.2). 
Liposomal properties are important for vaccine stability and uptake. Cationic liposomes are 
adsorbed at a higher efficiency due to electrostatic interactions with M cells and APC (204). For 
this reason, the cationic phospholipid DC-Cholesterol (3ß-[N-(N',N'-dimethylaminoethane)-
carbamoyl]cholesterol) was used in formulating the liposomes to provide a positive surface 
charge. Moreover, it has been shown that cholesterol enhances adjuvant immunostimulation 
and formulation stability in vaccine delivery systems (203, 204, 206). Another liposomal 
modification, PEGylation, is widely used to improve shielding, stability and retention time in the 
intestine and lymph nodes (204, 206). Liposomal PEGylation is a process of shielding the lipid 





the formulation from bile salts, increase retention time through interactions with mucin and 
even increase mucosal immune responses (209). Therefore, 1,2-distearoyl-sn-glycero-3-
phosphorylethanolamine (DSPE)-PEG2000 amine was included in the liposome formulation. 
Particle size, particle size distribution and surface charge are the most important parameters to 
determine particle quality. Size of liposomes is related to particle bioavailability, thus the aim 
was to achieve 80-400 nm particles, which has been reported to be optimal for rapid uptake 
and bioavailability (219). 
Liposomes were formulated using a microfluidic mixing technique, which allows for the simple, 
reproducible and fast production of liposomes (245, 261). In this process, organic solvent and 
an aqueous phase are pushed through microchannels in a microfluidic mixing cartridge where 
a rapid mixing results liposome formation (245, 262). The ratio of the two liquids (flow ratio) 
and the flow rate can be controlled to enable control over particle size. Other advantages of 
using the microfluidic mixing technique includes ease of maintaining size and low size 
distribution, also low toxicity solvents (ethanol) can be used which is important for oral vaccine 
production (262). 
 
Figure 2.2 Schematic representation of liposome-based oral vaccine formulation 
2.1.3 Therapeutic oral vaccination for CRC 
Prime-boost vaccination strategies are used to achieve strong and persistent immune responses 
to vaccination. The immune system responds more robustly to previously encountered antigens 





antigen (263). Prime-boost vaccinations comprise an initial immunisation (prime) followed by 
one or more repeated immunisations (boosts) to expand the response. In mouse studies, an 
optimal time for boosting depends on the antigen and response being measured and varies 
between 14-21 days after the prime immunisation (263, 264).  
Oral vaccination has advantages for CRC treatment due to the location of the tumour and 
potential to stimulate local immune responses in the GIT. For this reason, a mouse model where 
the tumour was located in the GIT was crucial for therapeutic treatment studies. An orthotopic 
mouse model was previously described were CT26 cells were injected into the wall of the mouse 
caecum leading to tumour growth in the large intestine (243). This model not only utilises the 
natural tumour location, but also provides the opportunity to use well-defined tumour-
associated antigens from CT26 colon carcinoma cells (243). However, a disadvantage of this 
model is that the size and growth of intra-abdominal tumours cannot be measured by direct 
visual investigation; therefore, a humane endpoint was predetermined prior to vaccination 
studies. 
2.1.4 Immune responses to therapeutic oral vaccination for CRC 
Immune responses to therapeutic oral vaccination can be detected in immune organs and 
tumour tissue. Immune cell expansion, cell infiltration into tumours, upregulation of activation 
markers and cytokine expression can all be used as indicators of anti-tumour immunity.  
2.1.4.1 Anti-tumour immune responses  
A number of pro- and anti-tumourigenic immune cells involve in CRC pathogenesis (Figure 1.2). 
It is important to investigate different populations of leukocytes, and in different ways, in order 
to understand more fully the effect of oral vaccination in generating anti-tumour immunity. 
Such changes can be investigated in lymphoid tissue (for example the mLN and spleen) or in the 
tumour itself. 
Changes in the cells and mediators in the TME that may indicate a shift from an 
immunosuppressive to an immunostimulatory responses are an important indicator of an 
effective immunotherapy (33, 34, 265). Therefore, analysis of the number and activation 
status/antigen experience of tumour infiltrating and lymphoid immune cells is important for 





tumour immunity as they can influence disease progression, depending on the interplay 
between pro- and anti-tumourigenic cytokines (266). 
2.1.4.2 Measuring immune activation following therapeutic oral vaccination for CRC 
Tumour-antigen specific CD8+ T cells are often critical in an efficient anti-tumour immune 
response. These cells recognise tumour antigens expressed on tumour cells and can directly 
induce death of the malignant cells (44). In addition to their cytotoxic activity, CD8+ T cells can 
further amplify an anti-tumour response by producing inflammatory cytokines, which stimulate 
other immune cells (267). CD4+ T cell activation and expansion is also important in anti-tumour 
immunity and can be used to determine therapeutic effects (57, 127). CD4+ T cells are pivotal 
for optimal activation and effector function of cytotoxic CD8+ T cells (46). Activated helper T 
cells can recognise tumour antigen on MHC class II expressing cancer cells and induce apoptosis 
directly or can support CD8+ T cell activity by producing pro-inflammatory chemokines and 
cytokines in secondary lymphoid organs or in the TME (32, 43). Additionally, B cells are a major 
population of lymphocytes that are required for an optimal T cell mediated anti-tumour 
immunity and also an upregulation of these cells can indicate positive vaccination outcomes 
(81, 265, 268, 269). 
More in-depth analysis of T cell subpopulations, for example activation status and cytokine 
expression, are important factors for predicting effectiveness of therapeutic vaccination (270). 
Receptors and proteins expressed on or in these cells can indicate activation (CD25), 
proliferation (Ki67), maturation status (CD62L/CD44) or previous antigen experience (CD122, 
CD44). Among the numerous cytokines expressed in the TME, several cytokines such as IFNγ, 
IL-10, IL-1β, IL-17A, IL-6 and TNF have been used as cytokine therapy for CRC treatment or as 
prognostic markers to predict disease outcomes (266). 
Large proportion of innate immune cells are found in the TME (30) as these cells are responsible 
for initiating and modulating adaptive immune response against cancer (270). Innate immune 
cells fight cancer by reacting to inflammatory signals in tumour tissue (27). It has been shown 
that these cells are necessary for T cell function (171), as they present TAA to T cells, as well as 
producing mediators that can modulate the activity of cells of both the innate (e.g. pro-
inflammatory macrophages) and acquired immune systems  (271). The innate immune system 
comprises numerous cell types and investigation of all of these cell subsets can be challenging. 





immunity are CD11c+, CD11b+ and F4/80+ innate immune cells. CD11c is known as DC marker. 
CD11c+ DC cells are associated with IFN production in tumour draining lymph nodes, which 
induce both mucosal and systemic anti-tumour T cell immunity after oral vaccination (171, 270, 
272). CD11b is expressed on various types of myeloid immune cells, which are associated with 
negative and positive outcomes in tumour progression and can be used as an innate immune 
cell targets for CRC therapy (27, 30, 271). F4/80 is a common marker of macrophages and can 
be used to distinguish TAM (271, 273). 
2.2 Chapter aims 
The aim of this research was to test the hypothesis that oral delivery of the AH1 (gp70423-431), 
immunodominant peptide from CT26 colon adenocarcinoma could stimulate local and systemic 
immune responses and delay growth of an intestinal tumour. This chapter validates subunit 
vaccines formulated in lipid-based formulations (W/O/W double emulsions and cationic 
liposomes), tests their ability to activate local and systemic immune responses in tumour-free 
mice as well as therapeutic efficacy to induce tumour rejection in an orthotopic mouse model 






2.3 Materials and methods 
2.3.1 Materials 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 3β-[N-(N’,N’-dimethylaminoethane)-
carbamoyl]cholesterol hydrochloride (DC-Cholesterol·HCl), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (DSPE-PEG(2000) Amine) and L-α-
phosphatidylcholine (Egg PC) were purchased from Avanti Polar Lipids, USA. The AH1/tetanus-
diphtheria toxoid peptide (H-SPSYVYHQFPMGLPILMQYIKANSKFIGIPMGLPQSIALSSLMVAQ-OH) 
and AH1 (SPSYVYHQF) peptide were obtained from Mimotopes, Australia. Pam2Cys-SKKKK (S-
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine x 
3 CF3COOH (Pam2Cys) was purchased from EMC Microcollections, Germany. Surfactants Tween 
80 (Polysorbate), Span 80 and Pluronic F-127 were purchased from Merk, Germany. Monoclonal 
antibodies F4/80-BV421 (T45-2342), CD3-BV510 (17A2), CD11b-BB515 (M1/70), CD11c-PE 
(HL3), CD4-PE-Cy7 (RM4-5), CD19-APC (1D3), CD8a-APC-H7 (53-6.7), CD122-BV421 (5H4), 
CD62L-FITC (MEL14), CD44-PE (IM7), CD25-APC (PC61), IL-2-BV421 (JES6-5H4), Ki-67-AF488 
(B56), IFN-γ-PE (XMG1.2), IL-17A-AF647 (TC11-18H10), Fixable Viability Stain (FVS) 620, Fixation 
and Permeabilisation Solution and Perm/Wash buffer were purchased from BD Biosciences, 
USA. The 5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) was obtained from 
Merk, Germany. PMA (Phorbol 12-myristate 13-acetate) and ionomycin were purchased from 
Sigma, USA; and Brefeldin A (BFA) from BioLegend, USA. Cell Trace Violet cell Proliferation kit 
was purchased from Invitrogen, Thermo Fisher Scientific, USA. The CT26 cell line (ATCC® CRL-
2638) was purchased from ATCC, USA.  
2.3.2 Mice 
BALB/c mice were obtained from the HTRU, University of Otago, and were housed under 
specific pathogen-free conditions and given food and water ab libitum. Female and male mice 
aged 6-12 weeks were used for the experiments. The experiments were approved by the Animal 
Ethics Committee, University of Otago (AEC 80/16).  
2.3.3 Preparation and characterisation of liposome nanoparticles (liposomes) 
Liposomes were manufactured by the microfluidic mixing technique using microfluidic 
cartridges on a NanoAssemblr Benchtop platform (NanoAssemblrTM BT v1.5; Precision 
NanoSystems, Canada). Absolute ethanol was used as an organic solvent to dissolve lipids and 





2.3.3.1 Optimisation of Egg-PC liposome preparation parameters using the microfluidic 
mixing technique 
Total flow rate, flow ratio and Egg-PC lipid concentration were optimised for liposome 
preparation. For total flow rate optimisation, Egg-PC lipid was dissolved in absolute ethanol at 
a concentration of 30 mg/mL. FITC conjugated ovalbumin (FITC-Ova) (274) was diluted in de-
ionised water at a concentration of 1.5 mg/mL. A range of total flow rates were tested (Table 
2.1) with a constant flow ratio 2:1 (aqueous phase:organic solvent). For flow ratio optimisation 
(Table 2.1), a total flow rate (8 mL/min) and final concentrations of Egg-PC (10 mg/mL) and FITC-
Ova (1 mg/mL) were used. Lipid concentrations (Table 2.1) were tested using formulation 
parameters as follow, FITC-Ova solution in de-ionised water (1.5 mg/mL), total flow rate 12 
mg/mL and flow ratio 2:1.  
Prior to formulation the solutions were loaded into 1-5 mL syringes (BD Biosciences, Singapore), 
pre-heated to 50°C in a water bath and loaded on the NanoAssemblr Benchtop platform. The 
formulations were collected in 15 mL tubes (Falcon, Mexico). 
Table 2.1 Optimised parameters for liposome preparation using a microfluidic mixing 
technique  
Parameters Tested range  
Total flow rate 4; 8; 10; 12; 16 mL/min 
Flow ratio 1:1; 2:1; 3:1; 4:1 
Lipid concentration  30; 90; 150; 240; 300 mg/mL 
 
2.3.3.2 Preparation and optimisation of PEGylated cationic liposomes for oral vaccine 
delivery 
DSPC, DC-Cholesterol and DSPE-PEG2000 lipids were used for the preparation of PEGylated 
cationic liposomes. The concentration and molar ratio between the lipids in organic solvent 
were optimised (Table 2.2). The FITC-Ova concentration was kept constant (1.5 mg/mL) in 
tested aqueous phases (Table 2.2) throughout the optimisation experiments. Lipids in an 
organic solvent and FITC-Ova in aqueous phase were pre-heated up to 55°C prior to loading on 
the microfluidic mixing platform. A 10 mL/min total flow rate and a 2:1 flow ratio were used for 






Table 2.2 Optimised parameters for PEGylated cationic liposome preparation 
Optimised parameters Tested values 
Molar ratio 
DSPC:DC-Cholesterol:DSPE-PEG2000 
64:32:4; 70:26:4; 72:24:4; 81:16:3 
Lipid concentration 10; 20; 30 mg/mL 
Organic solvent Ethanol; Ethanol/DMSO 
Aqueous phase H2O; PBS; 10 mM Tris; 25 mM Tris 
 
For the vaccine studies, AH1td peptide and Pam2Cys adjuvant were dissolved in de-ionised 
water at a final concentration of 2 µg and 0.5 µg per 100 µL, respectively. DSPC:DC-
Cholesterol:DSPE-PEG2000 lipids were dissolved in absolute ethanol at 70:26:4 molar ratio (final 
concentration of 10 mg/mL). The following microfluidic parameters were used: total flow rate 
10 mL/min and flow ratio 2:1 between aqueous phase and organic solvent solutions. Liposome 
suspensions were dialysed for 24h against deionised water (water was replaced every six hours) 
using a 0.1-0.5 kDa molecular weight cut-off (MWCO) membrane in order to remove ethanol 
from the formulations and maintain the fixed concentration of peptide and antigen in liposome 
suspensions. 
2.3.4 Preparation of W/O/W double emulsion 
Water-in-oil-in-water double emulsions were prepared using a two-step emulsification method 
as previously described (227). 2.8% Tween 80 non-ionic surfactant in phosphate buffered saline 
(PBS) (v/v) (W1) was added drop-by-drop to soybean oil containing 15.9% Span 80 (v/v, oil 
phase) and the emulsion (final W1:Oil ratio of 1:1) was homogenised for 5 min, 6000 rpm at 
room temperature (IKA Laboratory Equipment, USA). 0.5% Pluronic F-127 non-ionic surfactant 
in PBS (W2) (w/v) was added drop-by-drop to the previously prepared W1/O emulsion and the 
2:2:1 W/O/W emulsion was stirred for 30 min, 500 rpm at 4°C (IKA Laboratory Equipment, 
Germany).  
For vaccine studies, AH1td peptide and Pam2Cys adjuvant were dissolved in W1 phase at a final 





2.3.5 Particle size and zeta potential 
The size and polydispersity index (PDI) of liposome particles were measured in de-ionised water 
(1:100 dilution) and the emulsion in PBS (1:100 dilution) using Dynamic Light Scattering (DLS; 
Zetasizer Nano, Malvern Instruments Ltd, UK) in acryl/acrylic cuvettes (Sarstedt, Germany). The 
zeta potential was measured in de-ionised water (1:100 dilution) using a folded capillary cell at 
25°C (Malvern Instruments, Ltd, UK).  
2.3.6 Encapsulation of FITC-Ova study 
FITC-Ova was prepared as previously described (274) and used for encapsulation studies. 
Following preparation of liposome suspensions with FITC-Ova, non-entrapped FITC-Ova 
conjugate (43 kD) was removed by dialysis using a 100 kD MWCO cellulose ester membrane 
(Spectrum Laboratories Ltd, USA) against aqueous phase for 48h replacing water every six 
hours. An aliquot of liposomes was then lysed by adding 5% Triton X-100 (Sigma, USA) and the 
amount of FITC-Ova was measured using a microplate reader (POLARstar Omega Microplate 
Reader, BMG Labtech, Germany) at 485/520 nm wavelength and quantified using a standard 
curve of FITC-Ova diluted in 5% of Triton X-100. The encapsulation efficiency (EE) of FITC-Ova 
was calculated using: 
% 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑢𝑠𝑒𝑑 𝑓𝑜𝑟 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 𝑥 100% 
2.3.7 Transmission electron microscopy (TEM) 
Liposome particles were visualised using negative staining TEM. A drop of sample was applied 
on a pre-treated EM carbon grid for 1 min. The excess liquid was dried and then the grid was 
stained with 1% uranyl acetate and 1% phosphotungstic acid for 1 min. After incubation the 
excess stain was blotted and the sample was examined using a Philips CM100 transmission 
electron microscope (Philips Electron Optics, The Netherlands). 
2.3.8 Stability analysis of lipid-based formulations 
2.3.8.1 Liposome stability 
For stability analysis, liposome suspensions were prepared as previously described and dialysed 
against deionised water in a 10 kDa MWCO membrane throughout the stability studies. The 





potential and FITC-Ova loading (EE) were analysed on days 0, 1, 4 and 7.  The stability studies 
were replicated 3 times with freshly prepared liposome suspensions. 
2.3.8.2 W/O/W emulsion stability 
For stability studies, W/O/W double emulsions were prepared as previously described and 
incubated for 7 days at 4°C, 25°C and 37°C storage temperature without stirring or shaking. 
Phase behaviour was observed on days 0, 1, 4, and 7 by transmitted light microscopy using an 
Olympus IX53 inverted microscope (Olympus, Japan). Photos of the emulsions were taken at 
each time points. 
2.3.9 In vivo cytotoxicity study 
2.3.9.1 Immunisation 
Naïve BALB/c mice were used for in vivo cytotoxicity studies. Mice were given 100 µL of vaccine 
by oral gavage (20G 38 mm, Fuchigami, Japan) with 1 mL syringes (BD, Singapore) once daily 
from days 1 to 4 (prime) and days 21 to 24 (boost, Figure 2.3). The prime-boost regiment was 
based on previously published data (263, 264). Vaccine formulations were prepared freshly 
prior the prime and boost immunisations and stored at 4°C between administrations for 4 days. 
The vaccines contained 2 µg/dose of AH1td peptide and 0.5 µg/dose of Pam2Cys adjuvant in 
liposomes (L-Vac), emulsions (E-Vac) or unformulated in PBS (Vac). Control mice were given 
adjuvant only (Adjuv) or PBS (Ctrl). In total, the experiment comprised five experimental groups 
with four animals in each group. Mice were monitored daily throughout the experiment. The 
experiment was repeated three times. 
  
Figure 2.3 Experimental scheme for in vivo cytotoxicity studies. Mice were vaccinated twice 
over 4 consecutive days with 17 days between each vaccination. Adoptive transfer of AH1 
peptide-labelled spleen cells were performed on the 28th day and the cell killing analysed on 
the 30th day  
2.3.9.2 Adoptive cell transfer 
Four naïve non-vaccinated BALB/c mice were killed by cervical dislocation on the 28th day of the 





(Falcon, USA). The single cell suspension was washed in complete RPMI media (Appendix Table 
7.1) at 400G for 5 min and red blood cells (RBC) were lysed using freshly prepared RBC lysis 
buffer (17 mM Tris-Cl, 0.16 M NH4Cl) for 10 min at room temperature. The cell suspension was 
washed (400G, 5 min) in RPMI and again strained through a 70 µm cell strainer. The cells were 
resuspended at 2 x 107 cells/mL in RPMI media and divided into two aliquots. One aliquot 
(pulsed cells) was incubated with AH1 peptide at a concentration of 10 µg/mL in RPMI media 
for 2 h at 37°C. After incubation the cells were washed twice in PBS at 400G for 5 min and re-
suspended at 2 x 107 cells/mL in PBS. The peptide-pulsed cells were stained with 1 µmol/L of 
CFSE for 8 min at room temperature. After incubation, an equal volume of foetal bovine serum 
(FBS) was added and the cells were washed twice. The unpulsed cells were stained with Cell 
Trace Violet according to manufacturer’s instructions for 20 min at 37°C and washed in RPMI 
media twice. Both aliquots of cells were diluted to 4 x 107 cells/mL in PBS, mixed at equal 
volumes and filtered through a 70 µm cell strainer. 
The mice were placed in a mouse restrainer and 200 µL of the cell suspension (8 x 106 cells) 
were injected IV into the tail vein of each mouse using 0.3 mL insulin syringes (0.33mm (29G) x 
12.7mm; BD Ultra-Fine, USA).  
2.3.9.3 Analysis of in vivo cell killing 
After 2 days (on the 30th experimental day), the mice were euthanised by cervical dislocation 
and spleens were collected. The spleens were passed through cell strainers and RBC lysis was 
performed as previously described. The cells were stained with live/dead Fixable Viability stain 
620 (1:1000 dilution) in PBS for 20 min at 4°C with rocking incubation and washed twice in PBS 
at 400G for 5min. The cells were re-suspended in fluorescence-activated cell sorting (FACS) 
buffer (4% of FBS in PBS; v/v) and analysed using a FACSCanto II flow cytometer (BD Biosciences, 
USA). The cells were normalised against the control group and in vivo cell killing was determined 
using formula: 
% 𝐶𝑒𝑙𝑙 𝐾𝑖𝑙𝑙𝑖𝑛𝑔 = (1 −
𝑃𝑢𝑙𝑠𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑈𝑛𝑝𝑢𝑙𝑠𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
)  𝑥 100% 
2.3.10 Isolation of immune cells from mice 
Tumour-free naïve BALB/c mice were used for immunogenicity studies. Mice were given 100 µL 
of vaccine by gavage (20G 38 mm) with 1 mL syringe once daily from days 1 to 4  (prime) and 





and boost immunisations and stored at 4°C between administrations for 4 days. The vaccines 
contained 2 µg/dose of AH1td peptide antigen and 0.5 µg/dose of Pam2Cys adjuvant in 
liposomes (L-Vac), emulsions (E-Vac) or unformulated in PBS (Vac). Control mice were given 
adjuvant only (Adjuv) or PBS (Ctrl). In total, the experiment comprised of five experimental 
groups with five animals in each group. Mice were monitored daily throughout the experiment 
and were killed at day 30. Spleens and mLN were collected and passed through 70 µm cell 
strainers. Single cell suspensions were washed in RPMI media at 400G for 5 min. RBC were lysed 
using RBC lysis buffer as previously described. After RBC lysis, the 5 x 106 of cells were re-
suspended in RPMI media and used for flow cytometric analysis. The experiment was repeated 
three times. 
 
Figure 2.4 Experimental scheme for immunogenicity studies. Mice were vaccinated twice over 
4 consecutive days with 14 days between each vaccination  
2.3.11 CT26 colon carcinoma cell line maintenance 
Mouse colon carcinoma CT26 cells were maintained in complete RPMI media (Appendix Table 
7.1) at 37°C with 5% CO2 in a Hera cell culture incubator (Heraeus, Germany). TrypLE Express 
(Gibco, USA) was used to dissociate adherent cells. 
For tumour cell injections, the CT26 cell monolayer was rinsed with PBS and the cells were 
dissociated and harvested using TrypLE for 5 min at 37°C. The cells were then washed twice in 
PBS at 400G for 5 min and resuspended at 1 x 106 cells/mL in sterile PBS for intraceacal (IC) 
tumour injection surgery. 
2.3.12 Intraceacal tumour injection surgery  
Subserosal IC injection of CT26 cancer cells was performed on 6-12 week-old BALB/c mice as 
described (243). Mice were anaesthetised with isoflurane. Local anaesthetic (Marcain, 2 mg/kg, 
SC) was applied at the surgery site prior to surgery, while Carprofen (5 mg/kg, once daily for 3 
days, SC) and Temgesic (0.1 mg/kg, once daily for 2 days, SC) were given to mice for pain control 
prior to surgery and during recovery. Amphoprim (30 mg/kg, twice daily for 3 days, SC) was 
given to prevent bacterial infections. Hair was removed from mouse’s ventral abdomen and a 





exteriorised and 25 µL (2.5 x 104 cells) of previously prepared CT26 tumour cells was injected 
into the caecal wall under 10x magnification. The caecum was replaced into the abdominal 
cavity and the body wall as well as skin was sutured with simple interrupted sutures. After the 
surgery, the mice were monitored and weighed daily for the duration of the experiment.  
2.3.13 Therapeutic oral vaccination 
Five surgeries were performed in each session and mice were randomly allocated to the five 
treatment groups. Mice treated with L-Vac, E-Vac or unformulated vaccine in PBS (Vac) received 
2 µg/dose of AH1td peptide and 0.5 µg/dose of Pam2Cys adjuvant. Control groups were given 
0.5 µg/dose of adjuvant only (Adjuv) or PBS (Ctrl). Mice were given 100 µL of vaccine by gavage 
(20G 38 mm) with 1 mL syringe once daily from days 6 to 9 after surgery (Figure 2.5). Vaccine 
formulations were prepared freshly prior the first vaccination and stored at 4°C between 
administrations. The surgery sessions were repeated until there were 8-10 mice in each 
treatment group. 
Mice were euthanised by cervical dislocation upon reaching pre-determined early humane 
endpoints or on the 17th day post-surgery (Figure 2.5). Spleens and mLN were collected and 
single cell suspensions were prepared for flow cytometry as previously described. The tumours 
were collected and mechanically disrupted in RPMI media, passed through 70 µm cell strainers 
and centrifuged at 400G for 5 min in RPMI media. The supernatants were frozen at -20°C and 
later used for cytokine analysis. The tumour cells were re-suspended in RPMI media and the 
cells were stained with 0.4% Trypan blue and the total number of live cells was counted using a 
haemocytometer. 
 
Figure 2.5 Experimental scheme for tumour studies. 2.5 x 104 tumour cells were injected in to 
the caecal wall 6 days prior vaccination. Mice were administered with four doses of vaccine 





2.3.14 Flow cytometry 
2.3.14.1 Surface staining 
Single cell suspensions were washed in PBS at 400G for 5 min before staining. Viability staining 
was performed with live/dead Fixable Viability Stain 620 (BD Biosciences, USA). Cells were 
incubated with 100 µL of viability stain (1:750 dilution in PBS) in the dark for 20 min at 4°C on a 
rocking incubator (Ratek, Australia) followed by cell washing with 3 mL of FACS buffer at 400G 
for 5 min. Cells were stained with optimised concentrations of antibodies that were determined 
via titration (Appendix Figure 7.1 and Appendix Table 7.2). For surface staining, the cells were 
incubated with 50 µL of antibody mix (diluted in PBS) in the dark for 30 min at 4°C on a rocking 
incubator. Stained cells were washed twice in 3 mL of FACS buffer at 400G for 5 min. Samples 
were re-suspended in FACS buffer for analysis. 
2.3.14.2 Intracellular cytokine staining 
For intracellular staining, single cell suspensions were diluted in RPMI media to 1 x 106 cells/well 
in 24 well plates (Costar, USA). The cells were stimulated with 10 ng/mL of PMA and 500 ng/mL 
of ionomycin for 2 h at 37°C followed by incubation with 1 µg/mL of BFA for 2 h at 37°C. 
Unstimulated controls were incubated with brefeldin A only (1 µg/mL) for 2 h at 37°C. After 
incubation, the cells were harvested and washed twice in 3 mL of PBS at 400G for 5 min. 
Previously described viability and surface staining were performed. Following surface staining, 
the cells were re-suspended in 100 µL of fixation and permeabilisation solution and incubated 
for 20 min at 4°C on a rocking incubator. Cells were washed in permeabilisation buffer at 400G 
for 5 min and re-suspended in 50 µL of optimised concentrations of antibody cocktail (diluted 
in the permeabilisation buffer) in the dark for 90 min at 4°C on a rocking incubator. The cells 
were washed with 1 mL of permeabilisation buffer at 400G for 5 min. Samples were re-
suspended in the FACS buffer for flow cytometric analysis. 
2.3.14.3 Flow cytometric analysis 
Flow cytometric analysis was performed on the FACSCanto II (BD Biosciences, USA). Data were 
analysed using FlowJo V10 software (Tree Star, Inc, USA). Cells were gated on live singlets. The 
populations of CD4+, CD8+ T cells and CD19+ B cells were gated on F4/80-CD11c-CD3+CD4+, F4/80-
CD11c-CD3+CD8+ and F4/80-CD11c-CD11b-CD19+, respectively (Appendix Figure 7.2). To 
distinguish innate immune cells, a gate was set on CD3-CD19- cells which were then analysed 
for expression of F4/80+, CD11c+, and/or CD11b+. For T cell subset analysis, gates were set on 





CD122+CD44+, CD62L+CD44- and CD62L-CD44+ (Appendix Figure 7.3). For intracellular cytokine 
expression analysis, a gate was set on CD3+ live singlets. Then, CD4+ and CD8+ cells were gated 
separately on IL-2+, Ki67+, IFNγ+, IL-17A+ cell populations (Appendix Figure 7.4). Fluorescence 
minus one controls (FMO) were used for cell gating for each fluorophore in the panel. 
Compensation beads Anti-Rat and Anti-Hamster Ig κ /Negative Control Compensation Particles 
Set (BD, USA) and Anti-Mouse Ig κ /Negative Control Compensation Particles Set (BD, USA) were 
used for single stain controls as per manufacturer’s instructions. 
2.3.15 Cytokine analysis 
To measure cytokine concentration in tumour tissue, tumour cells supernatants were analysed 
using BD Cytometric Mouse/Rat Bead Array (CBA) (BD Biosciences, USA) as per the 
manufacturer’s instructions. Briefly, to capture cytokines, 50 µL of samples were incubated with 
60 µL of capture beads for 60 min at 25°C and later mixed with 50 µL of detection antibodies 
against TNF, IL-1β, IL-6, IL-17A, IFNγ, IL-10 cytokines. The samples were incubated again for 60 
min at 25°C and washed in wash buffer at 200G for 5 min. Samples were re-suspended in wash 
buffer for a flow cytometric analysis on a FACSCanto II flow cytometer. Cytokine concentrations 
were determined using FACSDiva Software (BD, USA). 
2.3.16 Statistical analysis 
Statistical comparisons between the groups were carried out using the non-parametric normal 
distribution one-way Kruskal-Wallis test (ANOVA) followed by Dunn’s multiple comparison post 
hoc test or two-way ANOVA test with Sidak’s multiple comparison test, performed using 
GraphPad Prism 7 (GraphPad Prism Software Inc, USA). If p values were ≤ 0.05, the result was 






2.4 Results and Discussion 
2.4.1 Liposomes as an oral vaccine delivery system 
In order to obtain optimal liposomes for an oral vaccine delivery using a microfluidic mixing 
technique, a number of optimisation experiments were carried out. These were divided into 
three parts. Firstly, microfluidic parameters were optimised to produce liposomes with the 
desired characteristics. For the second part, optimal liposome formulations were developed for 
oral vaccine delivery. Lastly, the stability of the final liposome formulation investigated prior to 
mouse studies. 
2.4.1.1 Microfluidic parameters to formulate model Egg-PC liposome particles 
Egg-PC lipid was used as a model lipid to investigate the effect of formulation parameters (flow 
ratio, total flow rate, lipid concentration) on obtained liposome characteristics (size, PDI, drug 
loading). The PDI is a measure of particle size distribution, which indicates whether particles are 
homogenous or polydisperse. FITC-Ova was used as a model drug for encapsulation 
experiments as the fluorescent label facilitates examination of protein entrapment and 
ovalbumin helps to illustrate predictive protein/peptide loading into liposomes. Egg-PC is a 
mixture of fatty acids and can be used as a model lipid for liposomes formulated using a broad 
range of phospholipids. Therefore, Egg-PC is a useful lipid to use to investigate the relationship 
between microfluidic parameters/lipid concentration and liposome characteristics. 
The flow ratio is a volumetric flow rate ratio or ratio between the amounts of aqueous and 
organic solvent phases pushed through the channels of a microfluidic cartridge. The stream 
between aqueous and solvent buffers can be adjusted by changing the flow ratio to achieve 
desired characteristics of the liposomes (245, 262). It was found that the size of Egg-PC 
liposomes, formulated using a 1:1 flow ratio, were larger compared to those prepared using 
higher aqueous:organic solvent flow ratios (Figure 2.6 A), which is in agreement with previously 
published data (245). Other flow ratios were suitable for manufacture of small (~100 nm) 
liposomes, preferable for rapid drug adsorption via oral delivery (219). The PDI was not 
impacted by changes in the flow ratio between aqueous phase and organic solvent. However, 
FITC-Ova loading negatively correlated (non-significantly) with increasing flow ratios. Reducing 
the amount of lipid, by increasing the ratio of aqueous to solvent phase (in which lipid is 
dissolved) means that there is less lipid (less material) to form particles, consequently reducing 





Total flow rates did not affect particles size, PDI or protein loading (Figure 2.6 B). However, there 
was a trend that the slower total flow rates resulted in higher reproducibility of the particles 
between the experimental replicas. The findings indicate that higher flow speed through a 
microfluidic mixing cartridge affected the reproducibility of liposome manufacture.  
Finally, increasing lipid concentrations correlated with increases in PDI and FITC-Ova loading. 
Particle size demonstrated a similar trend, however this was not significant (Figure 2.6 C). Higher 
concentrations of lipids mean that there is more material to form liposomes and more protein 
will be entrapped into particles. However, the size and size distribution of the particles was also 
affected making liposome populations more heterogeneous. As previously reported, lipid 
concentration and composition significantly affect liposome characteristics (262). 
Based on these optimisation studies a 2:1 flow ratio was selected for further experiments to 
obtain liposomes with an optimal size (80-200 nm), particle size distribution and the highest 
possible protein loading. A total flow rate of 10 mL/min was selected as optimal for particle 
reproducibility. Finally, lower lipid concentrations were preferred to produce smaller particles 
with lower size distribution. However, as lipid concentration positively correlates with protein 
loading and this is a key parameter in vaccine design, this needs to be optimised with the final 






Figure 2.6 Optimisation of microfluidic parameters for Egg-PC liposome formulation. The 
impact of (A) flow ratio, (B) total flow rate and (C) Egg-PC concentration on particles size, PDI 
and FITC-Ova loading were investigated. Data was analysed using a one-way ANOVA test 
followed by Sidak’s multiple comparison post hoc test (n=3, SD ± mean, *p < 0.05, **p < 0.01, 
***p < 0.001)  
2.4.1.2 Preparation of cationic DSPC/DC-Cholesterol/DSPE-PEG2000 liposomes for an oral 
vaccine delivery 
The cationic liposomes developed for oral vaccine delivery were composed of three lipids: DSPC, 
DC-Cholesterol and DSPE-PEG2000. Long saturated DSPC (18:0 PC) was used as the main lipid. 
The mucus of the small intestine is negatively charged, therefore DC-Cholesterol was added to 
the formulation as a source of positive charge and to increase stability (206). DSPE-PEG2000, 
which interacts with mucus layer, was included to increase retention time in the intestine and 





The impacts of the molar ratio between the lipids, lipid concentration and the aqueous phase 
on liposome formulation was examined (Table 2.3). Ethanol was chosen as an organic solvent, 
as it has low toxicity, which is important for oral vaccines, and the flow rate and ratio were kept 
constant at the pre-determined levels. De-ionised water was the optimal choice for aqueous 
phase as other tested phases resulted in larger polydisperse particles (Table 2.3). A molar ratio 
of 70:26:4 DSPC:DC-Cholesterol:DSPE-PEG2000 at a concentration of 10 mg/mL was optimal for 
production of cationic (+27.2 mV), homogeneous (PDI = 0.231), 60 nm particles (Table 2.3). 
Higher concentrations of lipids resulted in greater surface charge; however, this may negatively 
affect bioavailability of the liposomes in the gut. Strong electrostatic interactions between 
cationic liposomes and negatively charged mucin in the gut was reported to lead to liposomal 
entrapment in mucin and impaired delivery to the M cells (275). 
A histogram of liposome size distribution of the optimised formulation (bold in Table 2.3) 
confirmed that liposomes were homogeneous and the average size was below 100 nm (Figure 
2.7). Smaller liposomes have been reported to have increased and accelerated passage across 
the cell membrane (219). TEM analysis of the particles confirmed that the formulated particles 
were vesicles with a well-defined spherical structure (Figure 2.8). Variation in particle size was 






















































































































Figure 2.7 Histogram of the size distribution of freshly prepared liposomes (optimised 
formulation) in water  
 
Figure 2.8 TEM image of liposome nanoparticles. Bar represents 2000 nm  
2.4.1.3 Stability of cationic DSPC/DC-Cholesterol/DSPE-PEG2000 liposomes 
In order to investigate the stability of liposomes, freshly prepared liposome suspensions were 
incubated at 4°C and 37°C for 7 days. Changes in size, size distribution (PDI), zeta potential and 
FITC-Ova in liposomes were measured overtime. Liposomes were stable upon storage for 7 days 
at 4°C, whereas incubation at 37°C resulted in an increase in particle size after 4 days of 
incubation (from 88 ± 10 nm to 160 ± 62 nm) (Figure 2.9 A). This was in agreement with a study 
by Elsana et al., where they reported that long term storage at 4°C does not affect liposome 
size, however the liposomes stored at 37°C were not stable and the size increased over time 





loss of positive surface charge (Figure 2.9 C). Stability analysis showed no drug release over 7 
days of incubation at 4°C (from 33 ± 5% to 33 ± 13%), whereas incubation at 37°C resulted in  
FITC-Ova release from liposomes (from 33 ± 5% to 11 ± 6%) (Figure 2.9 D). Overall, stability 
analysis has shown that liposome vaccines were stable at 4°C for one week, thus a formulation 
could be stored for administration of all doses of the prime or boost. 
 
Figure 2.9 In vitro stability of liposome nanoparticles over 7 days of incubation at 4°C (grey 
line) or 37°C (black dashed line). (A) Particle size, (B) PDI, (C) zeta potential and (D) FITC-Ova 
remained in liposomes are shown. Data was analysed using a two-way ANOVA followed by 
Sidak’s multiple comparison post hoc test (n=3, mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001)  
2.4.1.4 Liposome vaccine (L-Vac) particle characterisation 
After optimisation of liposome particles for vaccine delivery, liposomes, containing vaccine 
components (AH1td antigen peptide and Pam2Cys adjuvant), were prepared and characterised. 
Non-significant increase in surface charge (23 ± 2 mV) was observed showing that cationic 
properties of liposomes remained stable after entrapment of the vaccine components (Table 
2.4). However, even though the liposome size was only slightly larger (121 ± 16 nm) compared 
to FITC-Ova containing liposomes (88 ± 10 nm), the PDI demonstrated  an increase from 0.18 ± 





two liposome populations (~9 nm and ~120 nm) after formulation with vaccine components 
(Figure 2.10) causing the higher PDI. These formulations were used for oral vaccine delivery as 
the larger population of liposomes fit in the size range (80-400 nm) for oral delivery to achieve 
rapid particle uptake and optimal bioavailability (219). The population of phospholipid 
containing particles that are < 10 nm have only small drug loading capacity, therefore the vast 
majority of drug is delivered within the large particles. 
Table 2.4 Measurements of freshly prepared liposome vaccines (L-Vac) (n=3, mean ± SD).  
Formulation Size, nm PDI Zeta potential, 
mV 
L-Vac 121 ± 16 0.57 ± 0.15 23 ± 2 
 
Figure 2.10 Histogram of the size distribution of L-Vac 
2.4.2 Water-in-Oil-in-Water double emulsion as an oral vaccine delivery system 
2.4.2.1 Soya bean oil based W/O/W double emulsion 
Water-in-oil-in-water double emulsions were used as the second lipid-based vaccine carrier as 
they can improve drug bioavailability and peptide transport into cells (223). Two surfactants, 
the hydrophilic Tween 80 and the lipophilic Span 80, were used in order to stabilise the W1/O 
interphase between the inner water phase (PBS) and the oil phase (soybean oil). The polymeric 
surfactant Pluronic F127 was used to stabilise the interphase between the W1/O emulsion and 
the W2 phase (227). 
Size and PDI of the emulsion were measured using DLS (Table 2.5). As expected, the particles 





emulsion was expected as many anionic and neutral emulsifiers can contribute to negative 
charges in emulsions (Table 2.5) (276). 
Table 2.5 Emulsion parameters on the first day after preparation (n=5). 
Size, nm PDI Zeta potential, mV 
2024.8 ± 217.9 0.776 ± 0.178 -33.2 ± 4.3 
 
 
Figure 2.11 Histogram of the size distribution of freshly prepared W/O/W double emulsion in 
PBS  
2.4.2.2 Stability of W/O/W double emulsion 
Emulsions were incubated for 7 days at 4°C, 25°C and 37°C for stability analysis. Phase 
separation was observed after one day of incubation at 37°C (Figure 2.12). After seven days of 
incubation phase separation was seen with all storage conditions and increased with increasing 
temperature. Transmitted light microscopy images showed an increase in particle size after 
seven days of incubation at 37°C, whereas incubation at 4°C and 25°C did not affect the size of 
the emulsion particles (Figure 2.13). The results demonstrated that although stability of the 
W/O/W double emulsions was prolonged at the lower storage temperature (4°C), phase 
separation occurs within seven days of preparation. To minimise an impact of phase separation 
on the efficacy of the emulsion vaccines, emulsion vaccines, freshly prepared before the prime 







Figure 2.12 Visual comparison and stability of soya bean oil based W/O/W double  emulsions 
incubated at indicated temperatures over 7 days  
 
Figure 2.13 Transmitted light microscopy images of the double emulsions on days 0, 1 and 7 
of incubation. 400x magnification, bars represent 20 µm  
2.4.3 Assessing efficacy of oral vaccines to induce immune responses in naïve mice 
Vaccination via the oral route must stimulate local and systemic immune responses to generate 
protection against cancer. Therefore, the ability of the oral vaccine formulations to induce 





immunised using a prime-boost vaccination strategy in order to maximise immune responses. 
Vaccines were composed of a long peptide AH1td containing the CD8 epitope, AH1 and two 
CD4 epitopes (from tetanus and diphtheria toxins) delivered with the immunostimulatory 
adjuvant Pam2Cys (Pam2Cys-SKKKK) in either liposomes or W/O/W double emulsions. Control 
groups received vaccine components in PBS, or were administered adjuvant in PBS or PBS only. 
The immune responses generated were evaluated in multiple ways; including cytotoxicity, 
expansion and activation of immune cells locally (in the mLN) and systemically (in the spleen). 
2.4.3.1 In vivo cytotoxicity 
An in vivo cytotoxicity assay was used in order to evaluate the potential of oral lipid-based 
vaccines to induce cytotoxic immune responses against tumour antigens in immunised mice. 
Mice were given vaccine by gavage once daily from days 1 to 4 (prime) and days 21 to 24 (boost). 
Due to low oral bioavailability and necessity to give large amount of antigen, four doses of 
vaccine was administered in the course of an each immunisation. On day 28, the immunised 
mice were injected with target cells labelled with the CD8 tumour peptide used in the vaccine. 
If the vaccine has stimulated the development and expansion of tumour peptide specific CD8+ 
T cells, the target cells should be killed (277). Similar number of control cells (not labelled with 
the CD8 tumour peptide) were also injected at the same time. Both populations of cells were 
stained with different fluorescent dyes, allowing quantification of the cytotoxic effect. On day 
30, the number of tumour antigen labelled target cells were measured in the spleens of the 
immunised mice. Oral vaccination with liposome and emulsion vaccines did not induce 
detectable cytotoxic immune responses against target cells (Figure 2.14). The results were 
comparable between the experiment replicates (Appendix Figure 7.5). This assay is widely used, 
but usually with antigens that are given by injection (277). In addition, it measures the 
development of systemic, rather than local gastrointestinal responses. These results suggest 
the oral vaccines were not capable of stimulating the expansion of high levels of cytotoxic CD8+ 
T cells. However, numerous different innate and adaptive immune cells are involved in anti-
tumour immune response (31, 32). The expansion and activation of these cells are important 
factors for clinical efficacy of oral vaccines (171, 278). Therefore, the immune profile of the 
immunised mice needed to be analysed in more detail, both locally and systemically, in order 






Figure 2.14 In vivo killing of adoptively transferred AH1 peptide-labelled spleen cells. Naïve 
mice were orally immunised with PBS (Ctrl), Pam2Cys in emulsion (Adjuv), AH1td peptide and 
Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). Data was analysed using a 
Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc test (n=4, mean ± SD)  
2.4.3.2 Lymphocyte expansion 
CD4⁺ and CD8⁺ T cells are essential for anti-tumour immunity (43, 44, 49, 126), therefore 
lymphocyte populations were further investigated in naïve mice given a prime and boost 
immunisation with the oral vaccine formulations. Local immune response analysis of T 
lymphocytes in the mLN showed an increase in the number and frequency of CD4⁺ T cells in 
mice vaccinated with the W/O/W double emulsion (E-Vac) versus the control groups that were 
given unformulated vaccine, adjuvant only or PBS (p < 0.01) (Figure 2.15 A and B). Results 
indicate that vaccination with E-Vac was able to induce robust helper CD4+ T cell expansion. In 
general, the role of CD4+ T cells in tumours differs depending on a number of factors including 
tumour stage (46). In combination with tumour-specific CD8+ T cells, CD4+ T cells can kill tumour 
cells (43), as well as contributing to tumour-induced immunosuppression and escape (127). 
Further analysis showed the total number of CD8⁺ T cells was increased in mice that were given 
E-Vac compared to mice that received control vaccines (p < 0.01), but there was no difference 
in cell frequency (Figure 2.15 C and D). Even though the oral vaccination did not induce an 
increase in the frequency of cytotoxic CD8+ T cell in mLN, the expansion of total number of these 
cells suggests that E-Vac has a capacity to effectively modulate local cytotoxic CD8+ T cell 
population and, possibly, tumour eradication. Therefore, the expansion of these cells is a 
positive indicator of activated immune responses. Vaccination with liposomes (L-Vac) showed 
similar trends but the data was not statistically different showing only partial responses. 
Another important lymphocyte population analysed in mLN was CD19+ B cells that can support 
T cell mediated immunity by production of tumour-specific antibodies (268). The frequency and 
number of CD19+ B cells was higher in mice vaccinated with the E-Vac and L-Vac formulations 

















compared to mice that received control vaccines (p < 0.05) (Figure 2.15 E and G). Both oral 
vaccine formulations triggered CD19+ B cells expansion suggesting that oral vaccines might 
induce local antigen-specific B cell-mediated immunity (279). 
 
Figure 2.15 Lymphocyte populations in mLN of tumour-free mice following oral immunisation 
with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). (A, C, E) frequency and (B, D, F) number of (A and B) 
CD4+ T cells, (C and D) CD8+ T cells and (E and F) CD19+ B cells. Data was analysed by using a 
Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc test (n=5, mean ± SD, *p 
< 0.05, **p < 0.01)  
In order to investigate systemic immunity after oral vaccination, immune cell analysis was 
carried out investigating mouse lymphocyte populations in spleen. There was no difference in 
the frequency or number of CD8+ and CD4+ T cells in mice given E-Vac or L-Vac compared to 
mice that received control vaccines (Figure 2.16 A-D). The second experimental replica 
demonstrated comparable results whereas the third replica showed decrease in lymphocyte 
populations after immunisation with E-Vac compared to control group (Ctrl) (Appendix Figure 





of lymphocytes in the gut rather than a systemic expansion, possibly due to local vaccine 
delivery along with more robust activation at the vaccine delivery site (174). Regardless the lack 
of systemic T cell expansion, local immune responses can be sufficient to eradicate tumours as 
immune cells from draining lymph nodes closely interact with the TME and highly influence 
tumour development (175). 
Analysis of CD19+ B cells in the spleen showed partly consistent results with local CD19+ B cell 
expansion as the cells were present at higher frequency after immunisation with E-Vac 
compared to control group (Ctrl) (p < 0.01) (Figure 2.16 E). Although, in contrast to previous 
results (Figure 2.15 F), there was no increase in the number of the cells compared to mice that 
received control vaccines (Ctrl and Adjuv) (Figure 2.16 F). Again, oral vaccination was more 
effective in triggering the expansion of local rather than systemic lymphocyte populations. In 
general, the role of B cells in tumour tissues remains controversial. Barbera-Guillem et al. has 
shown that depletion of B cells positively correlated with reduced tumour burned in mouse 
model of CRC and 50% of CRC patients (81). Immunosupressive functions and negative-B cell 
impacts on tumour progression might be induced by B regulatory cells (87). Contrarily, other 
studies have demonstrated that B cells are required for optimal CD4+ and CD8+ T cell anti-
tumour immunity in B16 melanoma in mice, and in human CRC tumours (268, 279). In addition, 
infiltration of B cells into various tumours including breast, ovarian, non-small cell lung and CRC 
cancer has correlated mostly with positive outcomes (83, 265, 269). Potential mechanisms for 
this beneficial effect include the role of B cells in antigen presentation and T cell activation, and 
direct anti-tumour effects through antibody-dependent cytotoxicity (268). B cell-based cancer 
immunotherapy has been tested in preclinical studies and has shown positive results in 
generating anti-tumour immunity and inducing T cell responses in various types of cancer (280). 
Further analysis of activation status and surface markers of B cell populations in mLN and spleen 







Figure 2.16 Lymphocytes populations in spleens of naïve mice following oral immunisation 
with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). (A, C, E) frequency and (B, D, F) number of 
lymphocytes. (A and B) CD4+, (C and D) CD8+ and (E and F) CD19+ populations. Data was 
analysed using a Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc test 
(n=5, mean ± SD, *p < 0.05, **p < 0.01)  
Overall, in naïve mice, oral immunisation with lipid-formulated peptide vaccines stimulated 
lymphocyte accumulation (CD4+ and CD8+ T cells, and B cells) in the mLN (Figure 2.15). This was 
an important finding for an oral peptide-based vaccine, which are usually non-highly 
immunogenic, and confirmed the ability of the vaccine to stimulate an immune response. That 
is was possible to see any changes in overall frequencies and numbers of these large populations 
of cells, suggests that oral immunisation with this subunit vaccine is highly immune stimulatory. 
With similar subunit vaccines, changes in immune responses are often subtle and can only be 
detected using exogenous antigens and/or transgenic cells (281) or MHC tetramers (247). 
However, further analysis of surface markers on T cells is necessary to determine the activation 





2.4.3.3 Lymphocyte activation 
Lymphocyte activation status is another parameter, which can provide important information 
on vaccine efficacy. In order to look at lymphocyte responses in depth, the expression of the 
activation markers CD62L (L-Selectin), CD25 (alpha chain of IL-2 receptor), CD44 (cell adhesion 
molecule), CD122 (beta chain of IL-2 and IL-15 receptor) and Ki67 (nuclear protein) were 
examined in spleen and mLN (Figure 2.17, Figure 2.18, Figure 2.19 and Figure 2.20). These are 
common markers used to distinguish naïve (CD62L+CD44-), activated (CD25+), antigen-
experienced (CD62L-CD44+), memory (CD122+CD44+) and proliferating (Ki67+) CD4+ and CD8+ T 
cells. 
T cell subpopulations were analysed in spleen to determine systemic activation. The frequency 
of naïve CD8+CD62L+CD44- and CD4+CD62L+CD44- cells was reduced in mice that received E-Vac 
compared to mice that received PBS or Vac control (p < 0.05) (Figure 2.17 A and B), indicating 
possible conversion from naïve to effector T cell populations after vaccination with E-Vac. 
Indeed, mice that received E-Vac had a higher frequency of activated CD8+CD25+ and CD4+CD25+ 
cells (p < 0.05) (Figure 2.17 C and D) and antigen-experienced CD8+CD62L-CD44+ and CD4+CD62L-
CD44+ cells (p < 0.05) (Figure 2.17 E and F) compared to mice that received control vaccines (Ctrl 
and Vac). Vaccination with emulsions also increased the frequency of a population of memory 
phenotype CD8+CD122+CD44+ and CD4+CD122+CD44+ T cells (p < 0.01) (Figure 2.17 G and H), 
confirming E-Vac’s effect on stimulating systemic T cell responses. The proliferation marker Ki67 
was also investigated (Figure 2.17 I and J), however T cells did not display upregulated 
proliferation after oral immunisation. Analysis of total numbers of T cell subpopulations showed 
corresponding results (Figure 2.18). The exception was CD8+CD25+ and CD8+CD122+CD44+ cells, 
which did not shown increased numbers of these cells as compared to control groups (Figure 
2.18 C and G). The results were variable among the experimental replicas indicating borderline 
immune responses generated with peptide vaccines (Appendix Figure 7.8 and Appendix Figure 
7.9), which is common to non-highly immunogenic subunit vaccines. 
Vaccination with L-Vac produced similar trends as to vaccination with E-Vac but the data was 
not statistically different (except the number of antigen-experienced CD4+CD62L-CD44+ cells 
which was significantly higher compared to PBS control group (p < 0.05)(Figure 2.18 F). Again, 







Figure 2.17 Frequencies of CD8+ and CD4+ T cell populations in spleens of naïve mice following 
oral immunisation with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) 
or emulsion (E-Vac). Frequency of live (A, C, E, G, I) CD8+ and (B, D, F, H, J) CD4+ (A and B) 
CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+, (G and H) CD122+CD44+ and (I and J) 
Ki67+ T cell populations. Data was analysed using a Kruskal-Wallis test followed by Dunn’s 






Figure 2.18 Numbers of CD8+ and CD4+ T cells in spleens of naïve mice following vaccination 
with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-
Vac). Number of live (A, C, E, G, I) CD8+ and (B, D, F, H, J) CD4+ T cells. (A and B) CD62L+CD44-, 
(C and D) CD25+, (E and F) CD62L-CD44+, (G and H) CD122+CD44+ and (I and J) Ki67+ T cells 
populations. Data was analysed using a Kruskal-Wallis test followed by Dunn’s multiple 





Local immune responses of CD4+ and CD8+ T cells in mLN were investigated (Figure 2.19 and 
Figure 2.20). In contract to systemic T cell responses, only the number of naïve 
CD4+CD62L+CD44- cells significantly decreased in mice vaccinated with E-Vac compared to mice 
that were given vaccine in PBS (Vac) (p < 0.05)(Figure 2.19 B) showing only partial local response 
to oral vaccination with E-Vac. However, no decrease in frequency of CD4+CD62L+CD44- cells 
was observed after vaccination with E-Vac or L-Vac, and there was no decrease in the number 
of these cells after vaccination with L-Vac (Figure 2.19 A and B). No significant differences in 
frequency or number of CD25+, CD62L-CD44+, CD122+CD44+ and Ki67+ populations of CD4+ T 
cells was found compared to control groups (Figure 2.19 C-J). Data from the second 
experimental replica demonstrated comparable results (Appendix Figure 7.10) and only one 
replica demonstrated variable results (Appendix Figure 7.11) possible due to modest immune 
responses generated by peptide vaccine. 
Analysis of CD8+ T cells in mLN showed similar results (Figure 2.20). No significant differences 
were detected among all investigated CD8+ T cell subpopulations after oral vaccination with E-
Vac or L-Vac. Overall, analysis of local T cells responses have revealed that oral vaccines were 







Figure 2.19 CD4+ T cell response in mLN of naïve mice following vaccination with PBS (Ctrl), 
AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). (A, C, E, G, I) 
frequency and (B, D, F, H, J) number of live CD4+ T cells. (A and B) CD62L+CD44-, (C and D) 
CD25+, (E and F) CD62L-CD44+, (G and H) CD122+CD44+ and (I and J) Ki67+ populations. Data 
was analysed using a Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc 






Figure 2.20 CD8+ T cell response in mLN of naïve mice following vaccination with PBS (Ctrl), 
AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). (A, C, E, G, I) 
frequency and (B, D, F, H, J) number of live CD8+ T cells. (A and B) CD62L+CD44-, (C and D) 
CD25+, (E and F) CD62L-CD44+, (G and H) CD122+CD44+ and (I and J) Ki67+ T cell populations. 
Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post hoc test 





In summary, these findings demonstrated that oral vaccination with subunit vaccines induced T 
cell responses by reshaping multiple T cell subpopulations in the spleen. E-Vac triggered the 
generation of CD44+CD122+ memory CD8+ T cells, which are protective against previously 
encountered antigens suggesting successful tumour antigen presentation to T cells (282). Fewer 
CD62L+CD44- CD8+ and CD4+ T cells were detected indicating there were fewer naïve/less-
differentiated cells T cells in spleens after vaccination. The reduction in naïve CD62L+CD44- cells 
correlated with the increased population of CD62L-CD44+ cells, suggesting a shift from naïve to 
antigen experienced T cells. It was also shown that E-Vac elevated expression of activated CD25+ 
T cells. 
Local T cell activation was observed in spleen but not observed in mLN (Figure 2.19 and Figure 
2.20). This was in contrast with lymphocyte expansion, which was detected in mLN but not in 
spleen (Figure 2.15 and Figure 2.16), implying distinct systemic and local T cell oral vaccination-
induced activation and expansion. At the local site, lymphocytes expand but do not exhibit 
activation markers, which may mean that once activated T and B cells exit the lymph node via 
the efferent lymphatics and traffic to infection/tumour/vaccine delivery site via the vascular 
system (passing through the spleen) to mediate their effector functions (283). Lymphocyte 
accumulation at the vaccine delivery site also explains why there was no systemic lymphocyte 
expansion detected in spleen but why some transiting activated cells were detected. In addition, 
systemic T cell activation implies that oral vaccines sufficiently induce both local and systemic 
lymphocyte responses. 
There was no changes in the expression of proliferation marker Ki67, despite the increased 
number and frequency of T cells in mLN. Possibly, the proliferation signalling has already been 
downregulated and the cells stopped proliferating before analysis. Another possible 
explanation, it could be that oral vaccines did not induce proliferation but cell migration into 
mLN. That would explain increased numbers of cells and lack of proliferation marker. 
Comparing the two lipid-based formulations, the smaller responses detected in naïve mice 
immunised with the liposome vaccine are likely related to antigen loading in vaccine particles. 
The EE of liposomes for a model protein was ~33.3% (Figure 2.9 A), meaning that only third of 
the antigen was delivered inside liposomes, in combination with adjuvant and protected against 
the gastric fluids. The rest of antigen was delivered in non-encapsulated form, which could not 
be protected against proteolytic degradation in gut, thus reducing immune stimulation. Besides 





interactions with gastric fluids, mucin or intestinal epithelium need to be taken into 
consideration analysing differences between E-Vac and L-Vac. 
2.4.3.4 Innate immune cell response 
Cells of the innate immune response are important in determining if potent effector immune 
responses are generated. Innate immune cells can play an important role in anti-tumour 
responses by cross-presenting tumour antigens to T cells and polarising pro-inflammatory 
immune responses via cytokine production (30, 270). Successful activation of cells of the innate 
immune system can expand the positive outcomes to therapeutic oral vaccination. Therefore, 
the impact of oral vaccination on cells of the innate immune system was quantified. Cell surface 
markers such as CD11c, CD11b and F4/80 have long been used to identify various populations 
of mouse innate immune cells. CD11c and CD11b are involved in cellular adhesion, and can be 
used to identify DC (CD11c+) and myeloid cells (CD11b+), respectively (171, 271). F4/80 is a 
glycoprotein used to identify mouse macrophages (F4/80+) (284). Therefore, the innate immune 
subpopulations were distinguished by the expression of these three surface markers. All 
combinations of these markers were analysed (CD11c+F4/80+CD11b+, CD11c-F4/80+CD11b+, 
CD11c+F4/80-CD11b+, CD11c-F4/80-CD11b+, CD11c+F4/80+CD11b-, CD11c+F4/80-CD11b-, CD11c-
F4/80+CD11b-) which represent various subtypes of immune cells.  
Subpopulations of innate immune cells were affected by oral vaccination (Figure 2.21 and Figure 
2.22). Analysis of local innate immune responses in mLN showed that the frequency and number 
of triple positive CD11c+F4/80+CD11b+ cells increased after vaccination with E-Vac compared to 
mice that received adjuvant or vaccine in PBS controls (p < 0.01) (Figure 2.21 A and B). 
Moreover, oral vaccination with E-Vac led to a lower frequency and number of myeloid CD11c-
F4/80-CD11b+ cells (p < 0.05) and CD11c-F4/80+CD11b- macrophages (p < 0.05) compared to the 
mice that were given control vaccines (Figure 2.21 C-F). Significant increase in the frequency of 
CD11c-F4/80+CD11b+ cells and decreased the number of CD11c-F4/80+CD11b+, CD11c-
F4/80+CD11b+ and CD11c-F4/80+CD11b+ cells after vaccination with E-Vac were also observed 






Figure 2.21 Innate immune cell populations in mLN of naïve mice following vaccination with 
PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes 
(L-Vac) or emulsion (E-Vac). (A, C, E) frequency and (B, D, F) number of (A and B) 
CD11c+F4/80+CD11b+, (C and D) CD11c-F4/80-CD11b+ and (E and F) CD11c-F4/80+CD11b- cell 
populations. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 
post hoc test (n=5, mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001)  
The frequency and number of innate immune cells were further analysed in spleen (Figure 2.22 
and Appendix Figure 7.13). Significant differences were observed only in two cell 
subpopulations following oral immunisation with L-Vac. The frequency of the 
CD11c+F4/80+CD11b+ cell population was significantly increased compared to PBS control (p < 
0.05) (Figure 2.22 A) and the frequency of CD11c-F4/80+CD11b+ cells decreased compared to 
the adjuvant control group (p < 0.05)(Appendix Figure 7.13 A). Oral vaccines reshaped innate 
immune cell profile only in one experimental replica indicating modest capability to affect 





Corresponding with previous results, oral vaccines were more effective in reshaping the innate 
immune cells populations in mLN rather than in spleen. 
 
Figure 2.22 Composition of innate immune cell populations in spleen of naïve mice following 
vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in 
PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). (A, C, E) frequency and (B, D, F) number of 
(A and B) CD11c+F4/80+CD11b+, (C and D) CD11c-F4/80-CD11b+ and (E and F) CD11c-
F4/80+CD11b- innate immune cell populations. Data was analysed using a Kruskal-Wallis test 
and Dunn’s multiple comparison post hoc test (n=5, mean ± SD, *p < 0.05)  
Results from this study support previous findings showing that vaccination with oral vaccines 
resulted in the accumulation of CD11b+ and CD11c+ cells (285, 286). An increase in cells 
expressing myeloid and DC markers, CD11b and CD11c, respectively, indicated the activation of 
innate immune responses in mLN. IFNβ producing CD11c+ DC subsets are critical at early stages 





of these cells with an oral vaccine may induce antitumor CD8+ T responses (272). Dong et al. 
used tumour cell lysate for oral vaccination against CRC and found reduced growth of 
subcutaneous CT26 tumours in a mouse model (171). They showed that CD11c+ DC were 
necessary for the stimulation of IFNγ producing CD8+ and CD4+ T cells. In addition, it was 
reported that activation of CD11b+ (integrin alpha M) cells induced anti-tumour innate 
immunity, promoted maturation of pro-inflammatory macrophages, regulated vascularisation 
and supressed tumour growth by inducing T cell recruitment in models of murine and human 
cancer (271). Overall, an increase in cells expressing CD11c+CD11b+ correlates with positive 
vaccination outcomes. In addition, the CD11c-F4/80-CD11b+ cell subpopulation represents 
myeloid precursor cells, which have been reported as being immunosuppressive and pro-
metastatic, promoting tumour growth (87). Hence, the reduction of these cells supports a shift 
to activated immunity and positive vaccination outcomes. An increase in cells expressing F4/80+ 
has been associated with cancer progression and increasing tumour size in mice (287) while 
depletion of F4/80+ cells correlated with tumour regression and improved immunotherapy (273, 
284). Our data revealed a decreased population of CD11c-F4/80+CD11b- cells upon vaccination, 
suggesting that this might positively influence immune responses. Overall, the results indicate 
activated innate immune cell prolife after immunisation with oral vaccines. 
Overall, this part of study demonstrated that oral administration of a peptide vaccine managed 
to modulate not only adaptive, but also innate immunity, showing potential for generating 
efficient immune responses where multiple immune cells would be involved in fighting cancer. 
2.4.3.5 Cytokine expression by T cells 
Cytokine expression  by T cells can be used as a prognostic marker as upregulation of IFNγ and 
IL-2 cytokines correlates with positive CRC outcomes (288), whereas IL-17A expression is 
associated with both positive and negative roles in CRC (53, 71). Analysis of cytokine expression 
in the spleen showed a decreased frequency of IL-17A+ expressing CD4+ cells in mice vaccinated 
with the liposome vaccine formulation compared to the adjuvant control group (p < 0.05), 
whereas the rest of the analysis did not reveal any significant differences (Figure 2.23, Appendix 
Figure 7.16 and Appendix Figure 7.17). No changes were detected in the analysis of cytokines-






Figure 2.23 Expression of cytokines in spleens of naïve mice following vaccination with PBS 
(Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-
Vac) or emulsion (E-Vac). The expression of (A and B) IFNγ, (C and D) IL-2 and (E and F) IL-17A 
cytokines in (A, C, E) CD4+ and (B, D, F) CD8+ T cells. Data was analysed using a Kruskal-Wallis 






Figure 2.24 Expression of cytokines in mLN of naïve mice following vaccination with PBS (Ctrl), 
Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) 
or emulsion (E-Vac). The expression of (A and B) IFNγ, (C and D) IL-2 and (E and F) IL-17A 
cytokines in (A, C, E) CD4+ and (B, D, F) CD8+ T cells. Data was analysed using a Kruskal-Wallis 
test and Dunn’s multiple comparison post hoc test (n=5, mean ± SD)  
It appears from this data that even though the lipid-formulated vaccines were able to stimulate 
changes in immune cell populations and T cell activation, they were not able induce measurable 
changes in cytokine profiles. It is possible that intracellular cytokine detection of cells 
restimulated with PMA and ionomycin is not sensitive enough to identify changes between 
cytokine-producing T cells as this method analyses all T cells rather than antigen-specific T cell 
subpopulations. Sensitivity is important when there are only small populations of antigen-
specific T cells present in the immune organs, which is likely the case when a peptide antigen is 
given orally. Therefore, methods that detects cytokine production in antigen specific T cells 





spot (ELISpot) assay where the number of cytokines producing immune cells is detected after 
specific stimulation with antigen peptide (248, 285). In addition, MHC multimer staining could 
be used that would allow the specific identification of antigen-specific cytokine-producing T 
cells (272). These methods would help to identify small T cell subpopulations and find subtle 
changes in cytokine expression after oral vaccination. 
2.4.4 Colorectal cancer treatment in an orthotopic mouse model 
To investigate the ability of the oral vaccines to stimulate a therapeutic anti-tumour immune 
response, the vaccines were tested in an orthotopic mouse CRC model. Mouse colon carcinoma 
CT26 cells were injected into the wall of the mouse caecum during surgery. Due to the 
complexity of the surgery, only a maximum of five surgeries/session could be done. Mice were 
then randomly allocated to one of five treatment groups. This approach was repeated over 
multiple days in order to achieve the final group sizes. The mice then received four doses of 
vaccines for four consecutive days on 6 to 9 post-surgery. Therapy was started on day 6 so as 
to allow time for the tumour cells to establish and proliferate. Mice were killed on day 17 post-
surgery based on previous studies ((243) and pilot studies that were carried out by Ginny Niemi, 
Department of Microbiology and Immunology, University of Otago), unless they reached pre-
determined humane endpoints earlier. 
2.4.4.1 Weight change 
Mice were treated with the same vaccines and controls as used in the vaccine efficacy 
assessment study detailed in Section 2.4.3. The weight of the mice was measured throughout 
the experiment to assess the general health of the mice (Figure 2.25). There was some weight 
loss in the immediate postoperative period, but this did not exceed 10%, which was in 
accordance with guidelines for assessing the health and condition of mice. There was no weight 







Figure 2.25 Mice weight throughout the experiment 
2.4.4.2 Tumour size 
Tumours were collected and measured at day 17 post-surgery. The tumours were of irregular 
shape and location (Figure 2.26) making weight a more appropriate measure rather than 
tumour area. If mice had multiple tumours they were pooled for weighing. 
 
Figure 2.26 Representative photos of mouse tumours (outlined with blue dashes) in situ. Mice 
were vaccinated with PBS (Ctrl), Pam2Cys in emulsion (Adjuv), AH1td peptide and Pam2Cys in 
PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac)  
Tumour weight analysis demonstrated smaller tumours in the groups vaccinated with either of 
the lipid-based vaccine formulations, L-Vac and E-Vac, in comparison to mice that received PBS 
as a control (p < 0.05) (Figure 2.27). Administration of unformulated vaccine or adjuvant in 






Figure 2.27 Tumour growth after vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or 
AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). Data was 
analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post hoc test (n=8-10, 
mean ± SD, *p < 0.05)  
Overall, oral vaccination with the AH1td peptide subunit vaccine formulated in lipid-based 
vaccine carriers, as liposomes and emulsions, reduced the growth of tumour cells in the GIT 
confirming therapeutic efficiency. Both vaccine formulations demonstrated therapeutic 
effectiveness regardless of the immune responses in naïve mice where E-Vac induced more 
robust immune responses than L-Vac. This implies that immune responses induced by oral 
immunisation in naïve mice might not accurately correspond to therapeutic effectiveness of the 
vaccine and immune system activation in tumour-bearing mice. For this, it is necessary to 
investigate anti-tumour immune responses after oral vaccination in tumour-bearing mouse 
model. 
2.4.4.3 Immune responses in lymphoid tissues of tumour-bearing mice 
Reduced tumour growth indicated that oral vaccination triggered anti-cancer immune 
responses. The next step was to investigate possible mechanisms and factors involved in the 
detected therapeutic efficacy of the oral vaccines. Knowing that the oral vaccines induced 
immune responses in tumour-free mice, analogous immune responses were analysed in 
immune organs of mice injected intracaecally with CT26 tumour cells. This was done in order to 
determine if oral vaccines stimulate similar immune responses in tumour-free mice and in the 
tumour model. 

























Mice underwent tumour injection surgery and then 6 days later were treated with the oral 
vaccines for 4 days. On day 17 mice were killed and systemic immune responses were evaluated 
by analysing splenic lymphocyte and innate immune cell populations as previously described in 
Section 2.3.14. No significant differences in T cell and innate immune cell populations were 
found after oral vaccination (Figure 2.28 and Figure 2.29). This was in agreement with studies 
in naïve mice. However, the frequency of CD19+ B cell was increased in spleen of naïve mice 
after vaccination with E-Vac (Figure 2.16), whereas tumour-bearing mice did not show this 
effect (Figure 2.28 E).  The results imply that the presence of tumour in mice alters the immune 
responses to oral vaccines. 
 
Figure 2.28 Lymphocyte populations in spleens of tumour mice following oral immunisation 
with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). Frequency (A, C, E) and total number (B, D, F) of live (A 
and B) CD4+, (C and D) CD8+ (E and F) and CD19+ populations. Data was analysed using a 






Figure 2.29 Innate immune cell populations in spleens of tumour mice following oral 
immunisation with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in 
PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). Frequency and total number of live (A) 
CD11c+F4/80+CD11b+, (B) CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) CD11c-F4/80-
CD11b+, (E) CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b- and (G) CD11c+F4/80-CD11b- 
populations. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 
post hoc test (n=4-6, mean ± SD)  
CD25+, CD44+ and CD122+CD44+ CD4+ and CD8+ T cell subpopulations were examined in both 
spleen and mLN. Similar to naïve mouse studies, no significant differences were found in T cell 
subpopulations in mLN (Figure 2.30). However, as opposed to studies in naïve mouse, treatment 
with oral vaccines did not induce T cell activation in spleen, as no significant differences were 






Figure 2.30 T cell populations in mLN of tumour mice following oral immunisation with PBS 
(Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-
Vac) or emulsion (E-Vac). Frequency of (A and B) CD25+, (C and D) CD44+ and (E and F) 
CD122+CD44+ (A, C, E) CD4+ and (B, D, F) CD8+ T cell populations. Data was analysed using a 






Figure 2.31 T cell populations in spleens of tumour mice following oral immunisation with PBS 
(Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-
Vac) or emulsion (E-Vac). Frequency of (A and B) CD25+, (C and D) CD44+ and (E and F) 
CD122+CD44+ (A, C, E) CD4+ and (B, D, F) CD8+ T cell populations. Data was analysed using a 
Kruskal-Wallis test and Dunn’s multiple comparison post hoc test (n=4-6, mean ± SD)  
These results are different from the findings in naïve mice, where systemic and local immune 
responses were found with multiple cell populations. The presence of cancer appears to have 
altered immune responses to oral vaccination, since there were no detectable differences 
between the treatment groups in the tumour studies. This might be due to the immune system’s 
interactions with tumours where this interplay shapes the immune phenotype in line with 
tumour progression (28). The immune system undergoes changes at different time points 
during disease progression (localised disease, tumour elimination or progressive metastatic 
disease). Tumour-associated inflammation, an immunosuppressive TME, the tumour stroma 
and direct interactions with cancer cells remodels the immune response potentially altering the 
composition of immune cell populations (289). At the time point chosen for analysis, tumour 





variable. This would hinder detection of immune responses to the oral vaccination. In addition, 
the naïve mice were vaccinated using a prime-boost vaccination strategy that expands immune 
responses and facilitates the detection of activated immune cells. Tumour bearing mice could 
not be vaccinated using this strategy due to the fast development of tumours in the mouse 
model. Therefore, responses would be difficult to detect without doing in vitro restimulations 
(248) or using antigen specific technologies such as MHC multimers (272). 
However, despite the lack of detectable immune responses in spleen and mLN, oral vaccination 
reduced tumour growth providing a functional read out that therapeutic immune responses 
were generated.  Cell populations in spleen and mLN are only one part of a complex network 
involved in anti-tumour responses. Tumour rejection or progression is highly associated with 
the TME and the immune cell composition at the tumour site. 
2.4.4.4 Immune responses in the TME 
In order to understand what determinants contribute to decreased tumour growth in the TME, 
the levels of cytokines in mouse tumours and the infiltration of immune cells were analysed. 
IFNγ, IL-10, IL-1β, IL-17A, IL-6 and TNF cytokines are part of the cytokine network in CRC, which 
shapes disease progression (266).  
On day 17, in mice where tumours were present, tumours were homogenised and levels of 
cytokines were measured. As tumour size was very variable the amount of media used to 
homogenise the tumours was varied according to tumour size. 
Only very low levels of cytokines could be detected and there were no significant differences 







Figure 2.32 Cytokines in mouse tumours after oral therapeutic vaccination with PBS (Ctrl), 
Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) 
or emulsion (E-Vac). Concentration of  (A) IFNγ, (B) IL-10, (C) IL-1β, (D) IL-17A, (E) IL-6 and (F) 
TNF cytokines per mg  of tumour tissue. Data was analysed using a Kruskal-Wallis test 
followed by Dunn’s multiple comparison post hoc test (n=5-6, mean ± SD)  
Tumour infiltrating lymphocytes (TIL) are another important determinant that has been used to 
predict CRC outcomes (57, 83, 265, 269). Therefore, analysis of TIL could provide information 
on anti-tumour immune-mediated mechanisms that led to the reduction of tumour growth. The 
numbers of CD4+, CD8+ T and B cells were analysed in tumour homogenates (Figure 2.33). The 
numbers of CD4+ T and B lymphocytes infiltrating into tumours increased after vaccination with 
subunit vaccines compared to control groups (Figure 2.33 A and C). Vaccination with E-Vac 
induced a significant increase in the  infiltration of CD4+ T cells into tumours compared to the 
mice that received unformulated vaccine in PBS (p < 0.05) (Figure 2.33 A). Vaccination with L-
Vac also showed a trend for increased numbers of CD4+ T cells however, the results were more 
variable and not significant. CD8+ T cells appeared to have similar trends but the differences 
were not significant (Figure 2.33 B). Lastly, vaccination with L-Vac induced infiltration of CD19+ 







Figure 2.33 Lymphocyte infiltration into tumours following oral therapeutic immunisation 
with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). Number of (A) CD4+, (B) CD8+ and (C) CD19+ B 
lymphocytes in tumours. Data was analysed using a Kruskal-Wallis test followed by Dunn’s 
multiple comparison post hoc test (n=7-9, mean ± SD, *p < 0.05, **p < 0.01)  
Tumour infiltrating innate immune cells also indicate anti-tumour immunity and can be used as 
predictive markers for CRC outcomes in mouse studies and human (77, 87, 271, 290), therefore 
analysis of innate immune cells expressing CD11c, CD11b and F4/80 surface markers was carried 
out. As shown in Figure 2.34, there were no measurable changes in the populations of innate 






Figure 2.34 Infiltration of innate immune cells into mouse tumours following oral therapeutic 
vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in 
PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). Number of (A) CD11c+F4/80+CD11b+, (B) 
CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) CD11c-F4/80-CD11b+, (E) 
CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b-, (G) CD11c+F4/80-CD11b- innate immune cells in 
tumours. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post 
hoc test (n=4-6, mean ± SD)  
The profile of immune cells in tumours can be used as a strong predictive marker for the disease 
outcome. Several research groups have developed an Immunoscore method, which predicts 
disease recurrence or overall survival based on CD3+ and CD8+ T cell infiltrates into tumours. A 
high Immunoscore positively correlates with disease-free survival; therefore, it can be included 






Analysis of the TME revealed that oral vaccines induced TIL accumulation in tumours. CD4+ T 
cell infiltration into CRC has been reported as positive prognostic marker and increased 
densities of these cells were associated with improved relapse-free and disease-specific survival 
(57). In addition, B cells infiltration into CRC positively contributes to disease progression and 
disease-specific survival (279). Tumour-antigen specific B cells have been reported to be able to 
support T cells to generate long-term anti-tumour responses (269). Overall, L-Vac and E-Vac 
vaccination induced an infiltration of lymphocytes into tumours, which might contribute to 







AH1-tetanus/diphtheria toxoid peptide and Pam2Cys adjuvant subunit vaccine components 
were prepared in lipid-based formulations for oral delivery. Oral vaccination was chosen as an 
optimal delivery route for CRC treatment that could induce local immune responses at the 
tumour site, as well as systemic responses. Cationic liposomes and W/O/W double emulsions 
were chosen as two vaccine carriers for their beneficial properties such as being able to 
encapsulate, protect and deliver vaccine components to a target site, to increase bioavailability 
and they have a simple manufacturing process. The two lipid-based formulations were prepared 
and optimised for mouse studies. Systemic and local immune activation in naïve mice was found 
in spleen and mLN after treatment with W/O/W emulsion formulations, while both stimulated 
functional therapeutic immune responses. In addition, the data indicate that both lipid-based 
oral subunit vaccines benefited CRC treatment by inducing anti-tumour immune responses and 
immune cell infiltration into tumours. The results demonstrate that the lipid-based formulations 
have the potential to benefit CRC treatment in humans. For human therapy, one or multiple 
CRC tumour-associated antigens could be delivered in the lipid formulations. 
Overall consideration of formulation and manufacturing requirements, immune response 
generated and ability to stimulate anti-tumour responses, suggests that the double emulsion 
formulation is preferable. However, liposomes have also demonstrated therapeutic efficacy. 
However as tumours were still present, studies should be carried out to determine if anti-
tumour responses could be further improved either by modifying the current formulations or 































3 Modified E-Vac and L-Vac vaccines and combination therapy 
3.1 Introduction 
Oral E-Vac and L-Vac, described in Chapter 2, have demonstrated ability to induce anti-tumour 
immune responses and reduce tumour growth, however the vaccines were not able to induce 
complete tumour rejection in the orthotopic mouse model of CRC. Therefore, the therapeutic 
effectiveness of the oral vaccines had to be improved in order to strengthen therapeutic 
potential of oral vaccination for clinical studies.  
There are multiple ways to boost therapeutic response to oral lipid-based vaccines including 
direct vaccine modification or combination therapy with other immunotherapies or treatment 
methods. Direct vaccine modifications can be applied to the vaccine components or vaccine 
carrier. Modifications of vaccine components aim to enhance immunogenicity and the overall 
immune response to antigen. Carrier modifications can improve particle stability or increase 
particle uptake in the GIT. Oral immunisation can be used in combination with non-
immunocompromising treatment methods such as therapeutic drugs or checkpoint inhibition 
immunotherapy. 
To test a broad spectrum of therapeutic response-inducing methods, two vaccine modifications 
were chosen, antigen and liposomal modification, as well as two combined therapies utilising 
NSAID and checkpoint inhibition immunotherapy. All of these strategies have been previously 
tested in preclinical or clinical studies and demonstrated positive results. Therefore, these four 
techniques cover a variety of methods that can potentially improve therapeutic outcomes of 
oral vaccination. 
3.1.1 Self-adjuvanting conjugate vaccines 
Toll-like receptor ligands covalently coupled to peptide antigens are known as ‘self-adjuvanting’ 
conjugate vaccines as these formulations have a built-in-adjuvant system, which can 
significantly enhance vaccine efficiency (256, 291). Adjuvant-antigen conjugates deliver antigen 
to APC whilst simultaneously inducing activation (292). Due to simultaneous antigen delivery 
and APC activation, self-adjuvanting conjugate vaccines improve antigen immunogenicity by 
increased induction of immune responses and enhanced cellular uptake (293). However, 
chemical conjugation of peptide with adjuvant limits ability to easily change antigens or use 




Pam2Cys was the first TLR used in conjugate vaccine development in the 1990s (254, 292). The 
antigen-adjuvant conjugates are able to mature DC, induce long-lasting memory and CD8+ T cell 
responses in humans (161, 294), and also trigger strong local inflammation, Th1 type cytokine 
and chemokine production in mice (150). Murine tumour experiments have demonstrated 
promising results towards enhanced therapeutic effect in cancer treatment (256, 292). 
Pam2Cys-synthetic peptide-conjugates modulated myeloid cell populations in tumours, 
increased CD8+ T cell populations in vaccine-draining lymph nodes and spleen, and reduced 
tumour growth. 
This built-in-adjuvant system was applied to the lipopeptide Pam2Cys-Ser-(Lys)4 adjuvant and 
AH1td peptide that were used as two separate components in the original lipid-based 
formulations (Chapter 2). Pam2Cys-Ser-(Lys)4 was attached covalently to AH1td peptide via 
solid-phase peptide synthesis by our collaborators Distinguished Professor Dame Margaret 
Brimble and Dr Paul Harris (University of Auckland). Previously it was shown that conjugated 
ligands retain their bioactivity and agonistic activity upon conjugation (291, 294) and the 
coupling does not have any negative impact. 
3.1.2 UEAI lectin-mediated targeting to M cells 
Lectins are highly specific carbohydrate-binding proteins. Cellular membranes are commonly 
composed of glycosylated lipids and proteins, therefore lectins are a good option to improve 
targeted delivery via lectin-glycan binding-mediated endocytosis. Due to the unique 
carbohydrate signature on various types of cells, certain lectins can preferentially bind to certain 
target cells. One of these lectins, Ulex europaeus agglutinin I (UEAI) is specific for α-L-fucose 
glycans. α-L-fucose glycans are expressed on the surface of M cells, thus the UEAI selectively 
binds to the M cells in the PP (295).  
UEAI has been tested on liposome and polymeric nanoparticles for oral drug/vaccine delivery 
and showed promising results. PLGA nanoparticles coated with UEAI were effectively 
transported to the small intestine demonstrating increased retention in the PP and exclusive 
binding to M cells (230). Local immune responses in the gut and antibody production following 
oral particle delivery confirmed the positive effect of UEAI modification and targeted delivery 
in mouse studies (186). UEAI-modified insulin-loaded liposomes decreased blood glucose level 
in comparison to uncoated insulin-loaded liposomes (218) demonstrating increased therapeutic 
efficiency due to the targeted delivery. Moreover, the UEAI-coated liposomes were able to 





antigen-specific IgA and IgG antibodies and IL-2 and IFNγ cytokines, compared to IM delivery or 
unmodified liposomes (193, 208). Therefore, functionalising the surface of L-Vac with UEAI 
could improve intestinal uptake and subsequently enhance the immune responses induced by 
the original L-Vac (Figure 2.27). 
UEAI can be attached to the liposomes in a two-step process involving cholesteryl 
hemisuccinate (CHS). In order to do this, CHS was included in the liposome formulation (208) 
and DSPE-PEG2000 was removed, as it may interfere with UEAI binding. The CHS was then 
activated to enable the formation of a stable amide bond with the N-terminus of UEAI (UEAI-L-
Vac). 
3.1.3 Nonsteroidal anti-inflammatory drugs as CRC therapeutic agents 
Use of NSAID has been associated with reduced risk of various types of cancer including CRC 
(120). For this reason, NSAID are part of tumourigenesis-suppressing chemopreventive 
strategies. They target the immune evasive mechanisms utilised by premalignant lesions and 
prevents cancer development (296-298). In addition, they can be used therapeutically, targeting 
tumour-associated inflammation to restore immunosurveillance and anti-tumour immune 
responses. 
NSAID such as aspirin, naproxen, sulindac, celecoxib and licofelone (LCF) have been extensively 
investigated in preclinical and clinical trials for the prevention and treatment of CRC (298). 
Multiple studies have revealed anti-cancer effects for these pharmaceutical agents (120). NSAID 
act on inflammation in the TME by inhibiting the activity of cyclooxygenases (COX-1 and COX-
2). COX-1 is a housekeeping protein responsible for tissue homeostasis while COX-2 is induced 
during inflammation and is often overexpressed in tumour tissues (Figure 3.1). COX modulates 
inflammation via production of inflammatory mediators called eicosanoids. One of these is 
PGE2, which fuels tumour-promoting inflammation by altering the balance between pro- and 
anti-inflammatory cytokines leading to immune suppression. PGE2 upregulation is found during 
colon carcinogenesis and is related to the proliferative, metastatic and proangiogenic potential 





Figure 3.1 Roles, functions and inhibitors of COX and LOX. White box indicates arachidonic 
acid, a substrate for the synthesis of inflammatory mediators (blue) regulated by enzymes 
(gray boxes) that belong to two major classes, COX and LOX (black boxes). COX and LOX 
inhibitors (red ovals) result upregulation (arrows up) and downregulation (arrows down) of 
biological roles (green) of the metabolites. 15-PGDH – 15-hydroxyprostaglandin 
dehydrogenase; HETE – hydroxyeicosatetraenoic acids. Figure taken and adapted with 
permission from Greene et al. (300)  
Another target of NSAID is 5-lipooxygenase (5-LOX), which metabolises arachidonic acid to 
inflammatory mediators called leukotrienes (301). 5-LOX is also overexpressed in early stages 
of carcinogenesis and inhibition of this enzyme led to reduced growth of tumour cells (302). 
LCF is a novel anti-inflammatory drug, clinically tested as an osteoarthritis treatment. LCF is 
known as a dual COX/5-LOX inhibitor, which demonstrated cytotoxic, anti-proliferative and anti-
angiogenic activities in cancer cell lines and mouse studies. LCF reversed stem-like properties in 
ovarian cancer cells (296); showed dose dependent inhibition of urothelial cell carcinoma, lung 
carcinoma and chronic myeloid leukaemia growth in mice (303, 304); as well as therapeutic 
effect in skin cancer and pancreatic ductal adenocarcinoma mouse models  (257, 305). Multiple 
preclinical studies have confirmed the therapeutic effect of LCF in the treatment of CRC (237, 
306). LCF supressed small intestinal and colorectal tumour growth in APCMin/+ mice in dose-
dependent manner (237).  
LCF modulates expression of pro-inflammatory molecules by inhibiting both COX enzymes, 5-
LOX-activating protein FLAP and LTB4 receptor (237). Furthermore, LCF induces apoptosis in 





also been reported to induce apoptosis in HCA-7 colon cancer cells via the mitochondrial 
pathway in a caspase-depended manner (307). 
These studies have demonstrated the therapeutic potential for LCF in the treatment of CRC, 
therefore LCF could improve therapeutic efficacy of peptide vaccines. As LCF is poorly soluble 
in water (0.001 mg/mL), delivery in a lipid based formulation, for example intercalated into the 
lipid bilayer of liposomes or the oil-phase of emulsions, is necessary. To facilitate this process, 
LCF can be coupled to an anchor composed of carbon tail, which can stabilise LCF in the 
hydrophobic phase of the formulations. Work from the Hook laboratory has shown that such 
modifications increase lipophilicity of LCF and can be used to develop lipid-based formulations 
(unpublished data). 
3.1.4 Checkpoint inhibitor immunotherapy 
Up-regulated expression of immune checkpoints on tumour cells is one of the mechanisms 
commonly utilised by malignant cells to escape immunosurveillance (54, 80). Immune 
checkpoints are regulators of immune responses that prevent autoimmune reactions and 
induce self-tolerance in normal tissues (105). Binding of the overexpressed receptors, for 
example programmed death-ligand 1 (PD-L1), PD-1, CTLA-4 or lymphocyte-activation gene 3 
(LAG-3) led to suppression of the activity of the tumour infiltrating immune cells (54). This is 
one reason why the immune system cannot eradicate malignant cells, even if a tumour has high 
levels of infiltrating immune cells. The immunotherapy strategy that uses specific monoclonal 
antibodies to block the interaction between immune checkpoints and their ligands is called 
checkpoint inhibitor therapy as described in Section 1.2.2.1. 
Antibody immunotherapy might not be sufficient to fully eliminate cancer cells, especially in 
checkpoint-deficient tumours; therefore, this approach is often combined with other 
immunotherapy strategies. Checkpoint inhibition in combination with therapeutic peptide 
vaccination has resulted in successful tumour elimination and prolonged survival in mouse 
studies and human trials (140, 308). 
The CT26 colorectal carcinoma (used in the orthotopic mouse model) is an immunogenic 
tumour with a high mutational load and up-regulated expression of PD-L1 (80), and therefore 
is a good candidate for checkpoint immunotherapy. PD-1 is expressed on T cells, thus PD-1/PD-
L1 interactions can be blocked with either anti-PD-1 or anti-PD-L1 antibodies (Figure 3.2). As 
monoclonal antibodies are large proteins, they have to be delivered by injection. For mouse 




to-five administrations per mouse (309, 310). The antibodies are administered when tumours 
are established and immune cell infiltrates are present. 
 
Figure 3.2 Checkpoint inhibitor immunotherapy using anti-PD-L1 and anti-PD-1 antibodies. 
PD-L1 is expressed on tumour cells, whereas PD-1 is expressed on T cells. The inhibition of PD-
1/PD-L1 interaction prevent immunosuppression of T cells and retains T cell ability to 






3.2 Chapter aims 
The emulsion (E-Vac) and liposome (L-Vac) vaccines demonstrated promising therapeutic effect 
in an orthotopic mouse model of CRC. The oral therapeutic peptide subunit vaccines reduced 
tumour growth, however did not manage to completely eliminate malignant cells. 
The aim of this chapter was to improve the therapeutic response of the E-Vac and L-Vac vaccines 
by adopting various vaccine modifications and combination therapies in order to achieve 
complete tumour elimination. These were: 
(1) conjugation of adjuvant directly to the tumour antigen,  
(2) liposome surface modification to improve uptake in the gut, 
(3) addition of a NSAID, and 





3.3 Materials and methods 
3.3.1 Materials 
AH1/tetanus-diphtheria toxoid peptide and Pam2Cys adjuvant conjugate (Pam2Cys-AH1td 
construct; 
(±)Pam2Cys-(L)-Cys-SKKKK-SPSYVYHQFGGSILMQYIKANSKFIGIPMGLPQSIALSSLMVAQ—OH) was 
synthesised in the Brimble Peptide Chemistry Laboratory, the School of Biological Sciences, the 
University of Auckland. Lectin from UEAI lectin was purchased from Sigma-Aldrich, USA. CHS 
was obtained from Avanti Polar Lipids, USA. N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), N-Hydroxysuccinimide (NHS), 1-iodobutane, potassium carbonate (K2CO3) 
were obtained from Merck, Germany. LCF ([6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-
dihydro-1H-pyrrolizin-5-yl] acetic acid) was obtained from Santa Cruz Biotechnology, USA. 
Monoclonal antibodies anti-mouse PD-1 (CD279; clone 29F.1A12) and rat IgG2a (clone 2A3) 
isotype control (anti-trinitrophenol) were purchased from Bio X Cell, USA. Monoclonal 
antibodies anti-mouse CD279 (PD-1; clone RMP1-14) and anti-mouse CD152 (CTLA-4, clone 
9H10) were purchased from BioLegend, USA. 
3.3.2 Pam2Cys adjuvant-peptide (Pam2Cys-AH1td) construct 
3.3.2.1 Preparation of Pam2Cys-AH1td emulsion vaccines 
To investigate the therapeutic efficacy of Pam2Cys-AH1td construct compared to the original E-
Vac or a combined construct emulsion vaccines, five different oral formulations were prepared 
(Table 3.1). Pam2Cys-AH1td conjugate (Con) or AH1td peptide were dissolved in PBS at a final 
concentration of 0.4 nmol/100 μL. Pam2Cys adjuvant was added into AH1td solution at a final 
concentration of 0.5 μg/100 μL (0.31 nmol/100 μL) as these concentrations were used in the 
primary vaccines (E-Vac and L-Vac). These solutions in PBS were used as vaccine controls (Con 
Vac and Vac) or formulated in W/O/W double emulsions (Con E-Vac and E-Vac). 
For emulsion preparation, Pam2Cys-AH1td construct (1 nmol/100 μL) or AH1td peptide (1 
nmol/100 μL) with Pam2Cys adjuvant (1.25 μg/100 μL) solutions in 1 mL PBS (for final volume of 
2.5 mL emulsion vaccine) were used as the W1 phase in the W/O/W double emulsion. 1 mL of 
2.8% Tween 80 non-ionic surfactant in PBS (v/v) (W1) was added drop-by-drop to 1 mL of 
soybean oil containing 15.9% Span 80 (v/v, oil phase) and the emulsion (final W1:Oil ratio of 1:1) 
was homogenised for 5 min, 6000 rpm at room temperature (IKA Laboratory Equipment, USA). 
0.5 mL of 0.5% Pluronic F-127 non-ionic surfactant in PBS (W2) (w/v) was added drop-by-drop 





min, 500 rpm at 4°C (IKA Laboratory Equipment, Germany). The final concentration of Pam2Cys-
AH1td construct and AH1td peptide was 0.4 nmol/100 μL and the final concentration of 
Pam2Cys adjuvant was 0.5 μg/100 μL (0.31 nmol/100 μL) in the W/O/W double emulsion. 
Table 3.1 Pam2Cys-AH1td-modified emulsion vaccine formulations 
Group name Dosage Description of formulations/vaccines 
Ctrl 100 µL x 4 doses PBS  
Vac 100 µL x 4 doses AH1td (2 μg or 0.4 nmol/dose) and Pam2Cys (0.5 μg or 
0.31 nmol/dose) in PBS 
Con Vac 100 µL x 4 doses Pam2Cys-AH1td conjugate (2.4 μg or 0.4 nmol/dose) in 
PBS 
E-Vac 100 µL x 4 doses AH1td (2 μg or 0.4 nmol/dose) and Pam2Cys (0.5 μg or 
0.31 nmol/dose) in emulsion 
Con E-Vac 100 µL x 4 doses Pam2Cys-AH1td construct (2.4 μg or 0.4 nmol/dose) in 
emulsion 
 
3.3.2.2 Preparation of Pam2Cys-AH1td liposome vaccines 
The final concentrations of Pam2Cys-AH1td construct and AH1td peptide in liposome vaccines 
were 0.4 nmol/100 μL/dose (Table 3.2). The final concentration of Pam2Cys adjuvant in non-
construct liposome vaccine (L-Vac) was 0.5 μg/100 μL, the same as to the original liposome 
vaccine. Microfluidic mixing was used for liposome preparation with a flow ratio of 2:1 and a 10 
mL/min total flow rate. Pam2Cys-AH1td construct (0.6 nmol/100 μL) or AH1td peptide (0.6 
nmol/100 μL) and Pam2Cys adjuvant (0.75 μg/100 μL), were dissolved in deionised water 
(aqueous phase). DSPC:DC-Cholesterol:DSPE-PEG2000 lipids were dissolved in absolute ethanol 
(organic solvent) at 70:26:4 molar ratio. Liposome suspensions were dialysed for 24h against 
deionised water using a 0.1-0.5 kDa MWCO membrane replacing water every six hours in order 
to remove ethanol from the formulations. 
Liposome size (Z-average), PDI and zeta potential were measured after dialysis as described in 
Section 2.3.5. 
3.3.3 UEAI lectin-coated liposomes 
UEAI lectin-coated liposomes were prepared using a two-step reaction involving liposome 
surface activation and coupling as previously described (208). Before this was done, the 




Liposomes consisting of DSPC, DC-Cholesterol and CHS were prepared using the microfluidic 
mixing technique (Figure 3.3 A). Formulation parameters used in the previous experiments were 
used (10 mL/min total flow rate and 2:1 (aqueous phase:organic solvent) flow ratio). Lipids were 
dissolvent in absolute ethanol. Deionised water was used as aqueous phase. Liposomes were 
dialysed for 12h against deionised water using a 0.1-0.5 kDa MWCO membrane in order to 
remove ethanol (water was replaced every three hours).  
Size, size distribution and zeta potential of the DSPC/DC-Cholesterol/CHS liposomes were 
measured using DLS as per Section 2.3.5. 
The surface of the liposomes was modified using carbodiimide crosslinker chemistry, EDC/NHS 
activation reaction, adapted from (208) to enable attachment of UEAI lectin (Figure 3.3 B). The 
carboxyl groups of CHS were esterified by incubating liposomes with 0.2 mol/L of NHS and 0.1 
mol/L EDC for 12h at 4°C with gentle stirring. After esterification, the liposome suspension was 
dialysed against deionised water for 24h at room temperature using a 0.1-0.5 kDa MWCO 
membrane in order to remove excess EDC and NHS. The liposome suspension was then 
incubated with different concentrations of UEAI lectin for 12h at 4°C (Figure 3.3 C) to attach 
amino groups of UEAI to activated esters on CHS. 
Particle size, PDI and zeta potential were measured using DLS as previously described in Section 






Figure 3.3 Preparation of UEAI lectin-coated liposomes. (A) Formulation of DSPC:DC-
Cholesterol:CHS liposomes. (B) Activation of carboxylic acid group of CHS by EDC/NHS 
coupling. (C) Conjugation of UEAI lectin on liposomes via a stable amide bond. Figure adapted 
from Li et al. with permission (208) 
For animal studies, the final concentration of AH1td peptide was 2 μg/100 μL and Pam2Cys 
adjuvant was 0.5 μg/100 μL in UEAI lectin-coated liposome vaccines (UEAI L-Vac). For this, 
AH1td peptide and Pam2Cys adjuvant were dissolved in deionised water (aqueous phase) at 
concentrations of 3 μg/100 μL and 0.75 μg/100 μL, respectively. DSPC/DC-Cholesterol/CHS were 
dissolved in absolute ethanol (organic solvent) at a molar ratio of 70:15:15 (at a concentration 
of 10 mg/mL). The aqueous phase and organic solvent solutions were mixed using 2:1 flow ratio 
and 10 mL/min total flow rate as in previous experiments. 100 μg/mL of UEAI lectin protein was 
used for liposomal surface coating as described above. 
The freshly prepared UEAI lectin-coated liposome vaccines were used for therapeutic cancer 
treatment in an orthotopic mouse model (Table 3.2) and were compared to the original L-Vac 




Table 3.2 Modified liposome vaccine formulations. 
Group name Dosage Description of formulation/vaccines 
Ctrl 100 µL x 4 doses PBS  
L-Vac 100 µL x 4 doses AH1td (2 μg or 0.4 nmol/dose) and Pam2Cys (0.5 μg or 
0.31 nmol/dose) in liposomes 
Con L-Vac 100 µL x 4 doses Pam2Cys-AH1td conjugate (2.4 μg or 0.4 nmol/dose) in 
liposomes 
UEAI L-Vac 100 µL x 4 doses AH1td (2 μg or 0.4 nmol/dose) and Pam2Cys (0.5 μg or 
0.31 nmol/dose) in UEAI lectin-coated liposomes 
 
3.3.4 Optimisation of licofelone-C4 (LCF-C4) emulsion and liposome vaccines 
3.3.4.1 LCF-C4 synthesis 
Licofelone-C4 (LCF-C4) (Figure 3.4) was prepared with assistance from A. Cho (School of 
Pharmacy, University of Otago), an undergraduate student who worked under the direct 
supervision of M. Naciute. LCF (150 mg, 0.39 mmol) and iodobutane (150 μL, 1.32 mmol) were 
dissolved in acetone (15 mL) and K2CO3 (600 mg, 4.55 mmol) was added. The reaction was 
heated at 80°C with stirring for 3h. The mixture was filtered, the solvent removed and the 
residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate as 
eluent) to give LCF butyl ester (37 mg, 74%) as a pale yellow solid. The chemical structure of the 
product was confirmed using 1H proton nuclear magnetic resonance (NMR) and high resolution 
mass spectrometry (HRMS). 
 





3.3.4.2 LCF-C4 liposome vaccine preparation 
LCF-C4 liposomes were prepared and characterised with assistance from A. Cho (School of 
Pharmacy, University of Otago), an undergraduate student who worked under the direct 
supervision of M. Naciute. For the optimisation experiments, DSPC/DC-Cholesterol or DSPC/DC-
Cholesterol/DSPE-PEG2000 liposomes were prepared. Lipids were dissolved in absolute ethanol 
together with different concentrations of LCF-C4. Deionised water was used as aqueous phase. 
Liposomes were formulated and characterised as described in Section 2.3.3. 
LCF-C4 entrapment in liposomes was quantified using high performance liquid chromatography 
(HPLC). Liposome formulations were diluted in acetonitrile/methanol (2:1) and filtered through 
a 0.2 μm filter. The quantification of LCF-C4 was carried out on an Agilent HPLC system (Agilent 
Technologies 1200 Series ELSD, USA) using an Agilent ZORBAX Eclipse XDB-C8 (80 Å, 3.5 µm, 2.1 
x 50 mm) HPLC column operating at 40°C and a flow rate of 0.5 mL/min. Elution was carried out 
in A (0.05% trifluroacetic acid in purified water) and B (acetonitrile): 10% B to 100% B in 8 min, 
hold for 8 min, then 100% B to 10% B in 1 min and hold for 3 min. The calibration standards 
were prepared using corresponding liposome components (LCF-C4, lipids) in 2:1 
acetonitrile/methanol. 
For therapeutic testing studies, the final concentrations of AH1td peptide and Pam2Cys adjuvant 
in liposome vaccines were 2 μg/100 μL and 0.5 μg/100 μL/dose, respectively (Table 3.3). The 
final concentration of LCF-C4 was 1 mg/mL which was dissolved in absolute ethanol together 
with 70:26:4 DSPC:DC-Cholesterol:DSPE-PEG2000 lipids prior to formulation. A 10 mL/min total 
flow rate and 2:1 flow ratio were used to make liposomes as in previous experiments. Ethanol 
was removed by rotary evaporation (IKA Rotary evaporator, Germany). 
3.3.4.3 LCF-C4 emulsion vaccine preparation 
For emulsion preparation, the final concentrations of AH1td peptide and Pam2Cys adjuvant 
were 2 μg/100 μL and 0.5 μg/100 μL/dose, respectively (Table 3.3). To formulate 2.5 mL of 
emulsion vaccine, solutions of AH1td peptide (5 μg /100 μL) and Pam2Cys adjuvant (1.25 μg/100 
μL) were mixed with PBS (1 mL final volume, W1 phase). 1 mL of 2.8% Tween 80 non-ionic 
surfactant was added to the W1 solutions (v/v) which was then added drop-by-drop to 1 mL of 
soybean oil containing 2.5 mg/mL LCF-C4  and 15.9% Span 80 (v/v, oil phase) and the suspension 
(final W1:Oil ratio of 1:1) was homogenised for 5 min at 6000 rpm at room temperature. 1 mL 




previously prepared W1/O emulsion and the 2:2:1 W/O/W double emulsion was stirred for 30 
min, 500 rpm at 4°C.  The final concentration of LCF-C4 was 100 μg/100 μL. 
In total, five vaccination groups were prepared for therapeutic testing of LCF-C4-modified oral 
vaccine formulations (Table 3.3). 
Table 3.3 LCF-C4 emulsion and liposome vaccines. 
Group name Dosage Description of formulation/vaccines 
Ctrl 100 µL x 4 doses PBS  
LCF 100 µL x 4 doses 100 μg/dose of LCF-C4 in emulsion 
E-Vac 100 µL x 4 doses AH1td (2 μg/dose) and Pam2Cys (0.5 μg/dose) in 
emulsion 
LCF E-Vac 100 µL x 4 doses LCF-C4 (100 μg/dose), AH1td (2 μg/dose), Pam2Cys (0.5 
μg/dose) in emulsion 
LCF L-Vac 100 µL x 4 doses LCF-C4 (100 μg/dose), AH1td (2 μg/dose), Pam2Cys (0.5 
μg/dose) in liposomes 
 
3.3.5 Oral vaccination combined with anti-PD-1 immunotherapy 
Previously optimised LCF-C4-modified oral vaccine formulations (LCF E-Vac and LCF L-Vac) were 
used in a combined treatment with checkpoint inhibitor immunotherapy (Table 3.4). The 
vaccines, composed of LCF-C4, AH1td peptide and Pam2Cys adjuvant and formulated either in 
double emulsion or liposomes were delivered orally (PO). Three doses (Figure 3.5 B) of anti-PD-
1 antibody or an IgG2a isotype control (Iso) were administered via IP injection at a concentration 






Table 3.4 Combined therapeutic oral vaccination with anti-PD-1 immunotherapy 
Group name Description of treatment/vaccines 
IP PO 
Dosage 100 µL x 3 100 µL x 4 
Ctrl PBS PBS 
PD-1 LCF Anti-PD-1 antibody (200 
μg/injection) 
LCF-C4 (100 μg/dose) in emulsion 
Iso LCF E-Vac Rat IgG2a isotype control 
(200 μg/injection) 
LCF-C4 (100 μg/dose), AH1td (2 μg/dose) 
and Pam2Cys (0.5 μg/dose) in emulsion 
PD-1 LCF E-Vac  Anti-PD-1 antibody (200 
μg/injection) 
LCF-C4 (100 μg/dose), AH1td (2 μL/dose), 
Pam2Cys (0.5 μg/dose) in emulsion 
PD-1 LCF L-Vac Anti-PD-1 antibody (200 
μg/injection) 
LCF-C4 (100 μg/dose), AH1td (2 μg/dose), 
Pam2Cys (0.5 μg/dose) in liposomes 
 
3.3.6 Therapeutic oral vaccination 
An orthotopic mouse model of CRC for therapeutic cancer treatment studies was established as 
per Section 2.3.12. The mice were given vaccine formulations orally once daily for four 
consecutive days starting on the 6th day after IC tumour injection (Figure 3.5). All oral 
formulations were freshly prepared prior to the first immunisation and were stored at 4°C 
between treatments. For combined therapy with oral therapeutic vaccination and anti-PD-1 
immunotherapy, the mice were given anti-PD-1 antibody or isotype control injections on the 
6th, 9th and 12th days post-surgery (Figure 3.5 B). 
Control groups were killed on the 16th day post-surgery, while treatment groups were killed on 
the 20th day after surgery, unless reaching humane endpoints earlier.  The clinical condition and 
weight of mice were monitored daily throughout the experiment. 
The mice were euthanised by cervical dislocation on the indicated analysis days (Figure 3.5). 
Spleens, mLN and tumours were collected and weighed and single cell suspensions were 





Figure 3.5 Experimental schemes for therapeutic cancer treatment studies. 2.5 x 104 tumour 
cells were injected into the wall of the caecum 6 days prior vaccination. Mice were treated 
with vaccine for four consecutive days. Control groups were analysed on the 16th day and 
treatment groups on the 20th day post-surgery (unless a humane endpoint was reached 
earlier). (A) Schedule for therapeutic treatments with Pam2Cys-AH1td construct, UEAI lectin- 
and LCF-C4-modified oral vaccine formulations. (B) Schedule for combined oral vaccination 
and anti-PD-1 immunotherapy treatment. Anti-PD-1 antibody or rat IgG2a isotype control 
were administered via IP injection on days 6, 9 and 12  
3.3.7 Flow cytometric analysis 
Cell surface staining was carried our as per Section 2.3.14.1 and analysed as per Section 2.3.14.3. 
To distinguish PD-1 expression on TIL, a gate was set on F4/80-CD11c-CD3+CD4+ (CD4+ T cells) or 
F4/80-CD11c-CD3+CD8+ (CD8+ T cells) cells, which were then analysed for expression of PD-1+. 
FMO were used for cell gating for each fluorophore in the panel. 
3.3.8 Statistical analysis 
Statistical comparisons between the groups were carried out using the non-parametric normal 
distribution one-way Kruskal-Wallis test (ANOVA) and Dunn’s multiple comparison test 
performed using GraphPad Prism 7 (GraphPad Prism Software Inc, USA). If p values were ≤ 0.05, 






3.4 Results and Discussion 
3.4.1 Self-adjuvanting emulsion vaccine  
Self-adjuvanting technology was investigated to improve the immune responses stimulated by 
the lipid-formulated oral cancer vaccines. AH1td peptide was covalently conjugated to Pam2Cys-
SKKKK adjuvant using a peptide linker. This was done by collaborators in the Brimble Peptide 
Chemistry Laboratory, School of Biological Sciences, the University of Auckland.  
The Pam2Cys-AH1td construct was used as an oral therapeutic CRC vaccine either delivered on 
its own dissolved in PBS (Con Vac) or formulated in a W/O/W double emulsion (Con E-Vac). The 
therapeutic response to these two formulations was compared to the peptide and adjuvant 
delivered as separate components in PBS (Vac) or in a W/O/W double emulsion (E-Vac). The 
amount (molar concentration) of AH1td peptide and Pam2Cys was kept consistent for each 
vaccine. The time points for tumour analysis was based on the previous experiment (Figure 2.5 
and Figure 2.27) which showed that while untreated control mice or those given control 
formulations (lacking antigen, adjuvant or unformulated) have to be killed at day 16 due to 
tumour size, animals treated with the lipid-formulated vaccine could be left longer. Therefore, 
in order to more stringently monitor the impact of the immune responses on tumour growth, 
including the impact of modifications made to the vaccines, animals treated with formulations 
were hypothesised to improve survival were killed at day 20 (unless humane endpoints were 
reached earlier). Due to this experiment design, differences in tumour growth were compared 
to the original vaccine, not the unvaccinated controls. The control mice were used to confirm 






Figure 3.6 (A) Tumour growth after vaccination with PBS (Ctrl), non-conjugated AH1td peptide 
and Pam2Cys adjuvant (Vac) or self-adjuvanting Pam2Cys-AH1td conjugate in PBS (Con Vac). 
Tumour weights were analysed 16 days after tumour injection. (B) Tumour growth after 
vaccination with non-conjugated AH1td peptide and Pam2Cys adjuvant (E-Vac) or Pam2Cys-
AH1td construct (Con E-Vac) in double emulsion. Tumour weights were analysed 20 days after 
tumour injection (closed symbols) or when humane endpoints were reached (open symbols). 
Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=5, 
mean ± SD)  
In line with the study carried out in the Chapter 2, tumour growth was similar for untreated 
mice (Ctrl) and mice treated with unformulated non-conjugated AH1td peptide and Pam2Cys 
adjuvant (Vac) (Figure 3.6 A).  The decision about when to analyse data from mice treated with 
the self-adjuvanting construct was difficult. These types of vaccines have generated potent 
immune responses when delivered by injection (256, 291, 292); however, there were no data 
on the use of such constructs for oral vaccination against CRC. Therefore, it was hypothesised 
that unformulated, the self-adjuvanting construct would have no or minimal activity and 
therefore mice were killed at day 16. In support of this, mice given the unformulated self-
adjuvanting construct (Con Vac) had similar weight tumours in comparison to the other controls 
(no vaccine or unconjugated peptide and adjuvant in PBS). AH1td peptides are amphiphilic 
molecules that might have self-assembling properties in aqueous buffer (PBS), moreover 
attachment of the lipopeptide Pam2Cys to the AH1td peptide increases the hydrophobicity of 
the construct, which supports micelle formation (311, 312). This could partially protect the 
active components of the self-adjuvanting vaccine delivered in PBS, however Con Vac did not 
demonstrate reduced tumour growth (Figure 3.6 A). 
Formulations were hypothesised to have therapeutic effect were examined on day 20, unless 
clinical humane endpoints were reached earlier (Figure 3.6 B). No difference in the tumour 
weights was found between the mice that were given the original E-Vac or the emulsion 





That there was no effect after treatment with the Pam2Cys-AH1td construct delivered in the 
emulsion was a surprising result. However, there is no previous research used W/O/W double 
emulsion as a carrier for oral delivery of self-adjuvanting peptide vaccines to treat CRC. The lack 
of efficacy may be explained by studying the mechanisms of peptide entrapment and escape 
from the inner aqueous phase of a double emulsion. During emulsion preparation, the self-
adjuvanting peptide construct was loaded into the inner aqueous phase (W1). The conjugation 
of the AH1td peptide to Pam2Cys-SKKKK adjuvant increased the overall hydrophobicity due to 
the lipophilic properties of the adjuvant. Hydrophobic regions of the peptide and adjuvant can 
interact with the interphase of the W1/O emulsion (313). This interfacial activity can disrupt the 
interphase and cause leakage leading to reduced stability of the emulsion (226). Consequently, 
escape of the self-adjuvanting peptide from the double emulsion may be facilitated. 
Unentrapped construct would not be protected from proteolysis and would not reach the M 
cells. Therefore, increased hydrophobicity of the construct, destabilisation of the interphase 
and uncontrolled release may explain the lack of efficacy of therapeutic oral vaccination with 
the Pam2Cys-AH1td construct in double emulsion. 
For future studies, osmolytes such as salts or small molecules could be used to stabilise the 
inner phase by interacting with lipophilic emulsifier and preventing peptide diffusion (226). 
Moreover, other research has demonstrated that the peptide release could be controlled by 
adjusting the composition of oil phase (224). 
Overall, oral delivery of self-adjuvanting vaccines either in PBS (Con Vac) or in emulsion (Con E-
Vac) did not demonstrate improved anti-tumour activity. 
3.4.2 Self-adjuvanting and UEAI lectin-modified liposome vaccines 
3.4.2.1 Characterisation of self-adjuvanting liposome vaccines 
The self-adjuvanting Pam2Cys-AH1td construct was further evaluated as an oral cancer therapy 
following formulation in liposomes. 
The Pam2Cys-AH1td construct was formulated in liposomes (Con L-Vac) following the method 
used for preparation of the primary liposome vaccines (L-Vac) described in Section 2.3.3.2. The 
molar concentration of the construct was the same as the molar concentration of the AH1td 
antigen peptide in the L-Vac formulation (Table 3.2).  
The characteristics of formulation are shown in Table 3.5. Con L-Vac liposomes were larger 




however the difference was non-significant. The size distribution (0.63 ± 0.09 vs 0.57 ± 0.15) 
and zeta potential (22.8 ± 4.3 mV vs 23 ± 2 mV) of Pam2Cys-AH1td liposomes were comparable 
to that of the L-Vac formulation. 
Table 3.5 Characterisation of freshly prepared AH1td-Pam2Cys liposomes (n=3, mean ± SD). 





244.1 ± 16.2 0.63 ± 0.09 22.8 ± 4.3 
 
The histogram of size distribution displayed two peaks showing two populations of liposomes 
with particle sizes varying between 15-50 nm and 200-1000 nm (Figure 3.7). Again, these two 
peaks were analogous to the L-Vac liposomes (Figure 2.10). 
 
Figure 3.7 Size distribution histogram of Pam2Cys-AH1td liposome vaccine (Con L-Vac) 
The surface charge of the Con L-Vac liposomes remained positive, which is preferable for an 
oral vaccine (Table 3.5). Overall results have shown that Pam2Cys-AH1td liposomes were similar 
to L-Vac, suggesting the construct did not affect liposomal characteristics and the Con L-Vac 
formulation could be used for the treatment of CRC in mouse studies. 
3.4.2.2 UEAI lectin-modified liposome preparation 
Liposomal surface modification with UEAI lectin was examined as a method for increasing 
vaccine uptake by M cells. In order to provide an anchor for UEAI attachment, CHS was added 





DLS. DSPC:DC-Cholesterol:CHS molar ratios of 60:20:20 and 70:15:15 resulted in relatively small 
liposomes (75.6 ± 12.6 nm and 96.8 ± 3.2 nm, respectively), whereas the lower molar ratio 
(80:10:10) of CHS increased the size of the liposomes to 377.6 ± 44.4 nm (Figure 3.8 A). 
Cholesterol and its derivatives, such as CHS, stabilise lipid bilayers and improve liposomal 
stability. They do this by intercalating between lipid chains, stabilising spacial arrangements and 
packing of the lipids (214). Therefore, when the molar ratio of CHS was low, particle size was 
increased. The PDI of all three formulations was <0.3 demonstrating homogeneous liposome 
populations, however the least disperse liposomes were obtained at 60:20:20 molar ratio 
(Figure 3.8 B). Liposomes had a positive surface charge at all molar ratios with no statistically 
significant differences between the formulations (Figure 3.8 C). The 70:15:15 DSPC:DC-
Cholesterol:CHS molar ratio was chosen for the UEAI coupling as the liposomes demonstrated 
small size, acceptable size distribution and positive surface charge. 
 
Figure 3.8 Optimisation of DSPC:DC-Cholesterol:CHS molar ratios. Analysis of liposome (A) 
size, (B) PDI and (C) zeta potential. Data was analysed using Kruskal-Wallis and Dunn’s 
multiple comparison post hoc tests (n=3, mean ± SD, *p < 0.05)  
The DSPC:DC-Choleterol:CHS liposomes were modified by coupling UEAI lectin to activated CHS 
on the surface of the liposomes. This was done using EDC/NHS carbodiimide chemistry. 
Different concentrations of UEAI lectin were used in the coupling reaction in order to determine 




with higher lectin concentrations is indicative of lectin attachment (208, 218). In accordance 
with the previous research, the size of the liposomes increased with increasing concentrations 
of UEAI lectin (Figure 3.9 A). The coating reached saturation at 100 μg/mL UEAI lectin when the 
size of the liposomes plateaued at 163.3 ± 4.3 nm. The coating with different concentrations of 
UEAI did not cause significant differences in PDI of the liposomes, however the high PDI (~0.4) 
indicated a more heterogeneous population of UEAI-coated liposomes, for at least some of the 
batches (Figure 3.9 B). Finally, there was a concentration dependent decrease in particle surface 
charge (Figure 3.9 C). Nevertheless, the liposomes maintained a positive surface charge (18.2 ± 
2.4 mV) at the optimal 100 μg/mL UEAI concentration and these particles were used for the 
mouse studies. 
 
Figure 3.9 Optimisation of UEAI concentration for DSPC:DC-Cholesterol:CHS liposome coating. 
Analysis of UEAI lectin-modified liposome (A) size, (B) PDI and (C) zeta potential. Data was 
analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=3-6, mean ± 
SD, *p < 0.05, **p < 0.01)  
The morphology of UEAI lectin coated-liposomes was confirmed by TEM (Figure 3.10). The 
images showed particles with the spherical morphology typical of lectin-coated liposomes 
(218). The average diameter of the particles seen in TEM images was slightly smaller as 









Figure 3.10 TEM image of UEAI lectin-coated liposome nanoparticles. Bar represents 1000 µm  
3.4.2.3 Vaccination with Con L-Vac and UEAI L-Vac formulations 
The therapeutic efficiency of these two modified vaccine formulations was tested and 
compared to the primary L-Vac in an orthotopic mouse model of CRC. The control group that 
received PBS was analysed on day 16 to confirm tumour growth (Figure 3.11 A).  
 
Figure 3.11 (A) Tumour growth after vaccination with PBS (Ctrl) control. Tumour weights were 
analysed 16 days after tumour injection. (B) Tumour growth after vaccination with 
unmodified liposome vaccine (L-Vac), Pam2Cys-AH1td construct in liposomes (Con L-Vac) or 
unconjugated AH1td peptide and Pam2Cys adjuvant in UEAI lectin-coated liposomes (UEAI L-
Vac). Tumour weights were analysed 20 days after tumour injection (closed symbols) or when 
reached humane endpoints (open symbols). Data was analysed using a Kruskal-Wallis test 




Similarly to the Con E-Vac, the Pam2Cys-AH1td construct-containing liposome vaccine (Con L-
Vac) did not improve therapeutic efficacy as compared to the L-Vac treated mice (Figure 3.11 
B). It is possible that conjugation of the adjuvant to the tumour antigen hindered the ability of 
Pam2Cys to bind TLR2 on the surface of APC. It has been found that the spacers used to join the 
adjuvant to the peptide and the position of Pam2Cys within the peptide can affect APC activation 
and overall immune responses to peptide epitopes (315). Zeng et al. showed that an insertion 
of two serine amino acids between Pam2Cys and the peptide increased overall immunogenicity 
of the vaccine in mouse studies. In addition, antibody titers were higher after immunisation 
with a synthetic peptide vaccine when Pam2Cys was positioned at the center of the peptide 
than it was positioned at the N-terminus (315). 
The UEAI lectin-modified liposomes (UEAI L-Vac) have been designed to increase uptake by M 
cells in order to induce more potent anti-tumour immune responses, as it has been reported 
such modifications can improve liposome uptake in the PP by 3 fold (295). Treatment of tumour-
bearing mice with UEAI L-Vac did not reduce tumour growth compared to the L-Vac treated 
mice (Figure 3.11 B). Previously published studies have shown therapeutic potential of UEAI 
lectin-modified liposomes compared to drug injection or intragastric delivery of unmodified 
liposomes in mouse studies (193, 208, 218). Li et al. used CHS for covalent coupling of the UEAI 
lectin on the surface of liposomes and have shown that oral administration of these liposomes 
reduce burst release of BSA along with improved systemic and local immune responses 
compared to BSA injection in mouse studies (208). Zhang et al. attached UEAI to 
phosphatidylethanolamine and formed liposomes that delivered insulin to the M cells and 
decreased blood glucose levels in rats demonstrating potential for oral drug therapy (218). 
There are a number of factors to consider in relation to our result. Firstly, it may be that uptake 
of the liposomes was already optimal and there was no need to coat the nanoparticles with a 
lectin. However, this is unlikely due to the number of published studies reporting improved 
uptake of liposomes after lectin coating compared to conventional liposomes (186, 193, 218). 
In our study, DSPC, DC-Cholesterol and CHS was used to make the UEAI lectin-modified 
liposomes, however DSPE-PEG2000 was excluded as it was hypothesised PEGylation might 
hinder UEAI binding to the liposomes by covering their surface. Without DSPE-PEG2000 the 
liposomes would be less stable and more susceptible to degradation in the GIT. Moreover, it 
has been reported that unmodified CHS has pH sensitive properties and can destabilise particles 
in acidic conditions (316). This could lead to a destabilisation of the lipid bilayer in the stomach 





conformational changes in the carboxylic acid group upon interaction with ions (317). However, 
this carboxylic acid group forms covalent bonding with NH2-terminus of UEAI, therefore lectin 
attachment impairs the pH sensitive properties of CHS. Nevertheless, pH caused destabilisation 
by unmodified CHS should be considered as a possible explanation for the lack of improvement 
in anti-tumour responses. For future studies, carboxylic acid derivatives (DSPE-PEG2000 
Carboxy NHS, DMPE-Glu) could be used in liposome preparation to improve the gastric stability 
and prevent the pH sensitivity issues. Finally, it must also be considered that due to the fast 
growth of the tumour in this model it will be difficult to make any improvement to the immune 
responses generated that can have an impact on tumour growth in the time period being 
examined. 
3.4.2.4 Expression of checkpoint receptors on TIL after vaccination with Con L-Vac and UEAI 
L-Vac 
Immune cell populations in the spleen and mLN of mice treated orally with Con L-Vac, UEAI L-
Vac and the control formulations were analysed by flow cytometry. No statistically significant 
differences were found between the treatment groups (Appendix Figure 7.18, Appendix Figure 
7.19, Appendix Figure 7.20, Appendix Figure 7.21 and Appendix Figure 7.22). This likely reflects 
the necessity for carrying out analyses of tumour-specific populations of cells, rather than 
looking globally at populations. 
The levels of PD-1+ and CTLA-4+ tumour infiltrating CD4+ and CD8+ T cells were examined (Figure 
3.12). The results showed potentially a trend for low numbers of cells expressing the inhibitory 
markers after vaccine therapy, but this decrease was not significant as data from control mice 
in particular was very variable. There was no diference between mice treated with the vaccine 
formulations. The results align with the rest of results that these two modifications did not 





Figure 3.12 Checkpoint receptor PD-1 and CTLA-4 expression on (A) CD4+ and (B) CD8+ T cells 
following an oral therapeutic immunisation vaccination with PBS (Ctrl), unmodified liposome 
vaccine (L-Vac), Pam2Cys-AH1td construct in liposomes (Con L-Vac) or unconjugated AH1td 
peptide and Pam2Cys adjuvant in UEAI lectin coated liposomes (UEAI L-Vac). Ctrl was analysed 
on the 16th day after surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 20 days after 
tumour injection (closed symbols) or when reached humane endpoints (open symbols). Data 
was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hot tests (n=4-5, 
mean ± SD)  
3.4.3 Therapeutic oral immunisation in combination with NSAID therapy 
The impact of a combination therapy using a NSAID LCF with oral vaccination was investigated 
as an option for improving CRC treatment. LCF is a preventive and therapeutic agent, which has 
the potential to re-shape the inflammatory TME. 
3.4.3.1 Formulation of LCF-C4-modified oral vaccines 
LCF is a poorly soluble drug, which makes it difficult to manipulate and formulate into vaccines. 
To facilitate LCF entrapment into lipid-based formulations, a tail made of four carbon chain (C4) 
was attached to carboxylic acid groups (Figure 3.4). Linear carbon chains are nonpolar 
molecules that forms hydrophobic interactions, therefore, the C4 tail acts as an anchor that can 





Iodobutane was used as a source of C4 chain and was coupled to carboxylic acid groups of LCF 
using an esterification reaction. The reaction product, licofelone-C4H9 (LCF-C4), was purified by 
silica gel column chromatography and analysed using 1H NMR spectroscopy. The 1H NMR 
spectrum confirmed the chemical structure of LCF-C4 (Figure 3.13). 1H NMR (400 MHz, 
Chloroform-d) δ 7.35 – 7.06 (m, 9H), 4.19 (t, J = 6.7 Hz, 2H), 3.81 (s, 2H), 3.57 (s, 2H), 2.91 (s, 
2H), 1.76 – 1.62 (q, J = 7.9 Hz, 2H), 1.43 (q, J = 7.3 Hz, 2H), 1.36 (s, 6H), 1.00 (t, J = 7.4 Hz, 3H). 
HRMS confirmed the compound structure, with the calculated HRMS (ESI+) for C27H30NO2Cl 
being 458.1857, while the measured value was 458.1835. 
Previous work in the Hook Laboratory has confirmed that LCF coupling to a carbon chain 
improves lipophilicity and intercalation into liposomes (personal communication). 
 
 
Figure 3.13 1H NMR spectrum of LCF-C4 
LCF-C4-modified liposomes were optimised for oral therapy (Table 3.6). In order to determine 
whether PEGylation interfered with LCF-C4 intercalation into liposome bilayer, since the both 
compounds are distributed on the surface of liposomes, DSPE-PEG200 was excluded from 
liposomes in one of the optimisation groups. Non-PEGylated liposomes were smaller (165.2 ± 
19.8 nm) compared to PEGylated liposomes (217.9 ± 81.8 nm and 238.3 ± 38.7 nm), while the 




was measured using HPLC. Non-PEGylated particles had the lowest drug encapsulation (28.5 ± 
0.5%), demonstrating that PEGylation positively affects LCF-C4 entrapment into liposomes. 
Higher concentrations (300 μg/dose) of LCF-C4 in liposomes resulted in lower EE (66.5 ± 0.3%) 
compared to the 100 μg/dose (75.3 ± 0.7%), suggesting that the loading limit has been reached. 
The highest EE was observed in PEGylated liposomes with 100 μg/dose of LCF-C4 in formulation. 
This formulation (LCF L-Vac) was chosen for in vivo studies. The unentrapped LCF-C4 was not 
removed from the final liposome vaccines in order to maintain a consistent dose of LCF-C4, 
peptide and adjuvant between treatment groups in mouse studies. This dose was in line with 
that previously used where LCF was given at a concentration of 5 mg/kg by injection, in 
combination with a therapeutic melanoma vaccine (257) 
Table 3.6 Characteristics of LCF-C4 liposomes (n=3-9, mean ± SD). 
LCF-C4-modified liposome 
formulations 
Size, nm PDI Zeta 
potential, 
mV 
LCF-C4 EE, % 
DSPC:DC-Chol + LCF-C4 (100 
μg/dose) 
165.2 ± 19.8 0.250 ± 0.01 16.5 ± 12.5 28.5 ± 0.2 
DSPC:DC-Chol:DSPE-
PEG2000 + LCF-C4 (100 
μg/dose) 
217.9 ± 81.8 0.268 ± 0.01 23.2 ± 4.4 75.3 ± 0.7 
DSPC:DC-Chol:DSPE-
PEG2000 + LCF-C4 (300 
μg/dose) 
238.3 ± 38.7 0.222 ± 0.02 27.1 ± 2.9 66.5 ± 0.3 
 
For emulsion vaccines, 100 μg/dose of LCF-C4 was added to the oil phase of W/O/W double 
emulsions to formulate the LCF-C4-modified emulsion vaccine (LCF E-Vac). The concentrations 
of AH1td peptide and Pam2Cys adjuvant were consistent with previous experiments. The 
addition of LCF-C4 into the double emulsion formulation did not affect the appearance or 
characteristics of the emulsion. 
3.4.3.2 Therapeutic oral vaccination with LCF-C4-modified emulsion and liposome 
formulations 
3.4.3.2.1 Tumour growth after vaccination with LCF-C4-modified formulations 
As with previous experiments, the control groups that received PBS (Ctrl) or LCF-C4 in emulsion 





in tumour weights between the Ctrl and LCF groups (Figure 3.14 A) meaning that LCF alone 
without vaccine components (antigen and adjuvant) did not reduce tumour growth. As a 
chemopreventitive drug, LCF has been shown to prevent tumour development in mouse studies 
when administered for a long period of time prior to spontaneous tumour development (237, 
303, 304). However, in treatment studies when LCF given by injection in combination with 
therapeutic vaccination, there was no reduction in tumour growth (257). Therefore, since LCF 
appears to be effective only when used over the extended time prior tumour development or 
in combination with other treatment, no therapeutic effect was expected, which was why these 
mice were killed at an earlier timepoint than E-Vac, LCF E-Vac and LCF L-Vac formulations. 
 
Figure 3.14 (A) Tumour growth after vaccination with PBS (Ctrl) or LCF-C4 in emulsion (LCF). 
Tumour weights were analysed 16 days after tumour injection. (B) Tumour growth after 
vaccination with emulsion vaccine (E-Vac), emulsion vaccine with LCF-C4 (LCF E-Vac) or 
liposome vaccine with LCF-C4 (LCF L-Vac). Tumour weights were analysed 20 days after 
tumour injection (closed symbols) or when mice reached humane endpoints (open symbols). 
Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=6-
7, mean ± SD)  
Combining oral vaccination with the NSAID LCF, did not improve rejection of CRC in this mouse 
model (Figure 3.14 B). No statistically significant difference in tumour growth was found in mice 
that were given the combination therapy with emulsion (LCF E-Vac) or liposome (LCF L-Vac) 
vaccines compared to oral vaccination with E-Vac (Figure 3.14 B). However, mice vaccinated 
with LCF E-Vac tended to develop smaller tumours compared to mice that received E-Vac. The 
mice received four doses of LCF formulated in oral vaccines (Figure 3.5 A), whereas in previous 
mouse studies a larger number of doses of LCF were administered in combination with 
vaccination or chemotherapy in order to achieve therapeutic effect (257, 296). Neumann et al. 
reported prolonged survival of melanoma-bearing mice when LCF was administered not only 
with the vaccine, but as a monotherapy after vaccination. Hence, with more doses a significant 
improvement in anti-tumour responses may have been found. LCF-C4-containing lipid-based 




immunisation for an extended period of time to achieve a desirable therapeutic effect to the 
NSAID combination therapy. Of note, no difference in tumour growth was observed after 
treatment with LCF L-Vac. Considering, that only ~75 % of LCF-C4 was entrapped in liposomes 
and the rest was delivered free in suspension, degradation of the unprotected LCF in the gut 
might have further reduced the effect of the combined treatment. 
3.4.3.2.2 T cell infiltration into tumours after combination therapy with LCF-C4 
Tumour cells often produce large amounts of inflammatory mediators such as PGE2 and 
leukotrienes due to overexpression of the COX-2 and 5-LOX enzymes that are responsible for 
synthesis of multiple eicosanoids (Figure 3.1) (299, 302). Chronic inflammation in the tumour 
often causes aberrant immune responses and immune anergy, leading to cancer escape from 
immune surveillance (59). It has been hypothesised that NSAID can promote anti-tumour 
immunity by reshaping the inflammatory TME and restarting immune responses. LCF, as a dual 
COX/5-LOX inhibitor, reduces production of PGE2 and other inflammatory mediators and is 
therefore a more potent therapeutic agent, and potentially able to reshape tumour immune 
responses. 
In order to investigate whether the combination therapy had an impact at a cellular level, TIL 






Figure 3.15 Number of (A) CD4+, (B) CD8+ and (C) CD19+ TIL following oral therapeutic 
immunisation with PBS (Ctrl), LCF-C4 in emulsion (LCF), emulsion vaccine (E-Vac), LCF-C4 in 
emulsion (LCF E-Vac) or liposome (LCF L-Vac) vaccines. Ctrl and LCF were analysed on the 16th 
day after surgery. E-Vac, LCF E-Vac and LCF L-Vac were analysed 20 days after tumour injection 
(closed symbols) or when reached humane endpoints (open symbols). Data was analysed 
using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=5-7, mean ± SD)  
No changes in the number of TIL were found between the treatment groups. There are a 
number of limitations with this data; firstly the tumours were of different size implying immune 
responses were having variable effectiveness in controlling tumour growth, tumours were 
analysed on different days, and only global cell populations were analysed, not antigen specific 
responses. 
3.4.4 Therapeutic oral immunisation in combination with checkpoint inhibitor 
immunotherapy and NSAID 
3.4.4.1 Tumour growth after treatment with combination immunotherapy 
Anti-PD-1 immunotherapy was added to the combination therapy for the next study to establish 
a triple therapy. This triple therapy targeted checkpoint inhibition (anti-PD-1), inflammatory 
signalling (NSAID LCF) and stimulation of anti-tumour immunity (oral vaccines). It was 
hypothesised that targeting multiple aspects of the oncogenic process would minimise tumour 




Three doses of anti-PD-1 antibody were delivered IP on days 6, 9 and 12 post-tumour injection 
(Figure 3.5 B). An IgG2a isotype control (Iso) was utilised to differentiate the non-specific 
antibody effects from the specific effect of blocking PD-1/PD-L1 signalling. Oral immunisation 
was carried out using the LCF-C4-modified emulsion (LCF E-Vac) and liposome (LCF L-Vac) 
vaccines (Figure 3.16).  
 
Figure 3.16 (A) Tumour growth after vaccination with PBS (Ctrl). Tumour weights were 
analysed 16 days after surgery. (B) Tumour growth after treatment with anti-PD-1 and LCF-C4 
in emulsion (PD-1 LCF), rat IgG2a isotype control and LCF E-Vac (Iso LCF E-Vac), and anti-PD-1 
antibody with LCF E-Vac (PD-1 LCF E-Vac) or LCF L-Vac (PD-1 LCF L-Vac). Anti-PD-1 and rat 
IgG2a isotype control antibodies were delivered via IP injection. Tumour weights were 
analysed 20 days after tumour injection (closed symbols) or when mice reached humane 
endpoints (open symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple 
comparison post hoc tests (n=6-7, mean ± SD)  
No significant differences in tumour weights were found between the treatment groups (Figure 
3.16 B). This demonstrates that anti-PD-1 immunotherapy did not improve therapeutic 
responses. Anti-PD-1 therapy is the most effective if there is upregulated expression of PD-L1 
on tumour cells and a large immune cell infiltration into tumours (318). Absence of these factors 
indicates that tumour cells escape immune surveillance via pathways other than PD-1/PD-L1 
interaction, therefore checkpoint inhibition has little effect. While CT26 tumours in an 
orthotopic mouse model have been reported  to have a high mutational load and elevated PD-
L1 expression (319), only low levels of PD-1 were detected on lymphocytes in mice treated with 
L-Vac or left untreated (Figure 3.12) and only relatively few TIL were detected (Figure 3.15). This 
might be the reason why anti-PD-1 immunotherapy did not improve the therapeutic outcome.  
Previous studies have confirmed that CRC tumours with weak lymphocyte infiltration were 
much less responsive to checkpoint inhibition (32).  However, some studies have reported 
successful anti-PD-1 monotherapy in the CT26 model, with reduced tumour growth and 





inhibition therapy only when applied with combined immunotherapy (321, 322). In addition, 
the number of infiltrating lymphocytes will be affected by immunisation. In this study, we used 
an oral vaccine with a single peptide tumour antigen, which will limit the potential pool of TIL. 
Also, immune cell infiltrates into CT26 tumours correlate negatively with tumour size, thus the 
size of the tumour might be influencing treatment efficacy (318). Tumour location can also 
predetermine therapeutic outcomes, orthotopic mouse models have more immunosuppressive 
TME and are less responsive to therapy compared to subcutaneous tumours (323). All these 
variables should be considered as possible modulators of anti-cancer therapy. 
3.4.4.2 PD-1 expression on TIL after combination immunotherapy 
The presence of PD-1 expression on tumour infiltrating CD4+ and CD8+ T cells was analysed in 
order to investigate if the checkpoint inhibition had a detectable impact on reshaping the profile 
of immune infiltrates into tumours (Figure 3.17). 
 
Figure 3.17 PD-1 expression in tumour infiltrating (A) CD4+ and (B) CD8+ T cells following oral 
therapeutic immunisation with PBS (Ctrl), anti PD-1 immunotherapy and LCF-C4 in emulsion 
(PD-1 LCF), treatment with IgG2a isotype control and LCF E-Vac (Iso LCF E-Vac), and combined 
anti-PD-1 treatment with LCF E-Vac (PD-1 LCF E-Vac) or LCF L-Vac (PD-1 LCF L-Vac) vaccines. 
Mice given Ctrl were killed 16 days post tumour injection while all others were killed 20 day 
post-tumour injection (closed symbols), unless they reached early humane endpoints (open 
symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc 
tests (n=4-6, mean ± SD)  
Mice that received PD-1 LCF plus E-Vac or L-Vac combined treatment tended to have fewer 
tumour infiltrating PD-1+CD4+ and PD-1+CD8+ T cells compared to control treatments (PD-1 LCF 
and Iso LCF E-Vac) (Figure 3.17). Even though the results are non-significant, the findings are 
suggestive that PD-1 blockade may be having an impact on TIL after combined therapy. 
Interestingly, this trend seemed to even in the absence of vaccination in PD-1 LCF control group, 




3.4.4.3 Systemic and local immune responses after combination immunotherapy 
Local immune responses were investigated in mLN in order to detect any changes in immune 
profile after combined therapy. However, no differences were found in the overall frequencies 
or numbers of lymphocytes between the treatment groups (Figure 3.18). Data suggests that the 
combined therapy was not able to reshape local lymphocyte populations. 
 
Figure 3.18 (A, C, E) frequency and (B, D, F) number of (A and B) CD4+ T cells, (C and D) CD8+ T 
cells and (E and F) CD19+ B cells in mLN. Tumour-bearing mice were treated with PBS (Ctrl), 
received anti-PD-1 immunotherapy with LCF-C4 in emulsion (PD-1 LCF), treatment with IgG2a 
isotype control and LCF E-Vac (Iso LCF E-Vac), and combined anti-PD-1 treatment with LCF E-
Vac (PD-1 LCF E-Vac) or LCF L-Vac (PD-1 LCF L-Vac) vaccines. Anti-PD-1 and rat IgG2a isotype 
control antibodies were delivered via IP injection. Mice given Ctrl were killed 16 days post-
tumour injection while all others were killed 20 days post tumour injection, unless they 
reached early humane endpoints (open symbols). Data was analysed using Kruskal-Wallis and 
Dunn’s multiple comparison post hoc tests (n=6-7, mean ± SD)  
Systemic T cell responses were investigated in spleens. Again, in accordance to the analysis of 





changes in lymphocyte subpopulations. No statistically significant differences were found in 
CD8+ and CD4+ T cells populations among the treatment groups (Figure 3.19 and Figure 3.20).  
 
Figure 3.19 (A, C, E, G) frequency and (B, D, F, H) number of (A and B) naïve CD62L+CD44-, (C 
and D) activated CD25+, (E and F) antigen-experienced CD62L-CD44+, (G and H) memory 
CD122+CD44+ CD8+ T cells in spleen. Tumour-bearing mice were treated with PBS (Ctrl), 
received anti PD-1 immunotherapy with LCF-C4 in emulsion (PD-1 LCF), treatment with IgG2a 
isotype control and oral emulsion vaccine (Iso LCF E-Vac), and combined anti-PD-1 treatment 
with LCF E-Vac (PD-1 LCF E-Vac) or L-Vac (PD-1 LCF L-Vac) vaccines. Anti-PD-1 and rat IgG2a 
isotype control antibodies were delivered via IP injection. Mice given Ctrl were killed 16 days 
post-tumour injection while all others were killed 20 days post-tumour injection (closed 
symbols), unless they reached early humane endpoints (open symbols). Data was analysed 





Figure 3.20 (A, C, E, G) frequency and (B, D, F, H) number of (A and B) naïve CD62L+CD44-, (C 
and D) activated CD25+, (E and F) antigen-experienced CD62L-CD44+, (G and H) memory 
CD122+CD44+ CD4+ T cells in spleen. Tumour-bearing mice were treated with PBS (Ctrl), 
received anti PD-1 immunotherapy and LCF-C4 in emulsion (PD-1 LCF), treatment with IgG2a 
isotype control and LCF E-Vac (Iso LCF E-Vac), and combined anti-PD-1 treatment with LCF E-
Vac (PD-1 LCF E-Vac) or LCF L-Vac (PD-1 LCF L-Vac) vaccines. Anti-PD-1 and rat IgG2a isotype 
control antibodies were delivered via IP injection. Mice given Ctrl were killed 16 days post-
tumour injection while all others were killed 20 days post-tumour injection (closed symbols), 
unless they reached early humane endpoints (open symbols). Data was analysed using 
Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=6-7, mean ± SD)  
No improvement in therapeutic treatment was found with the triple therapy (Figure 3.16), in 
line with that no changes in systemic and local T cell immune responses were detected. The 
findings suggests that anti-PD-1 immunotherapy in not effective for this mouse model of CRC. 





effect in reawakening defence mechanisms of the immune system against malignant cells. 
Other checkpoint inhibition therapies such as CTLA-4 inhibition might also be ineffective due to 
low CTLA-4 expression on tumour infiltrating T cells (Figure 3.12). This suggests that CT26 







The original E-Vac and L-Vac oral formulations were modified and combined with 
immunotherapies in order to achieve improved cancer therapy and tumour rejection in an 
orthotopic mouse model of CRC. Self-adjuvanting conjugate vaccines were formulated in double 
emulsions and liposomes. The M cell binding lectin, UEAI, was conjugated on the surface of 
liposomes. The NSAID LCF was modified and formulated into both lipid-based formulations and 
finally, PD-1 checkpoint blockade was used along with NSAID therapy and oral vaccination. All 
these formulations were tested in in vivo mouse studies. None of these approaches 
demonstrated the capacity to inhibit tumour growth any better than the original vaccine 
formulations. The NSAID therapy with LCF formulated in an emulsion formulation showed the 
most promise and extended dosing with LCF should be investigated. Triple therapy with anti-
PD-1 antibodies, LCF and oral vaccination did not induced detectable local and systemic immune 
responses and did not have sufficient therapeutic effect to reduce tumour growth. The 
investigated methods were techniques known to improve either oral vaccine formulations or 
overall CRC therapy. Considering that little or no effect was achieved with these methods, novel 
and alternative approaches should be applied and tested in order to advance therapeutic 





Emulsion and liposome microswimmers 




















4 Emulsion and liposome microswimmers for oral vaccine delivery 
4.1 Introduction 
In Chapter 3, several modifications were applied to the original E-Vac and L-Vac formulations, 
or the oral vaccination was combined with other treatment methods, in order to eliminate a 
CRC tumour. However, none of the modifications or combined therapies significantly improved 
tumour rejection or anti-tumour immune responses in mice.  
A more recent innovation in vaccine delivery was explored in this chapter. Numerous novel 
targeted and/or triggerable drug delivery systems have been developed, for example virus-like 
particles, gold, pH-, sono-, thermo-, photo-sensitive particles, micelles, nanogels, hydrogels, 
produgs, microrobots, nanosystems (324).  Such systems have been suggested to have a 
number of benefits including targeted delivery, reduced off-target toxicity and increased 
bioavailability or retention time of pharmaceutical active agents to treat various diseases (324). 
One of these novel approaches is based on utilising bacteria for drug/vaccine delivery; these 
have been described as hybrid bioswimmers, bacteriabots, bacteria-based microrobots or 
bacteria-driven microswimmers (325-329). Bacteria based-delivery systems have been 
investigated over the past few years in preclinical studies for applications including cancer 
treatment (327, 330, 331). However, there are no published studies investigating application of 
the bacteria-driven microswimmers (microswimmers) for oral vaccine delivery. 
4.1.1 Bacteria-driven microswimmers for vaccine delivery 
Microswimmers are a two-component microsystem composed of a biological component 
(bacteria) and synthetic component (particle) (326). Microswimmers are engineered to 
specifically deliver particles, which are attached to bacteria, to a target site. It is a microscale 
system and the delivery can target inaccessible sites of human body. Bacteria have natural 
motor and sensor capabilities, which are essential functions for survival that allows bacteria to 
react to their surroundings (326). Bacteria respond to environment factors (temperature, 
chemicals, pH) by moving towards positive stimulus (e.g. nutrients) or away from negative 
stimulus (e.g. predators). These movements, regulated by flagellar motor proteins and guided 
by sensor receptors, are called taxis. Microswimmer vaccine systems uses the sensor/motor 
capabilities of bacteria to direct the vaccine to a target site via bacterial taxis (chemotaxis, 





been also investigated, such as utilising bacterial surface properties and interactions with cells 
to facilitate targeted delivery (325).  
Anticancer therapy is one of the applications of microswimmers that has been investigated in 
preclinical studies. Han et al. showed that microswimmers composed of paclitaxel-loaded 
liposomes and tumour-targeting Salmonella typhimurium (S. typhimurium) bacteria (flagelatted 
enteric bacteria that preferentially accumulate and replicate in solid tumours) demonstrated 
strong tumour targeting and killing properties in in vitro experiments (327). Other in vitro 
studies demonstrated that Escherichia coli (E. coli) attached to doxorubicin-loaded magnetic 
nanoparticle could reach and kill 4T1 breast cancer cells under magnetic guidance (331). 
Moreover, Magnetococcus marinus delivered drug-loaded liposomes into hypoxic regions of 
tumours with magnetic guidance when injected near the tumour in mouse studies (330). These 
findings confirm that microswimmers may be useful for active tumour therapy. However, none 
of the studies investigated vaccine delivery using microswimmers. 
In vivo biomedical applications requiring injection of microswimmers into the body is limited 
due to concerns regarding safety, for example pathogenicity, inflammation and antibiotic 
resistance (166, 334). Therefore, the use of microswimmers in a nonsterile environment, such 
as the GIT, may be more feasible since it minimises the risk of systemic inflammation. As many 
species of bacteria are part of the commensal microbiota of the GIT, microswimmers have 
potential to be used for oral vaccine delivery. Microswimmers, composed of bacteria and 
vaccine particles, could potentially improve vaccination outcomes in several ways.  
Firstly, the immune responses to vaccination could be improved via the natural adjuvant 
properties of bacteria (166).  Bacteria contain many cell wall structures that are known 
microbial PAMP including lipopolysaccharide, lipoteichoic acids and flagellin (166). Recognition 
of these by APC via PRR results in the activation of multiple inflammatory pathways, cytokine 
production and increased MHC expression (157). In addition, APC activation via PRR generates 
more efficient T cell responses (159). For this reason, many bacterial components have been 
previously used in vaccines as adjuvants and have stimulated efficient immune responses (294, 
335). While these features are also present in bacterial vector vaccines (166, 336), a major 
advantage of microswimmers is that the bacteria do not need to be genetically engineered to 
express foreign vaccine antigens. Instead they are simply attached to the vaccine, improving the 





E. coli express bacterial type I pili, which have lectin molecules at the tip of the pili (325). The 
lectins can bind mannose molecules on epithelial cells potentially increasing the retention of 
the microswimmer vaccines in the intestinal tract and facilitating vaccine delivery to M cells. It 
has been shown that this improved E.coli binding to mannose-functionalised surfaces, 
compared to those bacteria strains that did not have type I pili (325). In addition, it has been 
shown that E. coli bacteria can activate the complement system but show low cytotoxicity in in 
vitro studies (325). 
E. coli microswimmers have the potential to increase retention and safely improve delivery of 
vaccines to the GIT. Due to these reasons, E. coli-vaccine microswimmers were chosen as an 
innovative technique for oral vaccine delivery, which might promote anti-tumour immune 
responses and tumour rejection.  
4.1.2 Bacteria attachment to vaccine 
In the microswimmer microsystem, the cargo (particle) is linked to the surface of the carrier 
(bacteria). Particles attached to bacteria in previous studies, include liposomes (327, 330, 337), 
emulsions (328), polymeric particles (325, 332), silica particles (329), polyelectrolyte multilayer 
nanoparticles (331), erythrocytes (333) and nanoerythrosomes (338). Numerous binding 
strategies were used to attach these particles to the bacterial surface (326). These binding 
techniques include reversible and non-reversible attachment strategies. Reversible binding is 
often based on hydrodynamic and electrostatic interactions, whilst non-reversible binding 
involves chemically linking to components of the bacterial surface (326). The viscoelastic 
properties and inherent surface characteristics of bacteria can be used to facilitate attachment, 
as can hydrophobic and electrostatic interactions (329, 331). However these types of 
interactions are often less stable than bioconjugations or chemical interactions. High affinity 
stable bioconjugations can be formed via streptavidin-biotin binding (325, 327, 337). Chemical 
interactions can be designed via covalent binding through amine groups on the surface of 
bacteria to carboxylated liposomes using carbodiimide chemistry (330). As these interactions 
can have different impacts on bacteria motility and behaviour (332, 337), it is important to 
select an attachment strategy that aligns with the proposed use of the microswimmers. 
The surface of gram-negative bacteria (including E. coli) contains many hydrophobic lipids. This 
allows interactions between the bacterial surface and lipid-based particles such as W/O/W 
double emulsion and liposomes. This interaction does not require any additional modifications 





stable binding, which has to be maintained in the GIT. Therefore, additional attachment 
strategies to produce stable microswimmers were examined. 
4.1.2.1 Electrostatic interaction in liposome microswimmers 
E. coli gram-negative bacteria have an outer membrane composed of negatively charged 
lipopolysaccharide groups causing a predominantly negative surface net charge (329). This 
enables noncovalent electrostatic interaction with particles with a positive surface charge (331). 
The L-Vac (developed in Chapter 2) liposomes are cationic and can therefore interact with the 
surface of E. coli without further modifications to generate an E.coli-L-Vac microswimmer 
vaccine (liposome microswimmers, Figure 4.1). 
 
Figure 4.1 Schematic representation of liposome microswimmers. Electrostatic interaction 
between negative surface charge-featuring E. coli and cationic liposomes  
4.1.2.2 Streptavidin-biotin binding in emulsion microswimmers 
Biotin-streptavidin binding is the most commonly used attachment strategy to achieve stable 
interactions between bacteria and particles (325, 332, 337, 338). Non-covalent biotin-
streptavidin interactions have been used in multiple molecular and cellular biology applications 
due to their highly specific and strong binding. However, this method requires surface 
modification of bacteria and particles. Biotinylation of E. coli bacteria can be achieved in several 
ways. The bacterial surface can be biotin-functionalised using biotinylated antibodies directed 
against a variety of bacterial epitopes (325, 333, 337). This technique requires preparation of 
biotin-modified antibodies with a long spacer arm between the antibody and biotin for optimal 
attachment of the particles. Biotin-expressing recombinant E. coli have also been used (332), 
which requires bacterial transformation. E. coli can also be efficiently biotinylated using the 
sulfo-NHS-LC-biotin biotinylation reagent that reacts with amines on the bacterial wall enabling 





streptavidin/avidin used as a cross-linker to join bacteria and particles or the particles can be 
streptavidin-functionalised and directly conjugated to biotinylated bacteria (333, 338). 
This sulfo-NHS-LC-biotin bacterial biotinylation method has been used to conjugate E. coli 
bacteria to the oil phase of W/O/W double emulsions (328). Singh et al. showed that 
streptavidin can adsorb to the oil phase of double emulsions, which enables binding of biotin-
functionalised E. coli bacteria to the double emulsion. This technique was chosen here to 
prepare E.coli-E-Vac microswimmers (emulsion microswimmers, Figure 4.2). 
 
Figure 4.2 Schematic representation of emulsion microswimmers. Streptavidin-biotin 
bioconjugation between biotinylated E. coli and streptavidin-functionalised W/O/W double 







4.2 Chapter aims 
Combination therapies and vaccine modifications did not improve tumour rejection in an 
orthotopic mouse model of CRC. Bacteria-driven microswimmers were hypothesised to be an 
effective method to improve immune responses due to the natural adjuvant and targeting 
properties of the bacteria. 
The overall objective of this chapter was to optimise microswimmers as a novel oral vaccine 
delivery microsystem. To achieve this, the following aims were addressed: 
(1) formulation of a liposome microswimmer vaccine, 
(2) formulation of an emulsion microswimmer vaccine, 
(3) evaluation of formulations in in vitro uptake assays, and  






4.3 Materials and methods 
4.3.1 Materials 
E. coli (K-12 MG1655) was kindly supplied by Department of Microbiology and Immunology, 
University Of Otago. Luria-Bertani (LB) Broth (Lennox) and agar were purchased from Sigma-
Aldrich, USA. EZ-Link sulfo-NHS-LC-biotin and Hoechst 33342 DNA stain solution were obtained 
from Thermo Fisher Scientific, USA and Germany, respectively. Streptavidin-DSPE conjugate 
was purchased from Nanocs, USA. Cationic DOTAP (1,2-dioleoyl-3-trimethylammonium-
propane) lipid was obtained from Avanti Polar Lipids, USA. Purified streptavidin, GM-CSF and 
monoclonal antibody CD11c-APC (N418) were purchased from BioLegend, USA. Monoclonal 
antibodies CD40-PE (3/23), CD80-biotin (16-10A1), CD86-PE-Cy7 (GL1) and streptavidin-APC-
Cy7, streptavidin-FITC were purchased from BD Biosciences, USA. 
4.3.2 Preparation of E. coli bacteria for coupling with oral vaccines 
4.3.2.1 E. coli growth and quantification 
The method was established and optimised with assistance from T. Kiwitt, a visiting student 
working under the direct supervision of M. Naciute. A sample of bacteria was taken from a 
frozen aliquot of E. coli bacteria using a sterile inoculation loop (Merk Millipore, USA), 
inoculated into 10 mL of sterile 2.5% (w/v) LB broth in a 50 mL tube and  incubated under 
aerobic conditions in an orbital shaker (Ratek, Instruments, Australia) at 37°C, 200 rpm for 15 
hours. Bacteria were then streaked out on a pre-prepared 1.5% (w/v) LB agar plate, which was 
incubated at 37°C for 15 hours (Heraeus incubator, Thermo Fisher Scientific, USA). The plate 
was stored at 4°C and prepared freshly every month throughout the experiments. Single E. coli 
bacterial colonies were used for further experiments. 
To determine E. coli colony forming units (CFU)/mL and the corresponding optical density (OD) 
values at 625 nm wavelength, an overnight bacteria culture was grown from a single E. coli 
colony. OD625 values were measured in a 10 mm quartz cuvette (Starna Pty Ltd, Australia) using 
a UV/visible spectrophotometer (Ultrospec 2100 pro, Amersham Biosciences, UK). The 
overnight culture was diluted at 1:10, 1:20 and 1:100 in LB broth and then again diluted 1:100. 
Serial dilutions (10-1, 10-2, 10-3, 10-4 and 10-5) were then prepared and 10 μL of each were plated 
in triplicate on agar plates. Agar plates were placed into a microbiological incubator at 37°C for 
15 hours. The dilutions giving single bacteria colonies were counted and the total CFU/mL 
calculated by multiplying by the dilution factors. The CFU/mL and associated OD625 value was 





4.3.2.2 Biotinylation of E. coli 
A single E. coli colony was isolated from an agar plate, inoculated into 20 mL of sterile 2.5% 
(w/v) LB broth and incubated in an orbital shaker at 37°C, 200 rpm for 15 hours. The OD625 was 
measured and the CFU/mL was quantified as in Section 4.3.2.1. The bacteria suspension was 
washed twice with 20 mL sterile PBS (filtered through 0.22 μm filter; Millex, Merk Millipore, 
Germany) at 1500G for 15 min. The bacteria were resuspended in 1 mL of sterile PBS containing 
1 mg/mL sulfo-NHS-LC-biotin and incubated in an orbital shaker at 37°C, 200 rpm for 2 hours. 
After biotinylation, the bacteria suspension was washed once in 4 mL of sterile PBS at 1500G 
for 15 min.  
To quantify biotinylation, bacteria were resuspended in 50 μL of 1 mg/mL Hoechst dye in PBS, 
incubated on a rocking incubator for 30 min at 4°C and washed once in 2 mL of PBS at 1500G 
for 15 min. The attached sulfo-NHS-LC-biotin was stained with 1:10 streptavidin-APC-Cy7 in 50 
μL of PBS for 45 min at 4°C and washed once in 2 mL of PBS at 1500G for 15 min. Biotinylation 
was analysed by flow cytometry (FACSCanto II) and data was analysed using FlowJo V10. The 
intensity of APC-Cy7 staining on Hoechst+ bacterial cells was determined. An unbiotinylated 
bacteria control was used to differentiate non-specific streptavidin-APC-Cy7 binding. 
4.3.3 Preparation of liposome microswimmers 
4.3.3.1 Cationic liposome attachment to negatively charged bacterial surface 
For optimisation studies, DSPC:DC-Cholesterol:DSPE-PEG2000 (70:26:4 molar ratio) and 
DSPC:DC-Chol (73:27 molar ratio) cationic liposomes were prepared and dialysed as per Section 
2.3.3.2. 1.5 mg/mL of FITC-Ova was dissolved in deionised water and used as the aqueous phase 
for liposome preparation. After washing, Hoechst-stained unbiotinylated and biotinylated E. coli 
were resuspended in the liposome suspension at a final concentration of 1x109 CFU/100 μL. 
Liposome-bacteria attachment was measured immediately using flow cytometry with the 
frequency of FITC+ and Hoechst+ cells being determined. Controls of unmixed liposomes and 
bacteria were also examined. 
For in vitro bone marrow derived dendritic cell (BMDC) uptake studies (described in Section 
4.3.5), FITC-Ova was formulated into liposomes at a final concentration of 1 mg/mL. 
Unentrapped FITC-Ova was dialysed out using a 100kDa MWCO membrane against deionised 
water for 48 hours. FITC-Ova entrapment was measured as per Section 2.3.6. The liposome-
bacteria vaccine with FITC-Ova (Bac L-VacFITC-Ova) was prepared by mixing the liposome 





For mouse studies, cationic liposomes were prepared as per Section 2.3.3.2. The final 
concentration of AH1td peptide and Pam2Cys adjuvant were 2 µg and 0.5 µg per 100 µL, 
respectively. The liposome suspension was mixed with E. coli (Bac L-Vac) at a final concentration 
of 1x109 CFU/100 μL prior to vaccine administration.  
4.3.3.2 Streptavidin-DSPE-modified liposome attachment to biotinylated E. coli 
DSPC:DC-Chol:DSPE-PEG2000 (70:26:4 molar ratio) liposomes were prepared as per Section 
2.3.3.2. 10 μg/mL or 50 μg/mL of streptavidin-DSPE was added to the mixture of other lipids in 
absolute ethanol and the preparation procedure was carried out as described previously 
(Section 2.3.3.2). 1.5 mg/mL of FITC-Ova was diluted in deionised water (aqueous phase) and 
used in liposome preparation. Streptavidin-DSPE liposomes were mixed with Hoechst stained 
and biotinylated E. coli at a concentration of 1x109 CFU/100 μL. Liposome-bacteria attachment 
was measured by flow cytometry as described above.  
4.3.4 Preparation of emulsion microswimmers 
4.3.4.1 Emulsion modification with streptavidin, streptavidin-DSPE and cationic DOTAP 
lipid 
The oil phase of W/O/W double emulsion was functionalised with streptavidin as previously 
described (328). A W/O/W double emulsion was prepared as per Section 2.3.4. Streptavidin, 
streptavidin-DSPE conjugate or cationic DOTAP lipid were added to the emulsion. Streptavidin 
(2.5 or 5 mg/mL) or streptavidin-DSPE conjugate (1 mg/mL) were diluted in the W2 phase prior 
to emulsification with W1/O (W2:W1/O ratio 1:4). The final concentration of streptavidin in 
emulsion was 0.5 or 1 mg/mL and the final concentration of streptavidin-DSPE conjugate was 
0.2 mg/mL. Cationic lipid DOTAP (12.5 mg/mL) was homogenised in the W1/O emulsion. The 
final concentration of DOTAP in a W/O/W double emulsion was 5 mg/mL. The zeta potential of 
DOTAP-modified emulsion was measured using DLS as previously described in Section 2.3.5. 
To analyse streptavidin adsorption to the oil phase, streptavidin-FITC (0.5 mg/mL) was diluted 
1:4 in W2 phase prior to emulsification with W1/O emulsion. The streptavidin-FITC 
functionalised emulsion was diluted 1:50 in PBS and the FITC signal was investigated by 
fluorescent microscopy using an Olympus IX53 inverted microscope (Olympus, Japan) with a 
fluorescent lamp illuminator (X-Cite, Series 120 Q, Lumen Dynamics Group INC., Canada) under 





4.3.4.2 Emulsion and E. coli conjugation 
For conjugation analysis, 100 μL of streptavidin or streptavidin-DSPE modified emulsion was 
mixed with 1x109 CFU of biotin-conjugated E. coli and stirred at 4°C, 500 rpm for 1 hour. The 
DOTAP-modified emulsion was incubated with non-conjugated E. coli. After coupling, the 
emulsion-bacteria suspension was diluted 1:50 in PBS and attachment was analysed by 
transmitted light microscopy under 1000x magnification with an oil immersion objective. 
For in vitro BMDC uptake studies, 0.5 mg/mL of FITC-Ova was formulated in the W1 phase. 
Streptavidin was diluted in the W2 phase at a final concentration of 1 mg/mL prior to 
emulsification with the W1/O emulsion. Biotin-conjugated bacteria were resuspended in the 
emulsion at a final concentration of 1x109 CFU/100 μL. Emulsion-bacteria vaccines with FITC-
Ova (Bac E-VacFITC-Ova) were stirred at 4°C, 500 rpm for 1 hour and used for BMDC stimulation. 
For in vivo tumour studies, the final concentration of AH1td peptide and Pam2Cys adjuvant were 
2 µg and 0.5 µg per 100 µL, respectively, in emulsion-bacteria vaccines (Bac E-Vac). Streptavidin 
was diluted in W2 phase during emulsion preparation at a final concentration of 1 mg/mL. The 
streptavidin-modified emulsion was mixed with biotin-conjugated E. coli at a concentration of 
1x109 CFU/100 μL for an oral vaccine. 
4.3.5 In vitro BMDC uptake studies  
4.3.5.1 Bone marrow cell isolation and growth 
Bone marrow cell isolation and differentiation was performed as previously described (339). 
Three BALB/c mice were killed by cervical dislocation. Femur and tibia bones were isolated and 
sterilised in 70% ethanol for 10 seconds. Bone marrow cells were flushed out with complete 
RPMI media using a 1 mL syringe. The cells were washed in RPMI media at 400G for 5 min and 
RBC were lysed using freshly prepared RBC lysis buffer (17 mM Tris-Cl, 0.16 M NH4Cl) for 10 min 
at room temperature. The cell suspension was washed again (400G, 5min) in RPMI and passed 
through a 70 µm cell strainer. The cells were diluted in RPMI media containing 20 ng/mL of GM-
CSF and plated into 6-well plates at a density of 5x106 cells/well in 5 mL. The cells were 
incubated in a 37°C incubator with 5% CO2. The cell growth media was supplemented with 20 
ng/mL of GM-CSF in fresh RPMI media on days 3 and 6. The BMDC were harvested on day 8 for 





4.3.5.2 BMDC stimulation with oral vaccine formulations 
On the 8th day of incubation, BMDC were collected and washed in RPMI media at 400G for 5 
min. The cells were counted and diluted up to 1x106 cells/mL in RPMI media, then plated into 
24 well plates at a density of 1x106 cells/well. 
Vaccine formulations containing 2.2 μg of FITC-Ova were added to 1 mL of BMDC (Table 4.1). 
Pam2Cys was added separately to the treatment groups at a concentration of 100 ng/mL (340). 
E-VacFITC-Ova, L-VacFITC-Ova, LCF E-VacFITC-Ova and LCF L-VacFITC-Ova were prepared as per Sections 
2.3.3, 2.3.4 and 3.3.4. Instead of AH1td peptide, FITC-Ova was used in E-VacFITC-Ova and L-VacFITC-
Ova vaccine formulations at final concentrations of 0.5 mg/mL and 1 mg/mL, respectively. The 
FITC-Ova concentration in liposome formulations were calculated after dialysis. The cells were 
stimulated for 24 hours at 37°C with 5% CO2 (Table 4.1). 
Table 4.1 Treatment groups for in vitro BMDC uptake studies 
 
4.3.5.3 BMDC staining and flow cytometric analysis 
After stimulation, the BMDC were collected into FACS tubes. Cells were washed twice in PBS 
(4000G, 5 min). The surface staining was carried out as per Section 2.3.14.1. BMDC were 
identified with anti-CD11c and maturation/activation with anti-CD40, anti-CD80 and anti-CD86 
antibodies. Flow cytometric analysis was performed on a  FACSCanto II and data were analysed 
using FlowJo V10 software. Cells were gated on live singlets using a FVS620 live/dead stain. The 
populations of CD40+, CD80+ and CD86+ BMDC cells were gated on CD11c+CD40+, CD11c+CD80+ 
Treatment group FITC-Ova, μg Pam2Cys, ng 
Untreated - - 
Free FITC-Ova 2.2 - 
Pam2Cys only - 100 
Free FITC-Ova+Pam2Cys 2.2 100 
E-VacFITC-Ova 2.2 100 
L-VacFITC-Ova 2.2 100 
LCF E-VacFITC-Ova 2.2 100 
LCF L-VacFITC-Ova 2.2 100 
Bac E-VacFITC-Ova 2.2 100 





and CD11c+CD86+, respectively (Appendix Figure 7.23). Staining controls were applied as per 
Section 2.3.14.3. 
4.3.6 Therapeutic oral vaccination with emulsion and liposome microswimmers 
Five vaccine formulations were prepared for in vivo tumour studies (Table 4.2). An orthotopic 
mouse model of CRC was prepared using IC tumour injection surgery as per Section 2.3.12. The 
mice were orally vaccinated once daily for four consecutive days starting on the day 6th post-
surgery according to previously established vaccination protocol (Figure 3.5 A). 
Control groups were euthanised by cervical dislocation on the 16th day post-surgery and the 
treatment groups were analysed on the 20th day. Tumours, spleens and mLN were collected and 
single cell suspensions were prepared as per Section 2.3.10. The single cell suspensions were 
used for staining and flow cytometric analysis as per Section 2.3.14. Tumours were weighed and 
fixed in 4% formaldehyde solution (Sigma Aldrich, USA) for 24 hours before being stored in 70% 
ethanol. 
Table 4.2 Mouse treatment groups for therapeutic oral vaccination with microswimmers 
Group name Dosage Description of formulation/vaccines 
Ctrl 100 µL x 4 doses PBS  
Bac 100 µL x 4 doses 1x109 CFU/dose in PBS 
E-Vac 100 µL x 4 doses AH1td (2 μg/dose) and Pam2Cys (0.5 μg/dose) in 
emulsion 
Bac E-Vac 100 µL x 4 doses AH1td (2 μg/dose) and Pam2Cys (0.5 μg/dose) in 
streptavidin-modified emulsion conjugated to 1x109 
CFU/dose biotinylated E. coli 
Bac L-Vac 100 µL x 4 doses AH1td (2 μg/dose) and Pam2Cys (0.5 μg/dose) in 
cationic liposomes attached to 1x109 CFU/dose E. coli 
 
4.3.7 Statistical analysis 
Statistical comparisons between the groups were carried out using the non-parametric normal 
distribution one-way Kruskal-Wallis test (ANOVA) and Dunn’s multiple comparison test, which 
were performed using GraphPad Prism 7 (GraphPad Prism Software Inc, USA). If p values were 





4.4 Results and Discussion 
4.4.1 Biotinylated E. coli 
E. coli were used as a carrier for the preparation of microswimmers. For biotin-streptavidin 
attachment, the surface of E. coli was coated with biotin. Sulfo-NHS-LC-biotin biotinylation 
reagent with medium length spacer arm was used for E.coli biotinylation (341). NHS ester forms 
amide bonds with primary amine groups in cell envelope proteins and the spacer arm of the 
linker reduces steric hindrance for biotin binding. Biotinylated E. coli were stained with Hoechst 
DNA stain to facilitate bacteria identification using flow cytometry. For quantification of 
biotinylated bacteria, streptavidin APC-Cy7 was used to label biotin on the surface of the 
bacteria.  
A high background (population of Hoechstlo and APC-Cy7hi) was seen in the analysis, due to non-
specific streptavidin binding of aggregated material (bacterial fragments, culture components) 
(Figure 4.3 A). The population of the biotinylated bacteria was identified based on the negative 
control (unbiotinylated bacteria). Analysis of three bacterial preparations showed that 36.8 ± 
20.7 % of E. coli were biotinylated (Figure 4.1 B). The frequency of biotin-functionalised bacteria 
using this biotinylation method has not been previously analysed (327, 328); however, 
biotinylation using this method was sufficient to form microswimmers in previous studies. Thus, 
the biotin-functionalised E. coli was conjugated to vaccine-containing liposomes and double 
emulsions. 
 
Figure 4.3 E. coli biotinylation with sulfo-NHS-LC-biotin. (A) Populations of biotinylated and 
unbiotinylated E. coli measured by flow cytometry. Biotinylated (positive control) and 
unbiotinylated (negative control) E. coli were stained with Streptavidin APC-Cy7. The % of 
bacteria in the gate is shown (top left of each graph). (B) The frequency of biotinylated E. coli 





4.4.2 Liposome microswimmers 
Two attachment strategies, besides hydrophobic interactions, were investigated for the 
formulation of liposome microswimmers. The first one was based on electrostatic interactions 
between the negatively charged E. coli and cationic liposomes. The second interaction utilised 
biotin-functionalised E. coli and streptavidin-modified liposomes. 
In the first strategy, liposomes and E. coli were coupled via electrostatic interactions. 
Suspension of cationic liposomes containing FITC-Ova were prepared as previously described 
(Section 2.3.3). The original L-Vac formulation was composed of DSPC:DC-Cholesterol:DSPE-
PEG2000 lipids. However, it was hypothesised, that PEGylation reduces positive surface 
potential by covering the surface of liposomes and could also interfere with binding to the 
bacteria. Therefore, non-PEGylated particles were developed with the liposome formulation 
being modified to consist of DSPC:DC-Cholesterol using a 73:27 molar ratio between the lipids. 
The DSPC:DC-Cholesterol liposomes had a positive surface charge (37.7 ± 2.1 mV), which was 
slightly higher than the DSPC:DC-Cholesterol:DSPE-PEG2000 liposomes, with comparable size 
(113.1 ± 1.4 nm) and PDI (0.226 ± 0.025) (Appendix Table 7.3 and Table 2.4). 
FITC-Ova was loaded into the liposomes to use as a marker to identify liposomes by flow 
cytometry analysis. Non-biotinylated, Hoechst stained E. coli were used for the conjugation. 
Prior to mixing with E. coli, both liposome suspensions (DSPC:DC-Cholesterol liposomes and 
DSPC:DC-Cholesterol:DSPE-PEG2000 liposomes) were clear, yellow liquids (Figure 4.4 A). Both 
liposome suspension became cloudy after mixing with bacteria and the appearance of both 
formulations was similar (Figure 4.4 B). After two hours of incubation at 4°C, the DSPC:DC-
Cholesterol liposome and bacteria suspension formed a gel-like phase, possibly due to 
liposome-bacteria aggregation (Figure 4.4 C). DSPC:DC-Cholesterol:DSPE-PEG2000 did not 
aggregate into a gel-like phase and the microswimmers remained in suspension over time 






Figure 4.4 (a) DSPC:DC-Cholesterol and (b) DSPC:DC-Cholesterol:DSPE-PEG2000 cationic 
liposomes (A) before mixing, (B) freshly mixed and (C) two hours after mixing with E. coli  
The addition of PEG to liposomes has multiple pharmaceutical benefits. It creates a corona 
around liposomes, which stabilises liposome dispersions, prevents liposome aggregation and 
cellular interactions (342). The results suggest that PEGylation stopped or reduced the 
aggregation of the cationic liposomes with E. coli. PEG is a hydrophilic molecule, thus the PEG 
corona reduces the hydrophobicity of the surface of liposomes reducing not only electrostatic, 
but also hydrophobic interactions with bacteria. The observed aggregation of non-PEGylated 
particles might also be caused by fusion with bacterial particles (343). Bactericidal effects of 
fusion liposomes (liposomes containing dimyristoylphosphatidylglycerol, DMPG) were 
previously investigated showing that the fusion with bacteria is caused by electrostatic 
interactions, Van der Waals interactions and hydration forces (343). These interactions are also 
applicable to cationic liposomes. Liposome fusion with bacteria can cause release of vaccine 
components or degradation of the components as tumour peptide might interact with bacteria 
proteases leading to less effective immune responses (335). For these reasons, and because the 
gel-like phase was impractical to use, only PEGylated liposomes were used for the preparation 
of liposome microswimmers. As it had been hypothesised PEGylation would inhibit liposome-
bacteria attachment this was then examined. 
For the attachment studies, E. coli were stained with Hoechst stain and liposomes were 
identified through the FITC signal. The attachment of E. coli and PEGylated cationic liposomes 
(DSPC:DC-Cholesterol:DSPE-PEG2000) was investigated using flow cytometry in freshly 
prepared samples (Figure 4.5 A). The presence of a double positive (FITC+Hoechst+) population 
indicated liposome/bacteria binding and the formation of microswimmers. The quantification 
of three batches of bacteria and liposomes showed that 46.6 ± 13.4 % of Hoechst+ E. coli were 
attached to FITC+ liposomes and 72.1 ± 12.6 % of FITC+ liposomes were attached to Hoechst+ 







Figure 4.5 (A) Attachment of cationic liposome to E. coli bacteria measured by flow cytometry. 
FITC-Ova was formulated in cationic liposomes and E. coli was stained with Hoechst. 
Attachment was measured immediately after mixing liposome suspension with E. coli and the 
% attachment is shown in the top right of the graph. (B) The frequency of Hoechst+ E. coli 
attached to FITC+ liposomes. (C) The frequency of FITC+ liposomes attached to Hoechst+ E. coli 
(n=3, mean ± SD)  
A third attachment strategy, based on streptavidin-biotin interactions, was applied to the 
formulation of liposome microswimmers. Previously prepared biotinylated E. coli bacteria were 
used for this study. Streptavidin-DSPE was used to generate streptavidin-functionalised 
liposomes loaded with FITC-Ova. PEGylated liposomes, containing 10 µg/mL or 50 µg/mL 
streptavidin-DSPE were prepared and characterised (Table 4.3). The higher streptavidin-DSPE 
concentration resulted in slightly larger liposomes. The low PDI indicated homogeneous 
liposome populations. Liposome coating with streptavidin did not affect the positive surface 
charge of the particles. Both formulations were tested in the bacteria attachment studies. 
Table 4.3 Characteristics of streptavidin-DSPE-coated liposomes (n=5, mean ± SD). 
Streptavidin-DSPE liposomes Size, nm PDI Zeta potential, mV 
10 μg/mL 96.3 ± 6.9 0.231 ± 0.072 41.4 ± 5.6 






Streptavidin-DSPE-modified liposomes were mixed with biotinylated E. coli bacteria and the 
attachment was quantified using flow cytometry as in Figure 4.5 A and as per Section 4.3.3.1. 
Results demonstrate that 46.2 ± 7 % and 54.1 ± 2.9 % of Hoechst+ E. coli was attached to FITC+ 
liposomes with 10 µg/mL and 50 µg/mL concentration of streptavidin-DSPE, respectively (Figure 
4.6 A). Accordingly, 82.8 ± 5.9 % and 80.2 ± 1.4 % of FITC+ liposomes with 10 µg/mL and 50 
µg/mL concentration of streptavidin-DSPE, respectively, were attached to biotinylated Hoechst+ 
E. coli (Figure 4.6 B). 
 
Figure 4.6 (A) The frequency of Hoechst+ biotinylated E. coli bacteria attached to FITC+ 
streptavidin-DSPE liposomes. (B) The frequency of FITC+ streptavidin-DSPE liposomes 
attached to Hoechst+ biotinylated E. coli bacteria (n=3, mean ± SD)  
Overall, it appears that electrostatic and hydrophobic interactions were sufficient to formulate 
microswimmers and streptavidin-biotin binding did not provide any significant additional 
benefit in the formation of microswimmers. Therefore, electrostatic interaction based-binding 
was used to prepare liposome microswimmers for future studies.  
Stability analysis of the liposome microswimmers was not feasible as bacteria and liposomes 
degraded over time in suspension. After 24h of incubation at 4°C, fewer particles (bacteria and 
liposomes) were detectable by flow cytometry. Liposome-bacteria fusion can have detrimental 
effects on both the bacteria (lysis) and the vaccine (degradation) as already discussed. Because 
of this, liposomes and bacteria were mixed freshly prior to each in vitro and in vivo experiment 
to minimise vaccine degradation. In these studies, for the preparation of microswimmer-based 
liposome vaccine, E.coli bacteria were mixed with the original L-Vac formulation (Bac L-Vac). 
4.4.3 Emulsion microswimmers 
The next step was to prepare and optimise the attachment of E. coli to the oil phase of W/O/W 
double emulsions (emulsion microswimmers). Light microscopy was used for the analysis of 
microswimmers, rather than flow cytometry, as particles of W/O/W double emulsions are 





interactions, a streptavidin-biotin attachment strategy and electrostatic interactions were 
tested for their potential to generate emulsion microswimmers. 
Bacteria-to-oil attachment was investigated in a suspension of non-modified E. coli and non-
modified W/O/W double emulsion. E. coli were motile after combination with emulsion. As 
expected, no emulsion to E. coli binding was observed with the unmodified components (Figure 
4.7). Hydrophobic interactions were not sufficient to form emulsion microswimmers. The 
bacteria will interact with the surface of oil droplets (the interphase between W2 and O/W1 
phases), which are stabilised by Pluronic F-127 and have a negative surface charge (Table 2.5). 
A negative zeta potential in these experiments represented the electrokinetic potential of the 
interphase between particles (O/W1) and dispersant (W2) (344). Therefore, electrostatic 
repulsion would prevent aggregation or fusion of emulsion droplets with the negatively charged 
polysaccharides on the bacteria surface (343). The results suggest that an alternative 
attachment strategy is necessary to form emulsion microswimmers. 
 
Figure 4.7 Unmodified E. coli bacteria with non-modified W/O/W double emulsion. The 
emulsion was diluted in PBS at 1:49 ratio. Bar represents 10 μm. Bacteria are visible as small 
rods  
It has been previously reported that streptavidin can be integrated into the oil phase of a 
W/O/W double emulsion, facilitating attachment of biotinylated E. coli to the oil phase of the 
double emulsion (328). Therefore, streptavidin-FITC was added to the W2 phase during 





localisation of streptavidin in the emulsion (Figure 4.8). The merged images of streptavidin-FITC 
and bright field (BF) confirmed that streptavidin integrates into oil droplets. Most oil droplets 
exhibited a similar level of fluorescence. The very bright staining is likely due to streptavidin-
FITC aggregates, as it has been reported that streptavidin may form large aggregates under 
certain conditions (345). 
The mechanism for the non-specific streptavidin adsorption to the oil phase is electrostatic 
interactions between amino-acid residues of proteins to lipids (346). The results confirmed that 
streptavidin was adsorbed to the oil phase and this technique can be used for the 
functionalisation of double emulsions with streptavidin. 
 
Figure 4.8 Images of fluorescent light microscopy of W/O/W double emulsion formulated 
with streptavidin-FITC. The emulsion was diluted in PBS at 1:49 ratio. Bar represents 10 μm  
The oil vesicles were functionalised with streptavidin through the inclusion of 1 mg/mL or 0.5 
mg/mL of streptavidin and 0.2 mg/mL of streptavidin-DSPE into the formulations (Figure 4.9 A-
C). The inclusion of streptavidin or streptavidin-DSPE had no impact on emulsion droplet size or 





Finally, the charge of the oil droplets was modified in order to investigate if charge interactions 
could be used to attach bacteria and make microswimmers. This was done by adding 5 mg/mL 
of cationic lipid DOTAP to the oil phase of the W/O/W double emulsion. DOTAP increased the 
zeta potential from -33.2 ± 4.3 mV to 5.8 ± 1 mV compared to the original emulsion formulation 
(Table 2.5). The cationic lipid did not have any impact on droplet size or the appearance of 
emulsion compared to unmodified emulsions (Figure 4.9 D). 
All the modified emulsions were mixed with biotinylated E. coli and bacteria-emulsion binding 
was investigated using light microscopy. Attachment of E. coli to oil vesicles was observed with 
both 1 mg/mL and 0.5 mg/mL streptavidin (Figure 4.9 A and B). Not all E. coli formed 
microswimmers, as free bacteria was visible in the water phase of the emulsion with both 
concentrations of streptavidin. While this analysis was not quantitative, it did not appear that 
the increase in streptavidin from 1 mg/mL and 0.5 mg/mL was beneficial for bacterial 
attachment. 
 
Figure 4.9 Light microscopy images of W/O/W double emulsion with biotinylated E. coli 
bacteria. Double emulsions were formulated with (A) 1 mg/mL, (B) 0.5 mg/mL of streptavidin, 
(C) 0.2 mg/mL streptavidin-DSPE or (D) DOTAP cationic lipid. The emulsion was diluted in PBS 






Emulsion microswimmers were also detected in the double emulsion with 0.2 mg/mL (0.02 wt 
%) of streptavidin-DSPE (Figure 4.9 C). Free E. coli were also found in the suspension showing 
that not all E. coli were associated with emulsion particles in this microsystem. It was 
hypothesised that streptavidin-DSPE would be more efficient in generating microswimmers as 
the streptavidin was covalently attached to the DSPE lipid, which could stabilise streptavidin 
localisation by intercalating into the oil phase of the emulsion and prevent desorption (346). 
However, there did not appear to be an improvement in bacterial attachment. It is possible that 
the amount of streptavidin-DSPE was too low to observe any visible improvement in bacteria-
oil droplet attachment as previous studies used higher concentrations of streptavidin to 
functionalise oil droplets in double emulsions (328). However, due to the high cost of 
streptavidin-DSPE it would not have been practical to increase the concentration of this 
conjugate in the double emulsion. Therefore, functionalisation of the oil droplets with 
streptavidin-DSPE was excluded from further studies. 
Finally, double emulsions were formulated with the cationic lipid DOTAP to generate a positive 
surface charge on the double emulsion and enhance electrostatic interactions with E. coli. This 
modification did not induce E. coli binding to double emulsions as no emulsion microswimmers 
were  detected (Figure 4.9 D). It is possible, that 5.8 ± 1 mV zeta potential is too low for 
electrostatic interactions with bacteria as this value represents a neutral rather than a positive 
surface charge. 
Biotin-functionalised E. coli formed microswimmers with double emulsions containing 1 mg/mL 
or 0.5 mg/mL concentrations of streptavidin or 0.2 mg/mL concentration of streptavidin-DSPE 
(Figure 4.9). A limitation of these studies is the method used to examine attachment is not 
quantitative, and it is difficult to visually assess the efficiency of bacteria-oil droplet attachment. 
Previous studies focus more on the strength of the conjugation or movement of the 
microswimmers, rather than quantification of microswimmers (328, 331), therefore, methods 
to accurately quantify bacteria attachment to emulsions are limited. Due to these limitations 
and the lack of quantitative data, the choice of the most appropriate formulation to form 
microswimmers might have been not completely accurate. Considering the cost of emulsion 
preparation and that microswimmers were observed in all three emulsions modified with 
streptavidin, the lower concentration of streptavidin (0.5 mg/mL) was chosen to prepare 
emulsion microswimmers for the future studies. Emulsion microswimmers were prepared 





4.4.4 In vitro BMDC study 
4.4.4.1 Viability of BMDC after incubation with vaccine formulations 
The use of microswimmers in research is new and has not been previously investigated for oral 
vaccine delivery. Since little is known about potential toxicity, uptake by immune cells or the 
immune stimulatory potential of this microsystem, in vitro experiments with BMDC were 
carried out. 
BMDC from BALB/c were used for these experiments. For these studies, the AH1td tumour 
peptide used in previous chapters was replaced with FITC-Ova to enable measurement of 
vaccine uptake. Pam2Cys adjuvant was delivered separately in the cell growth media to 
guarantee comparable BMDC stimulation among the treatment groups. The concentration of 
Pam2Cys (100 ng/mL) for in vitro studies was chosen based on previously published studies 
(340). BMDC cells were stimulated with free vaccine components (FITC-Ova protein or/and 
Pam2Cys adjuvant) as controls or with the various vaccines, formulated with FITC-Ova. The 
vaccines included the original vaccines (E-VacFITC-Ova and L-VacFITC-Ova) and the microswimmer-
based vaccines (Bac E-VacFITC-Ova and Bac L-VacFITC-Ova) or LCF-C4 vaccines (LCF E-VacFITC-Ova and LCF 
L-VacFITC-Ova). Licofelone-modified vaccines were included in this study to test whether NSAID 
delivered with vaccine formulation altered immune responses in vitro. All BMDC were 
incubated with vaccines that contained 2.2 µg of FITC-Ova and 4.7 µg of cationic lipids (25 µg of 
total lipids) in liposome-based vaccines. 
For the viability study, 1x106 of BMDC were incubated with free vaccine components or vaccine 
formulations for 24h. After incubation, the cells were stained with a viability stain and live cells 
were quantified using flow cytometry. The frequency of live cells remained above 95% for all 
treatment groups (Figure 4.10). Neither free vaccine components nor vaccine formulations 
were toxic to BMDC cells, confirming the low toxicity of the formulations. It has been reported 
that cationic liposome-induced cytotoxicity is concentration dependent and significant killing 
appears at a concentration of 100 µg/mL of cationic liposomes (201). In support of this, no effect 
on BMDC viability was detected following stimulation with liposome vaccine-based 
formulations containing 25 µg/mL of cationic liposomes, of which 4.7 µg/mL was cationic lipids. 
The viability of Bac E-VacFITC-Ova and Bac L-VacFITC-Ova treated BMDC was comparable to other 
treatment groups showing that E. coli and vaccine co-stimulation of BMDC did not induce 






Figure 4.10 BMDC viability after 24h of stimulation with free Pam2Cys adjuvant and lipid-
based vaccines. BMDC were stained with viability stain FVS620 and analysed using flow 
cytometry. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 
post hoc test (n=3, mean ± SD) 
4.4.4.2 In vitro BMDC uptake 
The next step was to measure in vitro vaccine uptake by BMDC. BMDC were stimulated with 2.2 
µg of free or formulated FITC-Ova. After 24h of stimulation, the FITC median fluorescence 
intensity (MFI) of live BMDC was measured by flow cytometry. The FITC MFI of the cells was 
compared with untreated BMDC and a right-shift of FITC MFI was observed in all treatment 
groups except Pam2Cys only treated cells (Figure 4.11 A). This suggests that vaccine or free FITC-
Ova uptake was initiated within all samples. 
The FITC MFI of live BMDC was quantified and compared between the treatment groups. An 
increase in FITC MFI was observed in all treatment groups that contained FITC-Ova. Surprisingly, 
only LCF L-VacFITC-Ova-treated BMDC demonstrated a significant increase in MFI compared to 
untreated and Pam2Cys control groups (p < 0.05) (Figure 4.11 B). This in an interesting finding 
suggesting that LCF might induce vaccine uptake by BMDC. The mechanism of how LCF induces 
vaccine uptake is not known and it is difficult to explain what factors induced these processes. 
Pharmacological effects and toxicity of NSAID may be related to their ability to interact, disturb 
and cross cell membranes (347). LCF interactions with a DPPC membrane were previously 
evaluated and it was shown that LCF can reduce the packing density and alter the structural 
organisation of a lipid monolayer, which might be related to pharmacological actions of the drug 
(348). This capability to interact with lipid membranes may be also involved in dramatically 
increased uptake of LCF-functionalised liposomes by BMDC. This effect was not seen after 






















































































































the relevant liposome control. This was expected, as it is known that cationic liposomes improve 
antigen uptake by BMDC due to electrostatic interactions with negatively charged DC 
membrane (167). 
Surprisingly, BMDC that were stimulated with microswimmer-based vaccine formulations Bac 
E-VacFITC-Ova and Bac L-VacFITC-Ova had reduced FITC uptake compared to the emulsion and 
liposome controls, but this reduction was not significant. DC have several methods for particles 
and soluble agent uptake including macropinocytosis and phagocytosis (125). Phagocytosis is 
receptor-mediated endocytosis that allows specific uptake of bacteria. Macropinocytosis is non-
specific antigen uptake by fluid-phase endocytosis that allows sampling of surrounding fluid. 
Usually, BMDC, generated in vitro, are highly phagocytic and macropinocytotic (349). It was 
hypothesised the use of bacteria would increase uptake as DC have receptors for recognising 
bacteria and taking them up via phagocytosis rather than unspecific uptake via fluid-phase 
endocytosis. However, we did not see a difference here of increased phagocytosis. It is possible, 
that some of phagocytosed E. coli were not attached to vaccine particles as not all E. coli formed 
microswimmers (Figure 4.9), which that might have negatively affected the FITC signal in BMDC 
cells. Also, in vitro results might not reflect in vivo uptake and antigen presentation. Platt et al. 
has previously shown that in in vivo studies DC cells express reduced antigen presentation due 
to decreased access to antigen while in in vitro experiments BMDC cells have constant 
stimulation with antigens (349). Therefore, DC cells in vivo might show different uptake patterns 






Figure 4.11 Vaccine uptake by BMDC after 24h of incubation. The formulations were prepared 
with FITC-Ova labelled protein. (A) Median FITC fluorescence intensity (MFI) of live BMDC 
cells measured by flow cytometry. Grey histograms show MFI of an untreated control cells, 
red lines indicate MFI of FITC+ BMDC after treatments with vaccine formulations. (B) MFI of 
FITC+ BMDC cells. Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison 





4.4.4.3 In vitro BMDC stimulation 
A major reason for using microswimmers is the adjuvant activity of bacteria, therefore the 
potential to activate BMDC with vaccine formulations was further investigated. The expression 
of CD40, CD80 and CD86 on FITC+ BMDC cells was measured after 24h of stimulation with 
vaccine formulations or controls. These co-stimulatory surface receptors are necessary for 
antigen presentation and stimulation of T cells, and often are used to detect activated and 
maturated DC cells (160, 272, 294, 350). 
The frequency of CD40+ and CD86+ on FITC+ BMDC increased after stimulation with Bac L-VacFITC-
Ova compared to free FITC-Ova (p < 0.01) and E-VacFITC-Ova (p < 0.05) treated cells, respectively  
(Figure 4.12 A and C). Bac E-VacFITC-Ova and Bac L-VacFITC-Ova had non-significant increases in MFI 
of CD40+, CD80+ and CD86+ on FITC+ BMDC compared to their corresponding controls E-VacFITC-
Ova and L-VacFITC-Ova, respectively (Figure 4.12). The results confirm that vaccine co-delivery with 
E. coli bacteria had the potential to enhance immune stimulation of oral vaccines due to natural 
adjuvant properties of E. coli bacteria that are induced by presentation of bacteria antigen 
epitopes (166). The stimulation was not sufficient to achieve significant differences, possibly, 
due to lower uptake rates of microswimmer-based formulations by BMDC as was seen in the 
Figure 4.11 B. Neither the addition of Pam2Cys to FITC-Ova nor the addition of LCF to the 
vaccines had any significant impact in in vitro stimulation of BMDC. In contrast to previous 
studies where Pam2Cys activated cytokine production and induced maturation of murine BMDC 
(340, 351), Pam2Cys did not increase BMDC activation in FITC-Ova+Pam2Cys BMDC group 
compared to FITC-Ova control group (Figure 4.12), which could be due the too low 
concentration (100 ng/mL) of Pam2Cys in cell growth media (351). 
Due to the high background with CD80 for FITC-Ova, which did not contain any 
immunostimulatory molecules, no increases in immune stimulation could be detected (Figure 






Figure 4.12 Frequency of (A) CD40+, (B) CD80+ and (C) CD86+ on FITC+ BMDC after 24h of 
incubation with vaccine formulations. FITC-Ova labelled protein was used in the formulations. 
Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=3, 





4.4.5 Therapeutic CRC treatment with Bac E-Vac and Bac L-Vac formulations 
The therapeutic effect and immune responses generated by oral vaccination with 
microswimmer-based Bac E-Vac and Bac L-Vac vaccines was further investigated in an 
orthotopic mouse model of CRC. 
4.4.5.1 Pilot safety study 
In order to confirm the safety of this approach, a pilot study was carried out where three healthy 
BALB/c mice were orally administered four doses of 1x109 CFU/100 µL in PBS for four 
consecutive days and monitored daily for twenty days. This dose of bacteria was similar to that 
used previously in mice where the mice were given five doses of bacteria on every second day 
via oral administration using gavage and was safe to use (352). 
Mice appeared bright alert and responsive throughout the pilot study and no change in mouse 
weight was observed (Figure 4.13). 
 
Figure 4.13 Mice weight throughout the experiment. Four doses of 1x109 CFU/100 µL of E. coli 
in PBS was orally administered once daily for four consecutive days starting from day 0  
4.4.5.2 Tumour growth 
Therapeutic treatment studies were carried out as previously described (Section 2.3.13). Mice 
were given four doses of vaccine formulations by oral gavage once daily for four consecutive 
days starting from the 6th day post-surgery. Control mice received 1x109 CFU/100 µL E. coli in 
PBS (Bac) or PBS only (Ctrl). Treatment groups received the original E-Vac or microswimmer-
based emulsion or liposome vaccines (Bac E-Vac or Bac L-Vac). Mice were monitored daily 
throughout the experiment. The control mice were analysed on day 16 after surgery. Vaccine-
treated mice were analysed on day 20 after surgery unless tumour growth affected mouse well-























being earlier. Due to this experiment design, as in Chapter 3, the differences in tumour growth 
was compared to the original vaccine, not the unvaccinated controls.  The control mice were 
used to determine that tumours were growing. 
No differences in tumour weights were found between the control groups (Figure 4.14 A) 
showing that E. coli bacteria alone does not have a therapeutic effect. Statistically significantly 
smaller tumours were found in mouse that were treated with Bac E-Vac compared to the mice 
that were given E-Vac (p < 0.05) (Figure 4.14 B). The representative photos of mouse tumours 
confirm that the mice that were given Bac E-Vac developed smaller tumours (Figure 4.15). The 
results demonstrated that microswimmer-based oral emulsion vaccine significantly reduced 
tumour growth and improved therapeutic outcomes from the oral immunisation.  
As hypothesised previously, this therapeutic effect may be caused by adjuvant properties of E. 
coli bacteria when presented together with the oral vaccine (166, 353). Also, E. coli might 
improve targeted delivery and retention due to the inherent ability of E. coli to bind epithelial 
cells in the gut (325). Bac L-Vac did not promote similar therapeutic improvement. A wide range 
of tumour weights were observed in this treatment group suggesting that vaccination might 
have been effective in some mice and had no effect in others. The differences in preparation 
techniques of emulsion and liposome microswimmers might have caused the different results 
between Bac E-Vac and Bac L-Vac treatment groups. Liposome-bacteria binding in liposome 
microswimmers was based on electrostatic and hydrophobic interactions that are rather weak 
compared to the streptavidin-biotin binding in emulsion microswimmers. It is possible that 
liposomes and bacteria dissociated in the gut due to weak interactions and the components of 
the microsystem were not co-delivered to the M cells, causing a diminished therapeutic effect. 
L-Vac degradation due to fusion with E. coli, resulting in the breakdown of liposomes and loss 
of encapsulated antigen, has to be also taken into consideration, which could also explain the 
lack of enhanced therapeutic effect. Overall, improved therapeutic effect of oral immunisation 






Figure 4.14 (A) Tumour growth after vaccination with PBS (Ctrl) or E. coli in PBS (Bac). Tumour 
weights were analysed on the 16th day after surgery. (B) Tumour growth after vaccination 
with emulsion vaccine (E-Vac), streptavidin-modified emulsion vaccine with biotinylated E. 
coli (Bac E-Vac) or cationic liposome vaccine suspension with E. coli (Bac L-Vac). Tumour 
weights were analysed on the 20th day (closed symbols), unless they reached early humane 
endpoints (open symbols). E. coli bacteria was used at a concentration of 1x109CFU/100 μL. 
Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc tests (n=6-
7, mean ± SD, *p < 0.05)  
 
Figure 4.15 Representative photos of mouse tumours (outlined with blue dashes) in situ. Mice 
were vaccinated with PBS (Ctrl), E. coli in PBS (Bac), emulsion vaccine (E-Vac), streptavidin-
modified emulsion vaccine with biotinylated E. coli (Bac E-Vac) or cationic liposome vaccine 
with E. coli (Bac L-Vac). Ctrl and Bac tumours were analysed on the 16th day after surgery. The 
rest were analysed on the 20th day post-surgery  
4.4.5.3 Systemic and local immune responses 
Therapeutic treatment with oral microswimmer-based vaccines showed reduced tumour 
growth in an orthotopic mouse model. In order to investigate whether local and systemic 
immune responses reflect the improved therapeutic outcomes in vaccinated mice, immune cell 
populations were investigated in mLN and spleen. 
CD4+, CD8+ T cells and CD19+ B cells were analysed in mLN and spleen as previously described 
in Section 2.3.14.3. No differences were observed in the frequency or number of lymphocyte 





seen in the spleen (Figure 4.17). Even though a therapeutic effect was observed, vaccination 
with microswimmer-based oral vaccines did not change the composition of local or systemic 
populations of lymphocytes. 
 
Figure 4.16 (A, C, E) frequency and (B, D, F) number of (A and B) CD4+, (C and D) CD8+ T cells 
and (E and F) CD19+ B cells in mLN. Tumour-bearing mice were vaccinated with PBS (Ctrl), E. 
coli in PBS (Bac), emulsion vaccine (E-Vac), streptavidin-modified emulsion vaccine with 
biotinylated E. coli (Bac E-Vac) or cationic liposome vaccine with E. coli (Bac L-Vac). Mice given 
Ctrl and Bac were killed 16 days post-tumour injection while all others were killed 20 day post-
tumour injection (closed symbols), unless they reached early humane endpoints (open 
symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc 






Figure 4.17 (A, C, E) frequency and (B, D, F) number of (A and B) CD4+, (C and D) CD8+ T cells 
and (E and F) CD19+ B cells in spleen. Tumour-bearing mice were vaccinated with PBS (Ctrl), E. 
coli in PBS (Bac), emulsion vaccine (E-Vac), streptavidin-modified emulsion vaccine with 
biotinylated E. coli (Bac E-Vac) or cationic liposome vaccine with E. coli (Bac L-Vac). Mice given 
Ctrl and Bac were killed 16 days post-tumour injection while all others were killed 20 day post-
tumour injection (closed symbols), unless they reached early humane endpoints (open 
symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc 
tests (n=6-7, mean ± SD) 
Similarly, CD4+ and CD8+ T cell analysis was performed in both mLN and spleen. T cell sub-
populations were analysed in this study including naïve CD62L+CD44-, activated CD25+, antigen-
experienced CD62L-CD44+ and memory CD122+CD44+ CD4+ and CD8+ T cells. No differences were 






Figure 4.18 Frequency of (A and B) naïve CD62L+CD44-, (C and D) activated CD25+, (E and F) 
antigen-experienced CD62L-CD44+, (G and H) and memory CD122+CD44+ (A, C, E, G) CD4+ and 
(B, D, F, H) CD8+ T cells in mLN. Tumour-bearing mice were vaccinated with PBS (Ctrl), E. coli 
in PBS (Bac), emulsion vaccine (E-Vac), streptavidin-modified emulsion vaccine with 
biotinylated E. coli (Bac E-Vac) or cationic liposome vaccine with E. coli (Bac L-Vac). Mice given 
Ctrl and Bac were killed 16 days post-tumour injection while all others were killed 20 day post-
tumour injection (closed symbols), unless they reached early humane endpoints (open 
symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc 






Figure 4.19 Frequency of (A and B) naïve CD62L+CD44-, (C and D) activated CD25+, (E and F) 
antigen-experienced CD62L-CD44+, (G and H) and memory CD122+CD44+ (A, C, E, G) CD4+ and 
(B, D, F, H) CD8+ T cells in spleen. Tumour-bearing mice were vaccinated with PBS (Ctrl), E. coli 
in PBS (Bac), emulsion vaccine (E-Vac), streptavidin-modified emulsion vaccine with 
biotinylated E. coli (Bac E-Vac) or cationic liposome vaccine with E. coli (Bac L-Vac). Mice given 
Ctrl and Bac were killed 16 days post-tumour injection while all others were killed 20 day post-
tumour injection (closed symbols), unless they reached early humane endpoints (open 
symbols). Data was analysed using Kruskal-Wallis and Dunn’s multiple comparison post hoc 
tests (n=6-7, mean ± SD) 
Microswimmer-based oral vaccine formulations did not lead to increased immune responses in 
the analysed cell populations despite the fact that therapeutic improvement was observed after 





changes of immune cell populations in tumour-bearing mice might be related to variations in 
tumour stages among the mice in each group. It is possible that anti-tumour responses could 








Changes made to the original vaccines in Chapter 3 did not improve therapeutic effect of the 
oral vaccines. For this reason, a novel vaccine delivery technique, bacteria attached to vaccines, 
was investigated for its potential to improve oral immunisation against CRC. It was hypothesised 
that attachment of E. coli to liposomes (liposome microswimmers) or emulsions (emulsion 
microswimmers) would improve adjuvant properties of the original E-Vac and L-Vac vaccines as 
bacteria contain many innate immunostimulatory agonists. In addition, the ability of E. coli to 
adhere to epithelial cells via lectin on bacterial pili to mannose on the epithelial cells, could 
potentially prolong vaccine retention in the intestine. In addition, non-pathogenic E. coli are 
suitable for oral delivery as the bacteria are administered to a non-sterile environment, which 
minimises concerns regarding the use of live bacteria in clinical applications. 
Liposomes were attached to E. coli via electrostatic and hydrophobic interactions. Emulsion 
microswimmers were generated using streptavidin-biotin interactions between biotinylated E. 
coli and streptavidin-functionalised double emulsions. In an in vitro study, microswimmer 
vaccine formulations demonstrated low toxicity and the ability to activate BMDC. Despite the 
fact that no changes in immune composition could be detected in spleen or mLN, treatment of 
tumour-bearing mice showed that an emulsion microswimmer-based oral vaccine could inhibit 
tumour growth and improve the therapeutic effect of the original E-Vac. Therefore, emulsion 
microswimmers have the potential to improve therapeutic outcomes from oral vaccination with 


















5 General discussion and future directions 
5.1 Study outcomes 
The main aims of this thesis were to develop an oral subunit vaccine for CRC treatment and to 
evaluate the vaccine candidates in preclinical studies using an orthotopic mouse model of CRC. 
The findings confirmed that lipid-based oral therapeutic subunit vaccines are able to induce 
local and systemic immune responses as well as reduce CRC tumour growth in mouse studies. 
CRC is one of the most commonly diagnosed cancers and causes around 9% of all cancer-related 
deaths worldwide (2). Surgery, chemotherapy, radiotherapy and targeted therapy are the 
standard CRC treatments strategies (1); however, immunotherapy has managed to achieve 
long-durable remission in a subset of patients where the other treatment methods were 
ineffective (95). These recent successes demonstrate the potential of immunotherapies to treat 
cancer, even at the terminal stages of the disease. However, immunotherapies are effective 
only in small numbers of patients and often show only a temporary benefit (23, 24). Over the 
past years, immunotherapies have been extensively investigated and modified to overcome 
these limitations and allow expanded use of immunotherapies to increase survival of cancer 
patients. 
Immunotherapies, including cancer vaccines, are designed to expand anti-tumour immune 
responses to eradicate malignant cells. For this reason, immunogenic tumours are the best 
targets for immunotherapies. However, some tumours are not immunogenic due to low or no 
expression of tumour antigens, reduced expression of MHC class I receptors, or through 
upregulation of immunosuppressive pathways (28). Cells from highly immunogenic tumours 
have many novel tumour antigens and retain the ability to present tumour antigens on MHC, 
meaning that immune cells can recognise the malignant cells. dMMR/MSI-H CRC is a subset of 
CRC that is considered to be immunogenic as the high mutational burden results in novel 
tumour antigens and immune cell infiltration into the tumour (18, 33). Several 
immunotherapeutic drugs such as anti-PD-1 and anti-CTLA-4 checkpoint inhibitors showed 
excellent results in clinical trials in the treatment of this genetic subtype-featuring CRC and have 
been approved for use by the US FDA (17, 95). However, there are no approved therapeutic 
subunit vaccines for CRC treatment. 
Several different types of therapeutic cancer vaccines have been investigated for cancer therapy 





bacterial-vector based vaccines (27). There are a number of advantages associated with the use 
of peptide vaccines. Peptide subunit vaccines can be personalised (contain neoantigens derived 
from a patient’s tumour) or non-personalised (contain common TAA that are frequently 
expressed in tumours) (133). The non-personalised vaccines reduce costs associated with this 
therapy and allow it to be used more widely. Other advantages of peptide vaccines include 
safety, as these vaccines are usually well tolerated and compatibility with other treatment 
methods such as checkpoint inhibition or radiation therapy (130, 137, 144).  It is common to 
use not only CD8+ but also CD4+ T cell-stimulating epitopes in peptide vaccines since CD4+ T cell 
activation is necessary for optimal CD8+ T cell stimulation (50). Therefore, in this thesis a CD8+ 
T cell-stimulating tumour antigen, AH1, from the murine CT26 CRC cell line was used (249) in 
combination with two universal CD4+ T cell-stimulating epitopes from the tetanus and 
diphtheria toxins (246). The peptides were combined into a long synthetic peptide since long 
peptides generate more efficient CD4+ and CD8+ T cell immune responses (145, 147, 150). 
Adjuvants were also included in the vaccine as peptide tumour antigens are usually not highly 
immunogenic and can fail to generate potent and durable immune responses (126, 138). TLR 
ligands have demonstrated excellent immunostimulatory potential in preclinical studies of 
peptide vaccines (160, 248) and the TLR2 ligand Pam2Cys was utilised as the primary adjuvant 
in this thesis. The vaccine composed of the long peptide (CD8+ T cell epitope from AH1 and CD4+ 
epitopes from tetanus and diphtheria toxins) and Pam2Cys adjuvant was used in the preclinical 
evaluation of oral vaccines for CRC treatment.  
The route of vaccine administration is important as it can predetermine successful immune 
system activation and induction of efficient anti-tumour responses (139, 174). In tumour 
treatment, both systemic and local immune activation is necessary in order to increase the 
likelihood of positive therapeutic outcomes. Local immune responses at the CRC location in the 
gut can be achieved by oral vaccine administration (171); therefore, this vaccine administration 
route was chosen for this study. In addition to the impact on immune activation, oral 
administration has other more practical advantages in that it is easy to administer, does not 
required trained personnel or sterile manufacturing conditions and is preferred by patients 
(176, 228). There are however major challenges to oral delivery, such as degradation of vaccine 
components and the low bioavailability of peptide antigens. Even though peptide vaccines are 
usually well-tolerated (130), adverse effects associated with peptide vaccine administration 





Pharmaceutical formulation science is ideally placed to combat the challenges of degradation 
and poor oral bioavailability. Liposome and double emulsion formulations were used as they 
are safe, biocompatible, easy to manufacture and can be readily scaled up. Lipid-based 
formulations also have the ability to co-encapsulate vaccine peptides and lipophilic adjuvants, 
which is important for co-delivery of the vaccine components to APC and optimal immune 
activation (227, 262). Additionally, liposomes have adjuvant activity while emulsions increase 
the bioavailability of peptides (196, 222). The biggest challenges for lipid-based formulations 
are formulation stability, both on the shelf and after administration. 
The two lipid-based formulations used in this thesis, W/O/W double emulsions and liposomes, 
entrap and co-deliver vaccine components in the inner compartment, which is protected by a 
lipid-based shell (oil phase or lipid bilayer, respectively). However, the particle characteristics 
were different between these two formulations. The liposomes were small (<200 nm), relatively 
homogeneous particles, while the emulsions were composed of polydisperse, large (from 100 
nm to micrometres), water-in-oil particles. The size difference is likely to have had an impact on 
particles uptake by the M cells present in the PP in the intestine (219). It has been reported that 
liposome size has an impact on their passage through intestinal epithelium where the M cells 
are able to uptake liposomes within the 80-2000 nm size range (219). The precise mechanism 
of emulsion uptake is unknown. However, the oil phase of the emulsion can act as a penetration 
enhancer altering cell membrane permeability and improving peptide uptake (184, 222). The 
liposomes were designed to have positive surface charge, while the emulsion oil droplets had 
negative surface charge. A cationic charge has been reported to prolong the retention of the 
particles in the negatively charged mucus in the gut, which is where liposomes are internalized 
(204, 206). Another difference between the two formulations is the proportion of vaccine 
components encapsulated into formulations. The liposomes were prepared using microfluidics, 
which involves microchannels where liposomes are formulated by controlled flow of different 
ratios of lipids in organic solvent and vaccine components in aqueous phase. Manufacture of 
the liposomes in this way resulted in a relatively low EE (33%) meaning that most of the vaccine 
antigen was not protected from gastric hydrolysis and would not be co-delivered to the APC.  
Co-delivery or synchronous delivery of antigen and adjuvant to the same APC is important as 
those APC that take up antigen without adjuvant are not efficiently stimulated (126). Finally, 
the emulsion was less stable upon storage and separated into distinct oil and water phases while 
the liposomes demonstrated long-term colloidal stability stability. In order to overcome this 
issue, formulations were freshly made prior to every experiment and stored at 4°C in between 





In addition, stability in the GIT should also be investigated as bile salts, pH and enzymes might 
affect the vaccine formulations (211, 212). These factors need to be taken into consideration 
when comparing the ability of the different formulations to induce anti-tumour immune 
responses and reduce tumour growth. 
Vaccination of naïve mice revealed the ability of both vaccine formulations to stimulate local 
and systemic immune responses. The emulsion vaccine induced multiple effects including local 
expansion of lymphocytes, changes in frequencies of local populations of innate immune cells 
and systemic T cell activation. Local expansion of immune cells in the mLN indicated that the 
emulsion vaccine was able to stimulate a local gastrointestinal immune response, which could 
contribute to immune killing of colorectal tumours. In addition, the emulsion vaccine activated 
systemic T cell populations indicating systemic defence against potential metastases in distant 
locations of the body. The liposome vaccine was not able to stimulate such robust responses. 
The formulations had a number of differences but the most likely cause of the poor responses 
is the low level of antigen encapsulation in liposomes. Overall, it was very encouraging to 
demonstrate that oral immunisation could generate anti-tumour immune responses that could 
potentially eliminate malignant cells not only at the primary tumour site but also systemically. 
This is important for the eradication of metastatic cancer cells.  
Although immune responses were detected locally and systemically, negative results were 
found using a number of assays including the in vivo cytotoxicity assay and assays measuring 
cytokine production and activation marker expression. It is possible that the vaccines were 
simply not able to stimulate these responses, but this is contradicted by the ability of 
vaccination to slow the growth of tumours, meaning it was, possibly, an assay sensitivity issue. 
To examine more sensitively cytokine expression and cell activation induced by oral 
immunisation, tumour antigen-specific T cells should be investigated rather than whole 
lymphocyte populations. This could be achieved in future by using analysis methods such as 
staining with MHC multimers, ELISpot based-techniques or transgenic mouse models (248, 285, 
354). These techniques would improve the detection of small populations of tumour antigen-
specific immune cells and allow the tracking of modest immune responses generated by oral 
vaccination. 
Both emulsion and liposome formulations reduced tumour growth in tumour-bearing mice, 
supporting the hypothesis that oral subunit vaccines can be used for CRC therapy. Despite only 





demonstrated positive therapeutic outcomes in an orthotopic mouse model of CRC. This 
indicates that even though the liposome vaccine did not stimulate significant changes in the 
analysed populations of immune cells, it was able to generate anti-tumour immune responses. 
This also confirms that for future analysis, tumour-specific T cells should be investigated in order 
to detect more subtle changes in immune responses. That subunit vaccines were able to reduce 
tumour growth as a monotherapy was an exciting and promising result. 
Immune responses in tumours and lymphoid tissues were also examined in tumour-bearing 
mice as CD4+ T cell and B cell infiltration into CRC tumours has been associated with positive 
disease outcomes and improved overall survival (57, 83). It was shown that oral immunisation 
with the liposome and emulsion vaccines increased lymphocyte infiltration into tumours 
confirming that stimulation with antigen induces accumulation of immune cells at the tumour 
site. However, a limitation with this data was that the rates of tumour growth were very variable 
(between and within groups), with some animals developing large tumours while others had 
small tumours or no tumour at all. Therefore, the tumours and the immune responses to the 
tumours were at different stages on the analysis day, which is reflected in the variability of the 
data. This meant there was no detectable differences among the populations of immune cells 
or expression of cytokines, surface receptors or proliferation markers on immune cells. As 
previously mentioned, broad immune cell populations were analysed in this study rather than 
tumour-antigen specific T cell subpopulations and differences between the groups may have 
been missed, both in this experiment and in the subsequent studies examining modified 
vaccines and combination therapies. It is a limitation of the current orthotopic CRC model that 
animals must be killed to determine tumour growth as the tumours in this model are not 
palpable and in vivo imaging techniques are required in order to facilitate the tracking of tumour 
growth. However, the orthotopic model was necessary to enable evaluation of the impact of 
local vaccine delivery and immune stimulation via oral immunisation. 
Although tumour growth was reduced, tumours were still present in most animals, showing 
tumour growth was likely only delayed. Therefore, a number of vaccine modifications were 
made to enhance adjuvant activity and vaccine uptake, and combination therapies were 
developed to further improve the therapeutic effect.  
Self-adjuvanting vaccines, which is when adjuvants are directly conjugated to the tumour 
antigen, have demonstrated promising results when administered by injection (256, 292). 





enhancement, as compared to the original vaccine, when delivered orally (unformulated or in 
emulsion or liposome vaccines). It is possible that the loading of self-adjuvanting constructs in 
lipid-based carriers or conjugation of the adjuvant to the tumour antigen hindered the ability of 
Pam2Cys to bind TLR2 on the surface of APC, which resulted in the loss of adjuvant potential 
and immunostimulatory activity (309). A limitation to this study was the lack of a positive 
control to show the Pam2Cys-AH1td conjugate could stimulate CD8+ T cell anti-tumour immune 
responses and that the lack of activity was due to either the oral delivery, lost activity after 
conjugation with peptide and/or formulation into the lipid delivery systems. 
Lectins are highly specific carbohydrate-binding proteins that can be incorporated into oral 
vaccines to allow selective interactions with glycan groups on M cells. Multiple studies confirm 
the positive effects of liposome surface modification with lectins, such as UEAI, on liposome 
uptake in the gut (193, 208, 218). Therefore, the liposome vaccine was coated with the lectin 
UEAI, as confirmed by DLS. However, it did not improve the therapeutic effect of the vaccine 
following oral delivery in the orthotopic tumour model. This result suggests two possibilities; 
either there was no improved uptake or uptake was improved but this did not translate into 
improved immune stimulation (i.e. the immune response that could be stimulated by this 
liposome formulation was already maximal). UEAI lectin-modified liposome binding to α-L-
fucose sugar could have been tested using an agglutination reaction with blood group O red 
blood cells, as these blood cells express α-L-fucose on their surface and UEAI lectin induces 
agglutination (355). Alternatively, UEAI lectin-modified liposome uptake could have been tested 
in an ex vivo retention study where the retention of fluorescently labelled liposomes in mouse 
GIT is measured using an imaging system or through histological analysis of PP (230). The UEAI-
modified liposomes that were used in these studies may have been less stable than the original 
liposomes as they were prepared without PEG2000 and a new compound, CHS, was introduced 
in the formulation. The CHS was necessary for the UEAI surface coating, however, it can 
destabilise liposomes in acidic conditions (316). PEG2000 was removed from the formulation as 
the PEG2000 corona could have interfered with the UEAI–CHS. However, PEG2000 improves 
the stability of liposomes. Therefore, the reduced stability of UEAI-modified liposome might 
have negatively affected the results. 
Combination therapy with NSAID has been reported to be able to both prevent (120) and treat 
(257) cancer. Therefore, the liposome and emulsion vaccines were modified with a LCF-C4. The 
LCF had a lipid tail added in order to optimise incorporation into the formulations (unpublished 





have smaller tumours, but this change was not significant. The study did, however, suggest the 
potential of LCF for therapeutic treatment of CRC. The therapeutic effect of LCF could be further 
investigated with higher and/or more frequent dosing. In a previous study prolonged 
administration of LCF by injection, together with vaccines or as a monotherapy, was required 
for therapeutic effect (257, 296). The dose used for the therapeutic melanoma treatment was 
5 mg/kg of LCF per injection similar to the dose in oral vaccines, however, the LCF was 
administered more frequently. It is also possible that a higher concentration of LCF is needed 
when given orally. It would be interesting to use a CRC model where the tumour develops more 
slowly, as treatment had an effect when LCF was delivered for extended period of time (296). 
Chemically induced models of CRC could be useful in these studies as the disease is more related 
to chronic inflammation in these mouse models and cancer therapy with an NSAID may be more 
effective (239, 298). 
Oral vaccines are compatible for use with other immunotherapies such as checkpoint inhibition 
immunotherapies, which are widely used to treat various types of cancer. PD-1 checkpoint 
inhibition is approved for dMMR/MSI-H CRC treatment by the US FDA (103); therefore, oral 
vaccination was combined with PD-1 inhibition. The combined therapy was not successful in 
this mouse model as no tumour reduction was observed. The antibody used and the dose at 
which it was used was based on work published by Duraiswamy et al. (309) and was consistent 
with other protocols reported in the literature (153, 310). Checkpoint inhibition therapy is the 
most effective for those CRC tumours that have high levels of immune infiltrates and high 
mutational load (95), as these tumours usually have elevated expression of checkpoint 
receptors. While CT26 colon carcinoma cells have a high mutational load (319), the PD-1 
blockade may not have been successful in the orthoptic CT26 model due to the low infiltration 
of T cells and low number of PD-1 expressing T cells in the tumours detected in our study. In 
support, low numbers of TIL in CT26 tumours were reported previously (318, 320) and a lack of 
therapeutic effect in mice treated with anti-PD-1 monotherapy (321, 322). 
Microswimmer-technology has not been previously tested for oral vaccine delivery. The 
concept behind this approach is that vaccine particles are attached to bacteria and delivered as 
a conjugated system to the gut. The immune-stimulatory potential of bacterial PAMP in vaccines 
was previously demonstrated as it induced robust immune responses and reduced tumour 
growth in mouse studies (166, 353). In this thesis, microswimmer-based emulsion vaccines 
significantly reduced tumour growth compared to the original emulsion vaccines. This effect 





an anti-tumour effect. There are multiple ways in which microswimmers could have potentiated 
the anti-tumour responses. Bacterial antigens could have boosted the immunostimulatory 
effects of the vaccine through bacteria surface molecule interactions with PRR. The interaction 
of E. coli with epithelial cells could also have prolonged retention of the vaccines in the GIT, 
boosting the immune response (325). This finding demonstrates the potential for the use of 
bacterial microswimmers for vaccine delivery and opens the way for clinical trials. Further, 
liposome microswimmers should be also modified to improve the stability of the bacteria-
liposome interaction as the electrostatic-hydrophobic based conjugation that was used in this 
study might not have been optimal. Stable streptavidin-biotin conjugation could be used to 
avoid potential liposome-bacteria dissociation in the gut. Also, liposome stability was an issue 
and it is possible that the liposomes were unstable due to liposome-bacteria fusion, which could 
have caused bacteria death as well as liposome lysis (343). This could be prevented by reducing 
electrostatic and hydrophobic interactions between the liposomes and bacteria. For this, non-
cationic liposomes could be tested as well as higher ratios of PEG2000 to reduce the fusion 
effect seen in the study. Overall, the study presents a novel approach for oral vaccine delivery 
and the therapeutic outcomes confirm the potential for human therapy. However, there are 
some considerations regarding the use of bacteria for human cancer studies.  The safety of this 
approach for cancer patients would need more investigation. Non-pathogenic bacteria strains 
should be used in this approach to avoid the risk of inflammation. In general, knowing that 
microbial therapies, probiotic and faecal microbiota transplants are being increasingly used, and 
all are showing good safety (356), the potential for microswimmers to be used in cancer therapy 
remain high. 
5.2 Future directions 
Oral vaccine formulations showed promising results for the treatment of CRC, however, the 
vaccine formulations should be further improved before transition to human therapy. 
Low peptide loading into liposomes is the first issue that might have negatively impacted the 
therapeutic effectiveness of the vaccine, as only one third of the tumour peptide was 
encapsulated into liposomes. Antigen encapsulation could be improved in several ways. As 
shown in the optimisation study, the EE increases with increasing concentration of lipids used 
in liposome formulation. Higher concentration of lipids results in higher peptide loading as there 
are more lipids to form liposomes, therefore, more peptide can be entrapped into liposomes. 





However, the larger liposome size might not be an issue as high drug bioavailability has been 
shown with liposomes varying in size from 150 to 400 nm (219). In addition, M cells can 
internalise liposomes that are up to 2000 nm in size, which allows for the production of larger 
liposome with improved drug loading. The concentration of entrapped tumour peptide could 
also be increased by using a higher peptide concentration. This would not improve the EE and, 
therefore, might not be practical as the cost and waste of non-entrapped tumour peptide would 
increase. Therefore, the optimal liposome preparation procedure should be established 
considering the cost/benefit of the vaccine in human therapy. 
Liposome stability after administration was not analysed in these studies as the main focus of 
the study was the therapeutic effect of the vaccine and immune responses induced by oral 
immunisation. However, it is important to investigate stability of liposomes in the gut as 
improvements here could benefit the immune responses generated. PEGylation is one of the 
methods that is used to improve the stability of liposomes. Other techniques that could also be 
tested would be the incorporation of bile salts into liposomes. These so called ‘bilosomes’ have 
been reported to have improved GIT stability and to have prevented release of bioactives ex 
vivo in GIT media (188, 211, 212). Adapting oral vaccine for human therapy, all vaccine 
candidates could be administered in enteric-coated capsules that protect the formulations from 
the acid pH and bile salts until the vaccines reach small intestine. That could improve stability 
and reduce vaccine degradation potentially improving therapeutic outcomes. 
W/O/W double emulsions were not stable upon storage as phase separation was observed 
within one week of emulsion preparation. W/O/W double emulsion stability is highly dependent 
on the stability of the W1/O fraction (226). The stability of this fraction could be improved by 
further optimising the ratio between the W1/O phases (226). In addition, thickeners such as 
xanthan gum or guar gum, which improve viscosity preventing oil droplets from coalescing, 
could be introduced into the formulation in future studies (225). The double emulsion used in 
the study was polydisperse, with high variability in the sizes of the oil droplets. Thus, emulsions 
with smaller oil droplets could be evaluated in future studies for oral vaccine delivery. The 
negative surface potential of double emulsions, caused by the non-ionic surfactants (276), could 
also be modified. A positive surface charge is more suitable for vaccines as it would facilitate 
interaction with negatively charged intestinal mucus. Therefore, surface charge could be 
modified by adding cationic lipids (such as DOTAP) to the oil phase, as it was done for the 
preparation of emulsion microswimmers. Lastly, a liposome-vaccine suspension could be used 





demonstrated extended release and, therefore, could be adapted in this study for additional 
protection of vaccine components (227). Other double phase systems such, as double 
nanoemulsions have been investigated, and while they are attractive as regards small particle 
size (100 nm) and high entrapment, there are still major issues with stability (220). Overall, 
modifications to improve the stability of the emulsion, the size of the oil droplets and the 
surface potential could be used to further develop the emulsion-based oral vaccine. 
The aim of this thesis was to investigate the use of oral vaccines to treat CRC. The oral route 
was chosen due to the many advantages discussed above and therefore other vaccine delivery 
routes were not investigated. However, since the vaccines were able to induce detectable 
immune responses and reduce tumour growth via oral delivery, it would be interesting to 
investigate vaccination outcomes if the vaccines were delivered via injection. This would 
provide information on immunisation outcomes when the vaccine is not affected by gastric 
hydrolysis and low oral bioavailability. 
Immunohistological analysis of the tumours was not performed in this study. For future studies, 
tumour sections could be investigated immunohistologically in order to characterise the extent 
of immune cell infiltration into tumours and to determine their location and distribution. This 
analysis would supplement flow cytometry findings. Immune infiltrates can be distributed in 
tumour stroma or tumour epithelium (32). It has been previously shown that cancer outcomes 
depend on the intratumoural distribution of TIL and APC, rather than the total number of 
tumour infiltrating immune cells (77, 78). High intraepithelium infiltration correlated with 
increased disease-free survival in CRC patients, while high stromal infiltration were linked to 
adverse survival outcomes (77). Immunohistological study would reveal whether oral 
vaccination altered the distribution of immune cells in tumours and reshaped the TME profile, 
which would help in understanding the immunomodulatory mechanisms induced by oral 
vaccines.  
Kinetic analysis of tumour growth and metastasis could also be performed in future studies. 
Fluorescent or bioluminescent markers to label CT26 tumour cells could be used to track these 
events (357, 358). Kinetic analysis would reveal the impact of oral vaccination on tumour growth 
or shrinkage after oral vaccination in real time, which was not possible in the tumour model 
that was used in the study. Also, one of the advantages of immunotherapy is that an efficient 
therapy can prevent tumour spread and recurrence due to immune memory and 





vaccination on metastasis was not analysed due to limitations related to tumour model. 
Therefore, fluorescent or luminescent tumours could reveal the potential of oral vaccines to 
induce systemic immune surveillance of metastasis, which is important for long-durable 
responses in human therapy. However, these studies were not performed due to lack of 
necessary imaging facilities. 
There are also a plethora of delivery systems and adjuvants that could be evaluated for use in 
oral cancer therapeutic vaccines. For example, PC7A polymer nanoparticles have been reported 
to activate cross-presentation by APC via the stimulator of interferon genes (STING) pathway 
and to induce tumour-specific T cells in a colon cancer model (359). Adjuvants that could be 
used in conjunction with Pam2Cys (activating synergistic pathways) could include cytosine 
guanine (CpG)-containing oligonucleotides, STING stimulating cyclic dinucleotides (CDNs) or 
monophosphoryl lipid A . The novel cationic, two-component, liposome-based adjuvant system, 
CAF1 could be used as it was able to induce long-lasting and strong T cell responses with good 
safety profiles in clinical studies (165). A promising adjuvant used in peptide vaccines is the TLR3 
agonist poly-IC or poly-ICLC (Hiltonol®) (130, 140, 144). This adjuvant have been broadly used 
in multiple cancer vaccines and demonstrated good safety/tolerability profiles and 
immunostimulatory capacity (130). 
In this study, a mouse tumour peptide antigen was used in the vaccine formulation. For clinical 
trials, personalised oral vaccines could be prepared using neoantigens. Previously, 
individualised neoantigen therapy has demonstrated positive effects in cancer treatment (140). 
An advantage of using particulate delivery systems is that different tumour antigens can be co-
delivered in a single vaccine. Personalised therapy with patient-specific tumour antigens can 
maximise the therapeutic effect of the oral vaccines. However, the cost of personalised therapy 
might be an issue for widespread use of this treatment. Formulations could contain generic 
tumour-associated antigens commonly found in CRC patients, to reduce the price of the 
treatment. However, the identification of immunogenic and universal tumour-associated 
antigens is necessary in this case (133). 
5.3 Conclusion 
The central hypothesis examined in this thesis was that formulation of peptide tumour antigens 
and an immunostimulatory adjuvant, in robust and appropriate vaccine delivery systems, could 
stimulate effective therapeutic local and systemic anti-tumour immunity against CRC following 





evaluated in an orthotopic CRC mouse model. Liposome and emulsion formulations were able 
to stimulate local and systemic lymphocyte activation in naïve mice and to slow the growth of 
the CT26 tumours. This is a novel and exciting finding as peptide vaccines have in the past failed 
to induce positive therapeutic outcomes. Especially, when given orally as this reduces vaccine 
effectiveness due to the harsh environment and barriers present in the GIT. An additional very 
promising result was the improvement gained by including bacteria as part of the formulation. 
Emulsion microswimmers were able to improve therapeutic treatment outcomes by reducing 
tumour growth. This finding reinforce the benefits that can be gained through therapeutic oral 
subunit vaccines. 
The study demonstrated exciting preclinical results that oral therapeutic lipid-based subunit 
vaccines can be successfully applied for the treatment of CRC and, in future, can be tested in 
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Appendix Table 7.1 Complete RPMI Medium 
Penicillin/Streptomycin solution (Gibco, USA) 10 mL 
Glutamax (Gibco, USA) 10 mL 
2-mercaptoehtanol (Gibco, USA) 0.055 mM 
Foetal bovine serum (FBS; Thermo Fisher scientific, USA) 50 mL 














































































































































































































































Appendix Figure 7.5 In vivo killing of adoptively transferred AH1 peptide-labelled spleen cells 
(A) second and (B) third replicas. Naïve mice were orally immunised with PBS (Ctrl), Pam2Cys 
in emulsion (Adjuv), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion 
(E-Vac). Data was analysed using a Kruskal-Wallis test followed by Dunn’s multiple 
comparison post hoc test (n=5, mean ± SD) 
 
Appendix Figure 7.6 Number of lymphocyte populations in spleens of tumour-free mice 
following oral immunisation with Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys 
in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). The second repeat of the experiment. (A) 
CD4+, (B) CD8+ and (C) CD19+ populations. Data was analysed using a Kruskal-Wallis test 







Appendix Figure 7.7 Number of lymphocyte populations in spleens of tumour-free mice 
following oral immunisation with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide 
and Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). The third repeat of the 
experiment. (A) CD4+, (B) CD8+ and (C) CD19+ populations. Data was analysed using a Kruskal-
Wallis test followed by Dunn’s multiple comparison post hoc test (n=5, mean ± SD, *p < 0.05, 






Appendix Figure 7.8 Numbers of CD8+ and CD4+ T cells in spleens of tumour-free mice 
following vaccination with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-
Vac) or emulsion (E-Vac). The second replica of the experiment. Number of live (A, C, E, G) 
CD8+ and (B, D, F, H) CD4+ T cells. (A and B) CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-
CD44+ and (G and H) CD122+CD44+ T cells populations. Data was analysed using a Kruskal-






Appendix Figure 7.9 Numbers of CD8+ and CD4+ T cells in spleens of tumour-free mice 
following vaccination with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-
Vac) or emulsion (E-Vac). The third replica of the experiment. Number of live (A, C, E, G) CD8+ 
and (B, D, F, H) CD4+ T cells. (A and B) CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+ 
and (G and H) CD122+CD44+ T cells populations. Data was analysed using a Kruskal-Wallis test 






Appendix Figure 7.10 Numbers of CD8+ and CD4+ T cells in mLN of tumour-free mice following 
vaccination with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or 
emulsion (E-Vac). The second replica of the experiment. Number of live (A, C, E, G) CD8+ and 
(B, D, F, H) CD4+ T cells. (A and B) CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+ and (G 
and H) CD122+CD44+ T cells populations. Data was analysed using a Kruskal-Wallis test 






Appendix Figure 7.11 Numbers of CD8+ and CD4+ T cells in mLN of tumour-free mice following 
vaccination with PBS (Ctrl), AH1td peptide and Pam2Cys in PBS (Vac), liposomes (L-Vac) or 
emulsion (E-Vac). The third replica of the experiment. Number of live (A, C, E, G) CD8+ and (B, 
D, F, H) CD4+ T cells. (A and B) CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+ and (G 
and H) CD122+CD44+ T cells populations. Data was analysed using a Kruskal-Wallis test 






Appendix Figure 7.12 Innate immune cell populations in mLN of naïve mice following 
vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in 
PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). (A, C, E, G) frequency and (B, D, F, H) number 
of (A and B) CD11c-F4/80+CD11b+, (C and D) CD11c+F4/80-CD11b+, (E and F) 
CD11c+F4/80+CD11b- and (G and H) CD11c+F4/80-CD11b- cell populations. Data was analysed 
using a Kruskal-Wallis test and Dunn’s multiple comparison post hoc test (n=5, mean ± SD, *p 






Appendix Figure 7.13 Composition of innate immune cell populations in spleen of naïve mice 
following vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and 
Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). (A, C, E, G) frequency and (B, D, 
F, H) number of (A and B) CD11c-F4/80+CD11b+, (C and D) CD11c+F4/80-CD11b+, (E and F) 
CD11c+F4/80+CD11b- and (G and H) CD11c+F4/80-CD11b- innate immune cell populations. Data 
was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post hoc test (n=5, 






Appendix Figure 7.14 Number of innate immune cell populations in spleen of tumour-free 
mice following vaccination with PBS (Ctrl), Pam2Cys in emulsion (Adjuv) or AH1td peptide and 
Pam2Cys in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). The second replica of the 
experiment. (A) CD11c+F4/80+CD11b+, (B) CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) 
CD11c-F4/80-CD11b+, (E) CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b- and (G) CD11c+F4/80-
CD11b- populations. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple 






Appendix Figure 7.15 Number of innate immune cell populations in spleen of tumour-free 
mice following vaccination with Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys 
in PBS (Vac), liposomes (L-Vac) or emulsion (E-Vac). The third replica of the experiment. (A) 
CD11c+F4/80+CD11b+, (B) CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) CD11c-F4/80-
CD11b+, (E) CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b- and (G) CD11c+F4/80-CD11b- 
populations. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 






Appendix Figure 7.16 Expression of cytokines in spleens of tumour-free mice following 
vaccination with Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). The second replica of the experiment. The expression 
of (A and B) IFNγ, (C and D) IL-2 and (E and F) IL-17A cytokines in (A, C, E) CD8+ and (B, D, F) 
CD4+ T cells. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 






Appendix Figure 7.17 Expression of cytokines in mLN of tumour-free mice following 
vaccination with Pam2Cys in emulsion (Adjuv) or AH1td peptide and Pam2Cys in PBS (Vac), 
liposomes (L-Vac) or emulsion (E-Vac). The second replica of the experiment. The expression 
of (A and B) IFNγ, (C and D) IL-2 and (E and F) IL-17A cytokines in (A, C, E) CD8+ and (B, D, F) 
CD4+ T cells. Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison 







Appendix Figure 7.18 Lymphocyte populations in mLN of tumour-bearing mice following oral 
immunisation with PBS (Ctrl), unmodified liposome vaccine (L-Vac), Pam2Cys-AH1td construct 
in liposomes (Con L-Vac) or unconjugated AH1td peptide and Pam2Cys adjuvant in UEAI lectin 
coated liposomes (UEAI L-Vac). Frequency (A, C, E) and total number (B, D, F) of live (A and B) 
CD4+, (C and D) CD8+ (E and F) and CD19+ populations. Ctrl was analysed on the 16th day after 
surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 20 days after tumour injection (closed 
symbols) or when reached humane endpoints (open symbols). Data was analysed using a 






Appendix Figure 7.19 Frequency of innate immune cell populations in mLN of tumour-bearing 
mice following oral immunisation with PBS (Ctrl), unmodified liposome vaccine (L-Vac), 
Pam2Cys-AH1td construct in liposomes (Con L-Vac) or unconjugated AH1td peptide and 
Pam2Cys adjuvant in UEAI lectin-coated liposomes (UEAI L-Vac). (A) CD11c+F4/80+CD11b+, (B) 
CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) CD11c-F4/80-CD11b+, (E) 
CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b- and (G) CD11c+F4/80-CD11b- populations. Ctrl 
was analysed on the 16th day after surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 20 
days after tumour injection (closed symbols) or when reached humane endpoints (open 
symbols). Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post 






Appendix Figure 7.20 Number of innate immune cell populations in mLN of tumour-bearing 
mice following oral immunisation with PBS (Ctrl), unmodified liposome vaccine (L-Vac), 
Pam2Cys-AH1td construct in liposomes (Con L-Vac) or unconjugated AH1td peptide and 
Pam2Cys adjuvant in UEAI lectin-coated liposomes (UEAI L-Vac). (A) CD11c+F4/80+CD11b+, (B) 
CD11c-F4/80+CD11b+, (C) CD11c+F4/80-CD11b+, (D) CD11c-F4/80-CD11b+, (E) 
CD11c+F4/80+CD11b-, (F) CD11c-F4/80+CD11b- and (G) CD11c+F4/80-CD11b- populations. Ctrl 
was analysed on the 16th day after surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 20 
days after tumour injection (closed symbols) or when reached humane endpoints (open 
symbols). Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post 






Appendix Figure 7.21 CD4+ T cell populations in spleen of tumour-bearing mice following oral 
immunisation with PBS (Ctrl), unmodified liposome vaccine (L-Vac), Pam2Cys-AH1td construct 
in liposomes (Con L-Vac) or unconjugated AH1td peptide and Pam2Cys adjuvant in UEAI lectin 
coated liposomes (UEAI L-Vac). (A, C, E, G) Frequency and (B, D, F, H) number of (A and B) 
CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+ and (G and H) CD122+CD44+ CD4+ T cells. 
Ctrl was analysed on the 16th day after surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 
20 days after tumour injection (closed symbols) or when reached humane endpoints (open 
symbols). Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post 






Appendix Figure 7.22 CD8+ T cell populations in spleen of tumour-bearing mice following oral 
immunisation with PBS (Ctrl), unmodified liposome vaccine (L-Vac), Pam2Cys-AH1td construct 
in liposomes (Con L-Vac) or unconjugated AH1td peptide and Pam2Cys adjuvant in UEAI lectin-
coated liposomes (UEAI L-Vac). (A, C, E, G) Frequency and (B, D, F, H) number of (A and B) 
CD62L+CD44-, (C and D) CD25+, (E and F) CD62L-CD44+ and (G and H) CD122+CD44+ CD8+ T cells. 
Ctrl was analysed on the 16th day after surgery. L-Vac, Con L-Vac and UEAI L-Vac were analysed 
20 days after tumour injection (closed symbols) or when reached humane endpoints (open 
symbols). Data was analysed using a Kruskal-Wallis test and Dunn’s multiple comparison post 

















































Appendix Table 7.3 Characteristics of DSPC:DC-Cholesterol liposomes 
 
Size, nm PDI Zeta potential, mV 
DSPC:DC-Cholesterol liposomes  113.1 ± 1.4  0.226 ± 0.025 37.7 ± 2.1 
 
